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Abstract
Fibroblast growth factors (FGFs) are involved in various cellular processes such as cell growth,
proliferation, differentiation, migration, angiogenesis, wound healing and embryonic
development. Human acidic fibroblast growth factor (hFGF1) binds non-selectively to all the
four FGF-receptors and is therefore considered as a powerful mitogen with broadest specificity.
However, pharmacological applications of hFGF1 are restricted due to the low thermal stability
of the growth factor. hFGF1 has low thermodynamic stability under physiological temperatures
which leads to impairment of cellular signaling process thereby preventing its potential
mitogenic properties. hFGF1 has a heparin binding pocket at the C-terminus which comprises of
positively charges residues. The interaction between the positively charged amino acids lead to
electrostatic repulsions, thereby rendering instability. To overcome this instability, hFGF1 binds
to the glycosaminoglycan, heparin which decreases the repulsion (s) between the positively
charged residues. However, binding of heparin poses a challenge for the use of hFGF1 in wound
healing. Thrombin converts fibrinogen to fibrin and works as first line of defense by blocking the
loss of blood. Intriguingly, thrombin also binds to heparin. Studies on wtFGF1 have
demonstrated the presence of secondary thrombin cleavage site in hFGF1. Thus, thrombin is
known to cleave hFGF1 at Arg 136 and render it biologically inactive. Usually, it is considered
that dependency of hFGF1 to heparin increases the plausibility of thrombin-induced degradation
of the growth factor. To tackle these downfalls, I have designed and constructed several point
mutations in hFGF1 to improve the thermal stability and cell proliferation ability and to subside
the heparin binding affinity of the growth factor.
In this dissertation, I studied single, double, triple, quadruple, and penta variants of Q54P,
S61L, H107S, K126N, and R136E and examined the thermal stability, bioactivity, and heparin

dependency of the protein. These studies indicate that site - directed mutagenesis in hFGF1 can
impact the inherent stability of the growth factor and role of heparin in hFGF1-FGFR receptor
interaction and activation.
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CHAPTER I

INTRODUCTION
Growth factors
Growth factors play a substantial role in intercommunication between cells via
ligand/receptor cell signaling. Cell signaling can be mediated by several different types of
ligands/effector molecules, including proteins. With protein ligands, cell signaling occurs in
three clear modes in succession - reception of the signal, transduction through relay molecules,
and cellular response by the target cell. Between cells, intercommunication begins with an
extracellular ligand binding to a specific receptor in an extracellular compartment of the target
cell. This reception is detected by a ligand that triggers the transduction signal, a chemical input
that acts inside the cell. Once the chemical signal has reached its target intracellularly, cell
undergoes the ligand-specific response. Growth factors, a family of proteins that are pertinent to
cell signaling influence growth and replication of new cells, cell repair, cell differentiation, and
cell survival in higher animals via the process of cell signaling.
In coordination with the process of cell signaling, four modes of signaling can occur (Table
1). One mode is autocrine secretion in which a cell signals itself by releasing a hormone that
binds to autocrine receptors on the same cell. Another mode of secretion is the paracrine
secretion wherein neighboring cells release factors onto each other’s extracellular receptors.
Third mode of secretion is intracrine secretion wherein the cell stimulates itself by a cellular
product that acts inside the cell. Endocrine signaling is in contrast to other modes of signaling as
the signal(s) is transported to cells via the bloodstream [1,2].
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Classification of the fibroblast growth factor family
According to sequence homology and phylogeny, the mammalian fibroblast growth factor
(FGF) family can be subdivided into 7 subfamilies (Table 1, Fig. 1) which are in contrast to gene
location analysis; wherein the FGF family is classified into 6 subfamilies (Table 2) [1-3]. Except
for the FGF11 subfamily which acts in an intracrine manner and FGF19 subfamily which are
endocrine FGFs, most of the FGF subfamilies act in the paracrine manner (FGF1, FGF4, FGF7,
FGF8, and FGF9 subfamilies). Only the members of paracrine subfamily bind to the heparan
sulfate [2].

Fig. 1: Phylogenetic tree of the Human FGF family. Sequence homology and phylogenetic
analysis reveals that FGFs can be arranged into 7 subfamilies. The branch length of each FGF
member is directly proportional to the evolutionary distance between each gene. FGF19, FGF21,
and FGF23 act as endocrine secretions [1].
Table 1: Phylogenetic analysis of the human FGF family. The human FGF gene family can
be subdivided into 7 subfamilies.
FGF subfamily
FGF1
FGF4
FGF7
FGF8
FGF9
FGF11
FGF19

Members of the subfamily
FGF1, FGF2
FGF4, FGF5, FGF6
FGF3, FGF7, FGF10, FGF22
FGF8, FGF17, FGF18
FGF9, FGF16, FGF20
FGF11, FGF12, FGF13, FGF14
FGF19, FGF21, FGF23

Mode of action
Paracrine [1]
Paracrine [2]
Paracrine [1]
Paracrine [2]
Paracrine [1]
Intracrine [1]
Endocrine [1]
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Table 2: Gene location analysis of the human FGF family.
FGF subfamily
FGF1

FGF4

FGF7

FGF8

FGF9

FGF11

Members of the subfamily
FGF1
FGF2
FGF5
FGF3
FGF4
FGF6
FGF19
FGF21
FGF23
FGF7
FGF10
FGF22
FGF8
FGF17
FGF18
FGF9
FGF16
FGF20
FGF11
FGF12
FGF13
FGF14

Gene location
5q31.3 [3]
4q27 [3]
4q21.21 [3]
11q13.3 [3]
11q13.3 [3]
12p13.32 [3]
11q13.3 [3]
19q13.32[3]
12p13.32[3]
15q21.2[3]
5p12 [3]
19p13.3 [3]
10q24.32 [3]
8p21.3[3]
5q35.1[3]
13q12.11 [3]
Xq21.1[3]
8p22[3]
17p13.1[3]
3q28[3]
Xq26.3[3]
13q33.1[3]

FGF is a prototype member of the family consisting of 23 related proteins with a
molecular weight ranging from 17 to 34 kDa [5]. They are largely responsible for growth and
development and strongly influence mitogenic events in endothelial and epithelial cells,
angiogenesis, wound healing, and regulation of cell growth and differentiation [6]. FGF induces
the metabolic processes by binding and activating specific tyrosine kinase fibroblast growth
factor receptors (FGFRs). This FGF-FGFR complex, in turn, induces downstream signaling
through common pathways such as the retrovirus-associated DNA sequences (RAS)/mitogenactivated protein kinase (MAPK), phosphoinositide-3-kinase (PI3K) / Protein kinase B (AKT),
and phospholipase-Cγ (PLCγ) pathways [5]. However, the structural bases for the specificity of
events triggered by individual members of the FGF family is still not known. Most FGFs are
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homologous to each other in their amino acid composition [6]. The FGF family consists of
structurally related polypeptide growth factors that share high affinity for heparin, interact with
FGFRs, and carry out distinct functions.
FGFs predominantly have a β-trefoil structure consisting of 12 antiparallel β-strands [7].
This globular β-trefoil core domain is flanked by N- and C-terminal regions that are highly
divergent in both length and sequence amongst different members of the FGF family. FGFs and
their target cells are widely distributed and expressed in several types of tissues. Biosynthesis
and activity of FGFs is complex and regulated at all levels of processing, including activation of
transcription, post-transcriptional modifications (capping, splicing, polyadenylation, and mRNA
stability), translation initiation, post-translational modifications (O-linked glycosylation, Nlinked glycosylation, phosphorylation, acetylation, methylation, and ribosylation), intracellular
trafficking, secretion, bioavailability, and ligand-receptor interactions [8].
Structure and function of the FGF family
FGF1 subfamily
The FGF1 subfamily is also known as the prototypical or archetypal family. FGF1, also
known as an acidic fibroblast growth factor and FGF2, also known as a basic fibroblast growth
factor, were the first FGFs to be isolated and identified. The prototypical Fgf genes comprise of 3
coding exons, out of which exon 1 contains the initiating codon- methionine. Even though this
subfamily is considered as paracrine FGFs, it behaves in an intracrine manner. None of the FGFs
from this group are secreted by the cell nor do they have the N-terminal hydrophobic sequence
instead, they are directly translocated to the nucleus [9-12]. The mRNA structure of this
subfamily is unique when compared to other FGFs because it does not include a signal peptide
sequence that targets FGFs for secretion through the classic ER-Golgi complex secretory
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pathway. FGFs employ a non-classical pathway to be secreted [11]. Also, the open reading frame
in FGF1 is edged by the termination codons, whereas FGF2 contains 5’ transcribed sequence that
initiates from upstream CUG codons for translation [12].
FGF1 and FGF2 differ significantly in both size and sequence, but both contain a core
region of homology encompassing 120–130 residues; which suggests that they are originated
from a common ancestral gene. Both the structurally related proteins have 53% protein sequence
homology. Both bind tightly to heparin and share many biochemical and biological properties
[13]. Thus, in the FGF1 subfamily, both FGF1 and FGF2 have a similar preference for N-sulfate
and 2-Osulfate, but FGF1 differs in that it also binds saccharide structures with 6-O-sulfated
heparin. This subfamily possesses three Heparin Binding Sites (HBS), the primary HBS1 and the
secondary binding sites HBS2 and HBS3 [14].
FGF1 is a single chain positively charged polypeptide with a molecular weight of about
15,967 Da and a pI of 7.73 [5]. FGF1 was originally purified from the brain using standard
chromatographic techniques such as ion-exchange chromatography, gel filtration, isoelectric
focusing, and reverse-phase HPLC. FGF-1 has a strong affinity for heparin and its purification is
greatly facilitated by heparin sepharose chromatography. Initially, FGF1 was recognized as a
polypeptide containing 140 amino acids. However, subsequent sequence analysis showed that
FGF1 was a 154 amino acids polypeptide. The shorter form represents a truncated version, where
14 amino acids are chopped off the N-terminus. FGF1 is fairly well conserved among species,
with 11 amino acids differing between human and bovine FGF1. FGF1 also has 19-25%
sequence homologies with interleukin-l-alpha and interleukin-l-beta but there is no evidence of
these homologies being biologically significant. However, it is of interest that these interleukins,
like FGF1 and FGF2, are not secreted proteins. FGF1 contains characteristic β-trefoil structure
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which is made up of 12 antiparallel β strands [5,6]. Human FGF1 contains three cysteine
residues (Cys 30, Cys 97, C131), unlike FGF2 which has four. Two of these, Cys 30 and Cys 97
are conserved in all FGF family members. Key residues responsible for interaction between
FGF1 and heparin or its receptor are characterized by the crystal structure [6]. FGF1 is unique
among FGFs because of its ability to bind and activate all known FGFRs, FGF-1 is considered to
be the universal FGFR ligand [15].
FGF2 has a molecular weight of 18 kDa and is well conserved among the other species.
Human FGF2 contains four cysteine residues (Cys 33, Cys 77, Cys 95, and Cys 100). As
mentioned in hFGF1, two of these cysteine residues (Cys 33 and cys 100) are conserved in all
FGF family members. Several studies have shown that none of the cysteine residues form
disulfide bonds. Site directed mutagenesis studies report that substitution of Cys 77, 95, and 100
to serine did not alter the cell proliferation activity of FGF2. On the other hand, substitution of
Cys 33 to serine led to 60% reduction in the biological activity of hFGF2. Baird and colleagues
showed that cell surface receptor-binding and heparin-binding domains of FGF2 are the same.
FGF1 and FGF2 are prototype members of the FGF family. They control a broad range of
biological functions from developmental processes during embryogenesis to various
physiological roles in the adult state, including the regulation of angiogenesis, wound healing,
organ development (eye, skin, brain, lung, limb, muscle, bone, blood, and heart), and
metabolism. FGF1 and FGF2 also possess broad mitogenic and cell survival activities, such as
cell growth, cell differentiation, tissue repair, tumor growth, and invasion. FGF1 and FGF2 are
known to play an important role in neurogenesis. FGF2 knock-out mice shows impaired brain
development, wound repair, and deformed bone formation [16]. FGF1 and FGF2 has been used
more widely for wound healing than FGF7 and FGF10. Also, recombinant human FGF1 (rh-
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FGF1) and recombinant human FGF2 (rh-FGF2) showed effective healing effects for the
treatment of ulcers and diabetic foot ulcers compared to FGF7 and FGF10. rh-FGF1 and rhFGF2 has a positive influence in curing ulcers, diabetic foot abscess, and second-degree burns
[17].
FGF4 subfamily
The FGF4 subfamily involves FGF4, FGF5 and FGF6. Human FGF4 is located in
extracellular space and nucleus. It has been reported that FGF4 and FGF6 are more stable than
FGF3 and FGF17 in absence of heparin [14]. Examination of crystal structure of FGF4 identified
2 heparin binding sites (HBS). The first heparin binding site spans the area between β6 and β7,
β9 and β10, and β10 and β12 strands which involve Lys 142, 144, 147, 183, 186, 188, and 189,
respectively. The second heparin binding site consists of three lysine residues (Lys 65, 81, and
158). Similarly, FGF6 also has two heparin binding sites. HBS1 spans the region between β10
and β12 strand and involves Lys 144, 185, and 194. HBS2 includes Lys 83 (found near the Nterminal of β1 strand) and Lys 158 on the β8 strand.
FGF5 is composed of a highly conserved core region which comprises of 12 β strands and a
signal peptide at the N terminus [18]. Human FGF4 plays an important role in the regulation of
embryonic development, cell proliferation, and cell differentiation. It is required for normal limb
and cardiac valve development during embryogenesis [19]. Human FGF5 plays an important role
in the regulation of cell proliferation and differentiation and is required for normal regulation of
the hair growth cycle. FGF5 functions as an inhibitor of hair elongation by promoting
progression from anagen, the growth phase of the hair follicle, into catagen the apoptosisinduced regression phase [20]. Human FGF6 plays an important role in the regulation of cell
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proliferation, cell differentiation, angiogenesis and myogenesis, and is required for normal
muscle regeneration and differentiation [21].
FGF7 subfamily
The FGF7 subfamily involves FGF3, FGF7, FGF10 and FGF22. The FGF7 subfamily is
unique among FGFs because its members are expressed exclusively by mesenchymal cells and
interact specifically with the b splice variant of FGFR2 (FGFR2b) resident in overlying
epithelium [22]. Members of the FGF7 subfamily are essential for organogenesis and tissue
patterning in the embryo, and mediate wound healing and tissue homeostasis in adult mammals
[23]. The varied functional roles of this subfamily is responsible for causing numerous diseases
such as congenital deafness (LAMM syndrome), lacrimo-auriculo-dento-digital (LADD)
syndrome, inflammatory bowel disease, Apert syndrome (AS), and prostate cancer [24].
FGF7 is also known as Keratinocyte Growth Factor (KGF). It has 10 well-defined beta
strands, which form five double stranded anti-parallel beta sheets. There is a single beta-sheet
hydrogen bond (which is also called as the 6th Beta sheet) between residues 137 and 141. This
poorly defined sixth beta- sheet has a helix-like nature in high resolution FGF-2 NMR structure
[25]. Apart from these little dissimilarities, the structures of KGF, FGF-1, and FGF-2 are very
similar with a Root Mean Square Deviation (RMSD) of about 0.89 Å based on the C-alpha
atoms [26]. Overlay of the heparin bound KGF structure on the heparin bound FGF-2 structure
shows that only Gln-152 of KGF superimposes very well with Gln-135 of FGF1 and FGF2,
whereas other residues in KGF differ from FGF1 and FGF2. Talking about the non-heparin
binding region, the nonpolar residue Val-143 of KGF superimposes with the high-affinity
residue Lys-126 of bFGF [25]. However, when the structures are superimposed, residue Thr-154
of KGF appears to be pointing toward the heparin-binding pocket, and thus may contribute to the
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binding energy lost by the valine. FGF7 plays an important role in the regulation of embryonic
development, cell proliferation and cell differentiation and is required for normal branching
morphogenesis [27].
FGF10 controls the epithelial-mesenchymal interactions that are important for lung
development [28]. FGF10 is 20 kDa heparin-binding protein essentially expressed by
mesenchymal cells and it binds strongly to FGFR2-IIIb while binds weakly to FGFR1-IIIb [29].
FGF10 can prevent lung-specific inflammation induced by traumatic or infectious lung injury.
The effect of FGF10 on lung-resident mesenchymal stem cells (LR-MSCs) was studied by
delivering FGF10 into the lungs of rats and it was found that FGF10 led to an increase of LRMSCs in treated lungs [30].
Terauchi et al., have reported that the hippocampus region of the mouse brain uses FGF22
as a target-derived presynaptic organizer [31]. The Cornu Ammonis, subfield 3 pyramidal neuron
is located within the hippocampus of the brain’s temporal lobe. This pyramidal neuron releases
FGF22 which stimulates the differentiation of the excitatory presynaptic terminals. FGF22dependent presynaptic differentiation requires two FGF receptors (FGFRs), FGFR2b and
FGFR1b, in dentate granule cells (DGCs), the major presynaptic neurons for CA3 pyramidal
neurons, and the downstream signaling molecules FGFR substrate 2 (FRS2) and PI-3 kinase
[31]. Signals mediated by FRS2 and PI-3 kinase are known to regulate gene expression.
There are significant differences in the heparin binding affinity of the FGF7 subfamily, with
minimum or no binding observed in FGF3 and FGF22. This difference conferred distinct
biological properties and functions to this subfamily [22]. According to the amino acid sequence
alignment, FGF3 was similarly stabilized by unmodified heparin and any of the singly desulfated
heparins [22]. In the case of FGF10, there was no obvious difference in the stabilizing effect of
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heparin and the singly desulfated heparins. Thus, the binding preferences of FGF10 are similar
but not equal to those of FGF3.
FGF8 subfamily
It includes FGF8, FGF17, and FGF18. Unlike other FGFs, an alternative splicing event
occurs at the N termini of FGF8 and FGF17 resulting in four FGF8 isoforms (FGF8a, FGF8b,
FGF8e, and FGF8f) and 2 FGF17 isoforms (FGF17a and FGF17b) [32]. FGF8a, the smallest
FGF8 isoform, represents the common core region of FGF8b, FGF8e, and FGF8f and the
remaining isoforms differ by the presence of additional N-terminal amino acid sequences of
variable length and sequence [33]. FGF17a and FGF17b resemble FGF8a and FGF8b,
respectively. On the other hand, FGF18 is not subjected to alternative splicing [34].
Members of FGF8 subfamily adopt a different conformation than the rest of the FGF family
members. They exhibit a well conserved N-terminus and a one-residue insertion (S95) in the β4–
β5 loop [35]. FGF8 plays a key role in the regulation of embryonic limb development,
embryonic brain development, and development of the gonadotropin-releasing hormone (GnRH)
neuronal system [36]. It is also required for cell proliferation, cell differentiation and cell
migration. FGF17 is also essential for embryonic eye, ear, and limb development, and as
signaling molecule in the induction and patterning of the embryonic brain [37]. FGF18 is
reported to play a crucial role in osteogenesis, cartilage formation, cell proliferation, cell
differentiation, and cell migration [38].
FGF9 subfamily
The FGF9 subfamily includes FGF9, FGF16, and FGF20. FGF9 is a potent mitogen
which is primarily produced by neurons [39]. FGF9 is broadly expressed in high levels
throughout the brain and kidney. FGF16 is highly expressed in olfactory bulb and heart, where it
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is required for cardiac cell proliferation [40]. FGF20 is a neurotrophic factor expressed in the
substantia nigra pars compacta and is associated with Parkinson’s disease [41]. FGF20 is
expressed at low levels in a limited set of tissues including adrenal tissues.
The FGF9 subfamily is the only subfamily which undergoes reversible homodimerization
[42]. This family shares approximately 62–73% amino acid sequence similarity and exhibit high
sequence homology between human and mouse. The FGF9 subfamily is important for epithelialmesenchymal interactions. This subfamily also controls the morphogenesis of lungs, small
intestine, inner ear, and cecum [43].
FGF11 subfamily
The FGF11 subfamily consists of FGF11, FGF12, FFG13, and FGF14. This subfamily is an
exclusion from the other FGF sub-families but shares high structural and sequence homology.
Members of the FGF11 subfamily are also known as FGF homologous factors (FHFs) and is
functionally different from the other FGF families. They share between 58-71% sequence
identity with each other and less than 30% sequence identity with other members of the FGF
family. These members regulate channel gating and intracellular signal trafficking by interacting
with the cytoplasmic C-terminal tails of voltage-gated sodium channels [13].
FGF19 subfamily
FGF19 subfamily consists of FGF19, FGF21, and FGF23. Unlike usual FGFs, FGF19
subfamily members lack a classic heparin-binding domain. This characteristic protects them
from the capture by local cells; therefore, they are secreted into the bloodstream and function as
hormones. Thus, this subfamily acts in an endocrine manner. However, the FGF19 subfamily has
a low affinity for heparin sulfate, and another co-receptor named Klotho is required to allow the
FGF19 subfamily to exert their biological functions. Relative to the five paracrine-acting FGF
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subfamilies, the FGF 19 subfamily displays the least sequence identity amongst its members.
The pairwise sequence identity between the core regions of members of FGF19 subfamily ranges
between 33% for FGF21 and FGF23 and 38% for FGF19 and FGF21. When compared, the
identity between the core regions of members of paracrine FGF subfamilies is significantly
higher and ranges between 88% for FGF9 and FGF16 to 54% for FGF7 and FGF10. Most of the
sequence divergence between FGF19 subfamily members shoots from the heparin binding
regions, specifically the β1-β2 loop and the segment between the β10 and β12 strands of the
paracrine ligands. Elimination of the heparin binding region from the sequence alignment data
increases the identity between FGF19 subfamily members and other FGF subfamilies to more
than 40%. Members of the FGF19 subfamily have varied functions such as regulating the
enterohepatic circulation of bile acid, regulating glucose and lipid metabolism, and maintaining
phosphate/vitamin D homeostasis [13].
FGF21 is a hormone secreted by the liver (hepatokine) but the bioactivity of FGF21 and
the actual mode of action still remains elusive [44]. FGF21 is an important inducer of glucose
uptake in adipocytes. When overexpressed in transgenic mice, it was found to reduce the dietinduced obesity, blood glucose, and the triglyceride (TG) levels [45]. FGF21 has appeared as an
essential metabolic hormone contributing towards managing glucose, lipid, and energy
homeostasis. Recombinant FGF21 have impressive effect in normalizing plasma glucose levels,
increasing insulin sensitivity, and reducing plasma TG and cholesterol levels in different diabetic
animal models including rhesus monkeys. Recombinant FGF21 serves as a potential unique
treatment to cure metabolic disorders [46]. FGF21 improves insulin-independent glucose uptake
into cultured 3T3-L1 mouse adipocytes and human adipocytes by the upregulation of glucose
transporter 1 (GLUT1) expression. Studies indicate that FGF21 controls adipocyte lipolysis and
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enhances adiponectin expression and secretion [47]. Reconstitution of adipose tissue by
transplanting white adipose tissue (WAT) from wild-type mice to lipoatrophic mice restores
FGF21 responsiveness. FGF21 controls the gene expression of uncoupling protein 1 (UCP1) in
brown adipose tissue (BAT) and WAT and significantly increases the presence of “brown-like”
adipocytes in subcutaneous WAT [48]. These outcomes may result in the thermogenic activities
of FGF21 and controlled weight-loss under high fat conditions. In mice, FGF21 expression is
upregulated in response to cold exposure and β-adrenergic stimulation [48]. In rats, exposure to
cold climate activate a distinct release of FGF21 from BAT, suggesting an endocrine role of
BAT as a source of FGF21 that can be related to thermogenic activation. In humans, changes in
the serum FGF21 concentrations correlate positively with thermogenesis and circulating FGF21
levels correspond to BAT activity during severe cold exposure in male individuals which
suggests that FGF21 maintains normothermia [49]. FGF21 agonist aids in the treatment of type 2
diabetes and obesity [50]. FGF21 plays an essential role in the regulation of glucose and lipid
metabolism in obese rodents and primates. FGF21, a hepatokine growth factor, has a satisfactory
role in glucose and lipid metabolism in mice. The first clinical trials of FGF21 analogs in type 2
diabetic patients exhibited lowered glucose efficacy [51]. Immunostaining of the pancreatic islets
revealed that the number of islets and insulin amount were elevated in FGF21 injected db/db
mice [52]. FGF21 is significantly expressed in pancreas and exerts its inflammatory role in
experimental pancreatitis [53,54].
FGF23 is secreted mainly by osteocytes and it acts as a phosphaturic factor that inhibits
1,25 dihydroxy vitamin D (1,25(OH)2D) and parathyroid hormone. FGF23 regulates the
concentration of phosphate that is important in cellular signaling, regulating plasma pH, bone
mineralization, and bone development. Increased serum FGF23 concentration has been
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associated with the progression of chronic kidney disease. To study the effects of FGF23 on
chronic kidney disease-mineral and bone disorder (CKD-MBD) and secondary
hyperparathyroidism (HPT), scientists conducted a study where they used FGF23 antibodies to
neutralize the effect of FGF23 using rat model. CKD-MBD rat models were fed on a highphosphorus diet and were treated with either a high dose or a low dose of monoclonal FGF23
antibody. The results showed that treatment with the monoclonal FGF23 antibody inhibited the
occurrence of HPT which decreased parathyroid hormone levels, increased vitamin D and
calcium levels, and restored bone markers back to normal level [55]. Tumor-induced
osteomalacia (TIO) is a type of a paraneoplastic condition recognized by hypophosphatemia
resulting from renal phosphate wasting. Overexpression of FGF23 leads to TIO while mutations
in the FGF23 gene cause autosomal dominant hypophoshatemic rickets [56]. FGF23 is a
dynamic player of vitamin D and phosphate metabolism [57]. FGF23 stops the expression of
Cytochrome P450 Family 27 Subfamily B Member 1 (CYP27B1) that encodes a protein which
controls the production of 1,25(OH)2D. FGF23 also induces Cytochrome P450 Family 24
Subfamily A Member 1 (CYP24A1) expression that encodes an enzyme that acts to reduce
1,25(OH)2D level [58]. A segment of FGF23 protein is divided into inactive N-terminal and Cterminal parts before or during the secretion process of FGF23.
hFGF1 structure
hFGF1 is the prototype member of fibroblast growth factor (FGF) family, a superfamily
that promotes cell signaling. Human acidic fibroblast growth factor (hFGF1) is a 16 kDa, singlechain globular protein with characteristic β-trefoil fold consisting of six β-strand pairs, three of
which form a six-stranded β-barrel structure [59]. Proteins that share the β-trefoil structure with
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FGFs are the Kunitz soybean trypsin inhibitors, the ricin-like plant and bacterial toxins,
interleukins, and various carbohydrate-binding proteins such as xylanase [60].
Sweet and coworkers were the first group to observe β -trefoil fold in the soybean trypsin
inhibitor. β -trefoil structural architecture was then characterized by Chothia and group [61].
hFGF1 comprises of 12 β -strands that form 6 β -hairpins (Fig. 2). Overall β- trefoil structure of
hFGF1 can be divided into a 6-stranded β-barrel, (top half, consisting of β-strands 1, 4, 5, 8, 9,
and 12) and a β -hairpin triplet (bottom part, comprising of β-strands 2, 3, 6, 7, 10, and 11).

Fig. 2: Secondary structure of hFGF1. Twelve β-strands are folded into β-trefoil structure [59].
A central axis of 3-fold symmetry separates the barrel into three trefoil subdomains of
approximately 40 amino acids each. hFGF1 structure is functionally divided into two parts heparin binding and receptor binding [62]. The heparin binding region (β-strands 6-12) are more
rigid and compact whereas the receptor binding part (β-strands 1-5).
Heparan Sulfate Glycosaminoglycan (HSGAG) binding and hFGF1-heparin interaction
FGFs are known for their potential biological functions such as cell proliferation and cell
differentiation, but FGFs have a short half-life in vivo and are readily degradable. They bind to
heparin present on the surface of cells. FGF signaling has been suggested to require heparin or
heparin sulfate (HS) [5,6]. HS is a highly sulfated linear polymer of alternating glucuronate
(GlcA) and N-acetylglucosamine (GlcNAc) monosaccharide units that undergo heterogenous
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deacetylation (N-sulfation on GlcNAc and O-sulfation on both GlcA and GlcNAc). HS regulates
FGF-FGFR signal transduction by stabilizing the FGF-FGFR binding, regulating FGF protein
level in extracellular matrix (ECM), and also conferring protection to FGFs against thermal
denaturation and proteolytic degradation [63]. In addition to facilitating the FGF-FGFR binding,
HS also acts as a storage reservoir for ligand and determines the radius of ligand diffusion by
controlling the gradients of paracrine FGFs in ECM. Amongst all the paracrine FGF subfamilies,
FGF22 is the only FGF that does not bind to HS. All the other paracrine FGFs interact with HS
with different affinities with FGF1, FGF2 and FGF7 having the highest binding affinity. The
positively charged residues in the heparin binding pocket of hFGF1 interacts with the negatively
charged heparin molecule. Heparin-binding site (HBS) in all FGFs is located within the core
region and spans residues in the ß1- ß2 loop and ß9 to ß12 strands [13, 59]. SDM studies infer
that charge reversal mutations of the lysine residues (K132, K127, K114, and K115) at the Cterminal of FGFs leads to loss of heparin binding affinity. Crystallographic and NMR studies
confirm that residues 126-142 (present at the C-terminal) of hFGF1 is responsible for heparin
binding. Interestingly the crystal structure contains no protein-protein interactions and each
monomer binds the heparin sulfate groups on opposing sides of the polysaccharide [59].
Crystal structure data on the FGF-FGFR-HS ternary complex revealed that heparin
promotes FGF signaling through the formation of a 2:2:2 and 2:2:1 (FGF: FGFR: HS) complex.
Schlessinger et al., reported a putative 2:2:2 complex formed between FGF2, FGFR1c, and decasaccharide heparin (dp10) [64]. The positively charged residues in hFGF1 facilitating the heparin
binding are K126, K127, N128, K132, R133, R136, and K142.
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FGFR1
Heparin

Heparin

FGF2

FGFR1

Fig. 3: The FGF2-FGFR1-heparin ternary complex. FGFR1 domains 2 (D2) and 3 (D3) are
purple and magenta, respectively, and FGF1 is green and orange. The heparin molecule is in
Corey-Pauling-Koltun (CPK) representation [12].
One half of this structure (1:1:1 complex) consists of a heparin chain bound to both FGF2
and FGFR1c, enhancing the ligand-receptor interaction (Fig. 3) [64]. The two 1:1:1 complex
were then held together through direct receptor (FGFR1c) contacts, together with the secondary
ligand-receptor (FGF2- FGFR1c) and heparin-receptor interactions. Contrary to this, Pellegrini et
al., pointed out a potential 2:2:1 FGF1-FGFR2c- deca-saccharide heparin (dp10) ternary
complex structure in which a single heparin chain bridged the gap between two FGF1-FGFR2c
complexes, making additional contacts with one of the receptor subunits [65].
Role of heparin in hFGF1-FGFR signaling
Heparin’s role in hFGF1-FGFR interaction and subsequent activation is an ongoing topic
of research. It is assumed that in addition to stabilizing hFGF1, heparin is also necessary for
receptor binding and activation [66]. From the crystal structures obtained previously, it is evident
that heparin plays a pivotal role in various biological processes, including hFGFR dimerization
and FGFR activation [67, 68]. For hFGF1 dimerization and FGFR activation, binding of heparin
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is crucial. In order to understand the biological activity of hFGF1, sucrose octasulfate (SOS), a
mimic of heparin was used [69]. This study showed that the monomeric form maintained by
hFGF1 retains its mitogenic activity to significant amounts, thereby inferring that oligomeric
form of hFGF1 is not important for its biological functioning [69].
Angulo et al., reported that length and sulfation patterns of glycosaminoglycans (such as
heparin) has a considerable impact on the bioactivity of hFGF1 [70]. They also showed that
dimerization of two hFGF1 monomers is not a mandatory step in hFGF1 activation. Their study
uses two synthetic hexasaccharides with different sulfation patterns [71]. These hexasaccharaides
bind to hFGF1 in its monomeric form. Numerous studies have reported that heparin is not an
absolute requirement for the cell proliferation activity of hFGF1 [72]. Heparin is only known to
stabilize the inherently unstable hFGF1 molecule. hFGF1 is known to have a short half-life in
vivo. Culajay et al., found that hFGF1 mutants, C30S, C97S, and C131S, increases the half-life
of hFGF1, yet these mutants were found to decrease the thermal stability of the growth factor
[73].
Apart from aiding in receptor activation, heparin also helps in stabilizing hFGF1 from
thermal degradation. In order to validate this concept, site directed mutagenesis were performed
on the growth factor. Out of all the variants generated on hFGF1, L58F exhibited considerable
increase in the thermal stability of hFGF1 [62]. In a varied approach, three other individual
substitutions (H35Y, H116Y, and F122Y) were tried and finally a quadruple mutant with L58F
was generated. H35Y/H116Y/F122Y/L58F displayed 7.8°C increase in the thermal stability and
also maintained the same mitogenic activity as wtFGF1 in spite of heparin independency [74].
Zakrzewska et al., combined three other mutations to the quadruple mutant to form a septa
mutant (H35Y/Q54P/S61I/L58F/H107G/H116Y/F122Y) to investigate if the inherent thermal
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and proteolytic stability of hFGF1 can be further enhanced [75]. As a result of this study, it was
found that the thermal stability of the septa mutant was 27°C higher than wtFGF1. Wong et al.,
showed that substitution of lysine to glutamine at position 132 in the heparin binding site
displays reduced heparin binding affinity, but still activates FGFR and induces early intermediate
gene transcription [76]. Interestingly, in the absence of heparin a quadruple mutant with the
K132E mutation plus the triple mutant Q54P/S61I/H107G was found to have mitogenic activity
equivalent to heparin-bound wildtype hFGF1 [77]. These studies conclude that heparin is not
mandatory for the biological activity of hFGF1.
One interesting study analyzing the intramolecular bonds of hFGF1 found that inclusion
of disulfide bonds at the N and C terminal could yield better stabilization of the growth factor
which led to the generation of K26C and P148C mutants [78]. These mutants were thought to
form a disulfide bond and lead to increase in the inherent stability of the growth factor.
Conversely, the mutants did exhibit increased thermal stability and mitogenic activity, in spite of
no disulfide bond formation. In conclusion, numerous efforts have been taken to improve the
thermal stability, proteolytic stability, and cell proliferation activity of the growth factor in a
heparin independent manner, yet a substantial understanding still remains elusive.
Interestingly, several other mutations in hFGF1 such as K132E, cysteine mutations
(C97S, C30S, C131S), H107G, and L58F have shown higher thermal stability, lack of heparin
dependent FGF-FGFR activation. Except for K132E mutation, all the other hFGF1 variants
exhibited higher mitogenic activity than wtFGF1 [79,80]. Studies have shown that hFGF1 can
lead to endocrinization, which demonstrates that mitogenic activity of hFGF1 can be
differentiated from the metabolic activity [81,82]. Xia et al., and Huang et al., have reported that
phosphorylation of S116R and combination of K126D, K127Q, and K132E mutations lead to
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decreased mitogenic activity but increased glucose-lowering activity. These variants of hFGF1
may be a potential therapeutic for type 2 diabetes [81,82].
Fibroblast Growth Factor Receptors (FGFRs)
There are only 18 FGFR ligands for the FGF family. FGF homologous factors (FHFs),
FGF11, FGF12, FGF13, and FGF14, do not bind with the FGF receptors [7]. FGF ligands carry
out their diverse functions by binding and activating the FGFR family of tyrosine kinase
receptors in an HSGAG-dependent manner. FGFs exert their physiological roles through binding
to FGFR and regulate developmental pathways, controlling events such as mesoderm patterning
in the early embryo till the development of multiple organ systems. There are four FGFR
(FGFR1–FGFR4) that encode receptors consisting of three extracellular immunoglobulin
domains (D1–D3), a single-pass transmembrane domain and a split cytoplasmic tyrosine kinase
domain [83]. FGFRs are expressed on many diﬀerent cell types and regulate key cell behaviors,
such as proliferation, diﬀerentiation, and survival, which make FGF signaling susceptible to
subversion by cancer cells [84].
FGFRs consist of an acid box that includes an acidic, serine-rich sequence in the linker
between the D1 and D2 domain. D1 domain of FGFR is responsible for receptor autoinhibition.
The base of D2 domain helps in the binding of each FGF (ligand) to FGF receptors on the cell
surface. Each FGF molecule interacts with the D2 domain of a second receptor through a
secondary receptor binding site, and mutation of ligand residues within this site reduces receptor
dimerization and signaling without affecting ligand-receptor binding [13]. The D2-D3 fragment
is important for ligand binding and specificity. An exon-skipping mechanism removes the D1
domain or acid box leading to various isoforms of the receptor (FGFR1-FGFR3) whereas an
alternative splicing process in the second half of D3 domain of FGFR1–3 yields b (FGFR1b–3b)
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and c (FGFR1c–3c) isoforms that have distinct FGF binding specificities and are primarily
epithelial and mesenchymal, respectively. Except for FGF1, all the other FGFs bind to epithelial
or mesenchymal FGFRs and activate both the spliced isoforms. Now, HSGAGs come into play
and bind to the ligand (FGFs), FGFRs dimerize, which enables the cytoplasmic kinase domains,
in turn, trans phosphorylating and activating the A-loop tyrosines (Fig. 4). A-loop
phosphorylation is followed by phosphorylation of tyrosines in the C tail, kinase insert and
juxtamembrane regions [64]. The two main intracellular substrates of FGFR are PLCγ substrate 1
(also known as FRS1) and FGFR substrate 2 (also known as FRS2). Phosphorylation of an
FGFR-variant tyrosine (Y766 in FGFR1) at the C tail of FGFR creates a binding site for the SH2
domain of PLCγ and is required for PLCγ phosphorylation, and activation, whereas FRS2
associates constitutively with the juxtamembrane region of the FGFR [85]. Phosphorylation of
FRS2 is essential for activation of the Ras-MAPK and PI3K-AKT signaling pathways.
FGFR-FGF binding interface
hFGF-FGFR binding interface studies report that hFGF1 makes contacts with Ig
domains, D2 and D3, along with the D2-D3 linker [9]. D1 and the serine rich linker between D1
and D2 inhibits FGF binding to the receptor. Additional reports suggest that mutant receptor
proteins lacking D1 have a higher binding affinity for the ligands. Of all the other FGFs, studies
related to hFGF1 will be discussed here to stay relevant to the aims of this project. Detailed study
on FGFR-FGF interaction reveals that hFGF1 residues interacting with D2 are more conserved
than the residues binding with the D3 domain of FGFR. Out of 140 residues, 39 residues of
hFGF1 are involved in receptor binding. None of these 39 residues are located in the heparin
binding site [86]. Crystallographic studies have demonstrated that mostly hydrophobic residues
of hFGF1 interact with the D2 domain of the receptor. This includes residues Y29, G34, F36,
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Y108, L147, and L149 of hFGF1 binding to K164, L166, A168, V169, and P170 of the D2
domain. Apart from hydrophobic interactions, electrostatic interactions also take place between
residues R49 and R51 of FGF1 and E163 and D247 of the D2 domain, respectively [65].
Moreover, interactions occurring in the D2-D3 linker region is a hydrogen bond interaction
between N109 of FGF1 and R251 of the linker region. Interactions between hFGF1 and D3
domain of the receptor involves both electrostatic and hydrophobic interactions. An electrostatic
interaction occurs between E101 of hFGF1 and R255 of the D3 domain, whereas hydrophobic
interactions happens between I257 of D3 domain and L103 and H107 of hFGF1 [65].
Study of the 2:2 FGF1:FGFR2 complex (PDB 1DJS) in the absence of heparin reveals
that the D2 and D3 domain of the FGFR make contacts with both the ipsilateral and contralateral
FGF1 ligand yet no ligand-ligand contacts are reported. Heparin bound FGF-FGFR dimer
structural complex can be symmetrical and asymmetrical. Study of the decasaccharide heparin
bound FGF1:FGFR complex (PDB 1E0O) shows that heparin binds to hFGF1 (residues 126142) through the heparin-binding region with further contacts between residues V175, H167,
K164, T174, K176, R178, and K161 of the D2 domain of FGFR and heparin [86].
FGF-FGFR regulation and signaling pathway
HSGAG dependent FGF-FGFR binding leads to receptor dimerization and transautophosphorylation of the tyrosine receptor. During the receptor activation of the tyrosine
kinase domain of FGFR1, the six tyrosine residues (Y653, Y583, Y463, Y766, Y585, and Y654)
are phosphorylated [83]. As tyrosine’s are phosphorylated, the receptor activity increases by
many folds. The phosphorylation of Y653 increases activity by 50-100 folds. Followed by the
phosphorylation of Y653. Other tyrosine residues (Y583, Y463, Y766, Y585, and Y654) are
phosphorylated, resulting in an overall 500-1000 fold increase in the receptor kinase activity.
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Phosphorylation of above six tyrosine residues accounts for the tyrosine kinase activity but not
for the STAT3 and PLCγ binding. Therefore, phosphorylation of the two additional tyrosine
residues - Y677 and Y766 are needed [85]. Activated FGFR initiates the major downstream
intracellular signaling pathways such as RAS-MAPK, PI3K-AKT, PLCγ, and Signal Transducer
and Activator of Transcription (STAT) [1]. Of these signaling pathways, activation of RASMAPK and PI3K-AKT pathways are mediated by phosphorylation of FGF receptor substrate 2α
(FRS2α). Phosphorylation of Y463 and the presence of CRK Like Proto-Oncogene, Adaptor
Protein (CRKL) facilitates the phosphorylation of FRS2α. Phosphorylated FRS2α also binds to
the membrane-anchored adaptor protein, growth factor receptor-bound 2 (GRB2), and the SH2
domain-containing protein tyrosine phosphatase-2 (SHP2) [87]. This finally leads to activation of
the RAS-MAPK and PI3K-AKT signaling pathway. RAS-MAPK signaling pathway stimulates
expression of several genes through phosphorylation of E26 transformation-specific (ETS)
transcription factors, which regulates the DNA interaction and gene expression [88] (Fig. 3). On
the other side, PI3K-AKT pathway inhibits the function of forkhead box class transcription
factor (FOXO1) and cytosolic tuberous sclerosis complex 2 (TSC2) [89]. PLCγ pathway, when
activated by the FGFRs, leads to the hydrolysis of phosphatidylinositol 4,5-bisphosphate which
produces inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 subsequently regulates
the subcellular calcium ion levels and DAG transduces the signal to the protein kinase C (PKC).
FGF-FGFR interaction also phosphorylates STAT1, STAT3, and STAT5, to regulate the STAT
pathway target gene expression (Fig. 4).
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Fig. 4: (A) A cartoon representation of the FGFR structure. The splicing of the third Ig domain in
FGFR1, FGFR2, and FGFR3 gives rise to Ig IIIb and Ig IIIc isoforms. (B) A schematic depiction
of FGF-FGFR signaling cascade. Upon binding of HSGAGs to FGF, FGFRs are activated.
Heparin promotes FGF signaling through the formation of a 2:2:2 and 2:2:1 (FGF: FGFR: HS)
complex. This leads to receptor autophosphorylation and activation of downstream signaling
pathways [88].
FGFR2 consists of three extracellular immunoglobulin (Ig)-like domains, a single
transmembrane domain, and two tyrosine kinase domains in the cytoplasmic region. In
particular, the formation of FGF2-FGFR2 complex involves two Ig-like ligand-binding domains
(D2 and D3 domains) of FGFR2. Similar to FGFR1, autophosphorylation of receptor tyrosine
residues in cytoplasmic domains contribute to the docking of the signaling molecules which
include, Src homology2 (SH2) domain proteins. The binding of SH2 domain-containing proteins
have been demonstrated in activation of MAPK pathways. Seven phosphorylation sites in the
cytoplasmic domain including Y463, Y583, Y585, Y653, Y654, Y730, and Y766 have been
identified in FGFR1 which are also well-conserved in FGFR2. Phosphorylation of FGFR2
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occurs on serine 779 (S779) in response to FGF2 [90]. S779 is situated adjacent to the
phospholipase Cγ binding Site, at Y766, and contributes to a putative binding site for the 14-3-3
phosphoserine-binding proteins. S779 is found to be essential for the potential activation of PI3K
and Ras/MAPK pathways. Furthermore, it has been demonstrated that S779 signaling is also
important for proliferation in both Ba/F3 (interleukin (IL)-3 dependent, hematopoietic) and
BALB/c 3T3 fibroblast cells. GRB2 directs the regulation of receptor tyrosine kinase (RTK)
FGFR2 and SHP2. A recent study by Ahmed et al., suggested that FGFR2 cycles between its
partially phosphorylated and its SHP2- dephosphorylated state(s) [91]. To determine the
significance of the six conserved tyrosine molecules in intracellular domain of FGFR3 for
signaling, activated mutant K650E-FGFR3 was constructed. It was found that K650E mutation
renders constitutive kinase activation and regulates activation of various FGFR3 signaling
cascades. Function of Y724 is also important for its role in phosphatidylinositol 3-kinase
activation, and phosphorylation of SHP2, MAPK, STAT1, and STAT3 [92]. In addition, tyrosine
phosphorylation of SH2-Bβ was observed when co-expressed with one weakly activated
(N540K-FGFR3) and a strongly activated (K650E-FGR3) mutants. Two phosphorylation sites of
FGFR3 are identified, Y724 and Y760, which are necessary for the binding of the SH2
domain(s) of SH2-Bβ. In this context, phosphorylation and nuclear translocation of STAT5, and
activated FGFR3 promotes elevated expression of SH2-Bβ [93].
Aberrations of FGFR Signaling
Binding specificity of FGF-FGFR depends on the variability in the primary sequence of
18 FGFs and the 4 FGFRs. The different isoforms formed due to splicing display tissue
specificity. For example, isoforms b and c are expressed usually in the epithelial tissue and
mesenchymal tissue, respectively and the corresponding ligands trigger the receptors on the other
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tissues. An exception to this is FGF1, which binds to both b and c isoforms of certain FGFRs.
Anomalies in the binding specificity can lead to pathological or diseased conditions such as,
cancer. Analyses of structural characteristics of FGF1, FGF2, FGF8, and FGF10 with their
cognate FGFRs display variation at the β1 strand length of the N-terminal region and the
alternatively spliced regions in D3 dictate their binding specificities [13]. Several evidences
suggest that FGFR activating mutation, overexpression, and aberrant activation of the RTK
signaling system can lead to excessive cell proliferation, angiogenesis, cancer, and other
pathophysiological changes.
Factors Influencing Specific Aberrations in FGFR Signaling
Fusion of FGFR Genes
Fusion genes are formed by the rearrangement of two independent genes and can occur as
a result of chromosomal translocation and inversion. FGFR gene fusions play an important role
in lung squamous cell cancer, oral cancer, thyroid cancer, gall bladder cancer and glioblastoma
with intact kinase domains. The FGF signaling is involved in cancer, resulting from
hematological malignancies. N terminus of a transcription factor of FGFR chromosomal
translocations in a fusion protein is fused to an FGFR kinase domain, leading to a kinase
activation. Most of the FGFR1 fusion proteins are identified in patients with the
myeloproliferative disorder stem cell leukemia/lymphoma syndrome (SCLL/8p11
myeloproliferative syndrome) [94]. Studies have shown that 3′ gene fusions of FGFR1 and
FGFR3 are related to myeloproliferative disorder and peripheral T-cell lymphoma, respectively.
8p11 myeloproliferative syndrome (EMS), a hematopoietic stem cell disorder is related to
chromosomal translocations of fusion genes, namely zinc finger 198-FGFR1. It has been
demonstrated that zinc finger 198-FGFR1 induces EMS-like disease in mice, with
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myeloproliferation and T lymphoma [95]. Recently, several fusion genes of FGFR1-3 along with
transforming acidic coiled coil containing protein 1 (TACC1), Transforming acidic coiled coil
containing protein 3 (TACC3), BAR/IMD Domain Containing Adaptor Protein 2 Like 1
(BAIAP2L1), BicC Family RNA Binding Protein 1 (BICC1), and adenosylhomocysteinase like 1
(AHCYL1) have been identified in multiple malignancies including glioblastoma, urothelial
bladder and cholangiocarcinoma [96]. Singh et al., reported that FGFR1 and FGFR3 gene
fusions with TACC1 and TACC3 have been identified in approximately 3% of the tumor
glioblastoma multiforme (GBM) [97]. It has been demonstrated that the abnormal localization of
fusion protein to mitotic spindle poles induces mitotic and chromosomal segregation defects.
FGFR3-TACC3 fusion gene was identified in a subset of bladder carcinomas [98].
Overexpression and Amplification of FGFR
Overexpression of FGFRs may lead to ligand independent FGFR signaling and is mainly
caused by focal amplifications. Overexpression of FGFRs are associated with the development
of several cancers such as lung cancer, brain cancer, prostate cancer, liver cancer, and MM along
with angiogenesis around the tumor. Overexpression of FGFR may either be due to
dysregulation of transcription or chromosomal amplification. Underlying mechanism of FGFRs
overexpression in the development of cancer still remains elusive. FGFR1 is found to be
amplified in approximately 18% of osteosarcoma, 7% to 20% of squamous non-small cell lung
carcinoma, 6% of small cell lung carcinoma, and 14% of breast cancer in the chromosomal
region 8p11-12 [99]. It has also been suggested that activation of FGFR1 in the non-transformed
human mammary cell line resulted in cellular transformation which is evidenced by epidermal
growth factor-independent cell growth, cell proliferation, loss of cell polarity, and epithelial-tomesenchymal transition [100]. In the case of breast cancers, amplification of FGFR1and/or

27

11q12-14 has been identified in the chromosomal region containing cyclin D1 (CCND1) and
amplification of several FGFs (FGF3, FGF4 and FGF19) have been found in 23% of hormone
receptor-positive (HR+) breast cancer, 27% of human epidermal growth factor receptor 2
(HER2) breast cancer, and 7% of triple-negative breast cancer [101]. Triple negative breast
cancer (TNBC) might carry amplification of FGFR2 in 6 out of 165 (3.6%) cases. This type of
breast cancer is very aggressive and respond poorly to the conventional therapeutic measures.
[102]. In addition, FGFR2 gene amplification and protein overexpression has been detected in
2/51 breast cell lines, out of which MFM223 and SUM52PE are the TNBCs. This amplification
of FGFR2 exerts effect on the activation of PI3K-AKT downstream signaling pathway, resulting
in inhibition of apoptosis. The FGFR2 amplification is hypersensitive to FGFR-targeted therapy
and is detected in 3% to 25% of gastric cancers [103]. Many reports have demonstrated that
overexpression of FGFR4 is associated in the development of several cancers including colon,
liver and prostate. According to a study on the conditional knockout mouse, prostrate
organogenesis and androgenic dependency and homeostasis depends largely on the presence of
FGFR2. Studies have also shown that in early stages of prostate cancer, in particular when the
prostatic intraepithelial neoplasia carcinoma is in situ of the prostate, there is an evidence of nonregulated FGF/FGFR signaling. Defective FGF/FGFR signaling has been implicated as a
mechanism for the occurrence of epithelial carcinoma and prostate cancer. The growth and
progression of gastric cancer requires the activation of the FGFR2 pathway with FGFR2 gene
amplification reported both in vitro and in vivo. FGFR2 gene has two different isoforms;
FGFR2b and FGFR2c. The gene undergoes alternative splicing in the third immunoglobulin
domain resulting in those two isoforms with different FGF ligand binding. FGFR2b isoform has
been specifically found to be overexpressed in FGFR2 induced gastric cancer. About 8% of
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gastroesophageal cancers display amplification of FGFR2 gene. FGFR1 gene is over-amplified
in lung cancer and estrogen receptor-positive breast cancer. The FGFR gene is also involved in
different translocations in hematological malignancies like myeloid and lymphoid cancer
wherein the immature cells never mature, consequently preventing proliferation. FGFR gene
expression also induces sarcoma tumors such as Ewing’s sarcoma, alveolar rhabdomyosarcoma,
and angiosarcoma, and FGFR-3 causes multiple myeloma and T-cell lymphoma. Amplification
in FGFR4 gene has been detected in approximately 7-8% of rhabdomyosarcoma patients [104].
Both FGF19 and FGFR4 are found to be overexpressed in the patients with hepatocellular
carcinoma (HCC) and therapeutically potential inhibitor of FGF19/FGFR4 are considered to be
effective for the patients suffering from HCC [105].
FGFR-activating Mutations
A number of FGFR activating point mutations are connected with various types of
cancers such as: liver cancer, bladder cancer, renal cell carcinoma, prostate cancer, lung cancer,
and breast cancer [106]. Specific aberrations in FGFR signaling have been identified which are
summarized as below:
•

Overexpression of FGFR due to gene amplification or post-transcriptional activation

•

FGFR mutated form induce dimerization and thus produce receptors which are either
constitutively active or exhibit an independent ligand binding for activation

•

Chromosomal translocations resulting in expression of FGFR-fusion proteins with
constitutive FGFR kinase activity

•

Alternative splicing of FGFR and isoform switching changes the binding affinity with
FGF ligands and as a consequence, it triggers the tumor growth of FGFs
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•

Elevated levels of FGF in cancer cells and substantial release of FGFs from the
extracellular matrix, resulting in paracrine/autocrine activation

Studies reported on FGFR-activating mutations and the related diseases are summarized
below:
FGFR1: According to the catalog of somatic mutations in cancer (COSMIC) data, five FGFR1
mutations are most commonly identified [107]. However, functions of only two mutations
(N546K and K656E) are known. In addition, a proline to arginine mutation in IgII-IgIIIa linker is
associated with mild Pfeiffer syndrome in FGFR1. The most notable FGFR1 mutated forms are
Y99C and C277Y which have been detected in Kallmann syndrome [108]. Also, a constitutively
active mutant of FGFR1 expression has been implicated in the development of prostate
carcinoma lesion. The FGFR1 mutations are highly applicable in the drug-targeted development.
Various other mutations of FGFRs have been detected in solid tumors related cancer cells.
FGFR2: FGFR2 mutations have been detected in 12 to 14% of endometrial cancer. According to
the COSMIC data, 12 mutations have been identified. Among these mutations, 7 activating
mutations are reported including P253R, N549K and S252W [109]. There are two particularly
notable mutation sites in FGFR2. First, a cysteine to glycine mutation in IgIII domain causing
apert and crouzon syndrome in FGFR2. Second, a conserved proline residue in the linker
between the IgII and IgIII extracellular domain of FGFR2 frequently mutating to arginine and
causing apert syndrome [110].
FGFR3: The first reported mutation of FGFR3 was Gly→Arg missense mutation (G380R) in its
transmembrane domain, resulting in achondroplasia [111]. Naski et al., reported that the mutated
form (R248C) of FGFR3 in the extracellular domain or introduction of K650E substitution in the
tyrosine kinase (TK) domain causes the autosomal dominant human skeletal disorders,
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hypochondroplasia, achondroplasia and thanatophoric dysplasia. It has been demonstrated
through the ligand-independent receptor tyrosine kinase phosphorylation and cell proliferation
studies that R248C and K650E mutations activate the FGFR3 receptor [112]. Ser→Cys (S365C),
a FGFR3-activating variant has been found to cause dwarfism. It has been observed that S365C
mutation could lead to downregulation of expression of the Indian hedgehog and parathyroid
hormone-related protein receptor genes, which ultimately reduces bone growth [113]. FGFR3
activating mutations have been identified in thanatophoric dysplasia. Among three FGFR3
mutations (G370C, S371C, and Y373C), the two common mutations are G370C and S371C. It
has been observed that G370C and S371C induce receptor dimerization and activation [114].
FGFR3 activating mutations have also been identified in various urothelial cell carcinomas
(UCC). The expression of K652E FGFR3 in normal urothelial cell results in constitutive
phosphorylation. The role of K652E FGFR3 in the kinase domain is still unclear. Martino et al.,
described that K652E mutation was not connected with the receptor dimerization as compared to
the other two mutants. It might be essential for the physical interaction with some downstream
signaling effector or for trans-phosphorylation of some tyrosine residues, such as Y762 [115]. A
study by Ahmad et al., suggests that K644E FGFR3 variant is not related to UCC [116]. The
mutations in the kinase domain including N540S, K650E, K650M, K650N, K650Q, and K650T
are rarer. FGFR3 gene mutations are also spotted in bladder cancer [117].
FGFR4: Different FGFR4 activating mutations in the kinase domain have been reported in 7-8%
of rhabdomyosarcomas, associated with advanced stage cancer and poor survival. Two of them
(N535K and V550E) occur at the auto-phosphorylation site, and thus induce constitutive
activation of the receptor. FGFR4 gene mutations are spotted in sarcomas.
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FGFRs mutations have been linked to various types of cancers. Correcting these
mutations, plausibly through gene therapy, can be expected to be a reliable treatment for cancers
ascribed to the FGFR mutations.
Therapeutic applications of FGF
Dysregulation of FGF signaling can lead to a variety of human conditions, such as
cancer, ineffective wound healing, metabolic syndrome, chronic kidney disease, and
cardiovascular diseases [118]. Tissue injury involves a complicated repairing process by which
some organisms can lead to complete regeneration of tissues. In the case of mammals, injury to
most tissues leads to scar formation [119]. Reparations and regeneration are demonstrated by a
large number of cytokines and growth factors. FGFs are the most effective growth factors that
control organogenesis and tissue homeostasis [120]. Since early 1980s, the US Wound Healing
Society and European Wound Management Association recommended FGFs for the treatment of
refractory ulcers. Some pharmaceutical companies such as Amgen, Merck, and Lilly have
significantly invested in the development of FGF-based drugs. Amongst the FGF family, FGF1,
FGF2, FGF7 (or keratinocyte growth factor 1 (KGF1)), and FGF10 (or keratinocyte growth
factor 2 (KGF2)) are integral to cutaneous wound healing [2].
There is a wide range of developing clinical applications for many different FGFs; however,
to stay relevant to the aims of this project, only those pertaining to hFGF1 will be examined.
FGF1 serves as a mitogen for different cell types [84]. However, FGF1/FGF2 double-knockout
mice do not exhibit any of the observable aberrations. These results suggest that the
developmental and physiological roles of FGF1 are highly restricted [121].
Immunohistochemical methods showed that expression of the FGF1 protein was undetectable in
intact skin, but it was mainly localized in higher amounts near the wound area and lesser at the
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edges. Moreover, in skin wounds, healing proteins were found in vast quantities around the
injury site and were produced by damaged inflammatory cells such as macrophages and noninflammatory cells such as endothelial cells. However, it has been shown that addition of growth
factors, including FGF1, to chronic wounds, can speed up the wound healing process and
enhance wound closure [122]. FGF1 has been effectively used as a possible therapy in many
cases that are characterized by damaged or diseased cells that require tissue regeneration such as
skin, nerves, blood vessels, and bone tissue. FGF1 promotes the migration of fibroblast and
keratinocyte cells to the wound area and accelerates the rate of angiogenesis, granulation, and
epithelialization processes [123]. Improvement in the deep burn wound along with an
acceleration in the healing time has been reported after applying recombinant human FGF1 (rhFGF1) at the injured site [124]. In China, rh-FGF1 was marketed specifically to cure the deep
second-degree burn wounds and chronic ulcers such as flat residual traumatic wounds, diabetic
ulcers, vascular ulcers, and bedsores [125]. The efficacy of the topical rh-FGF1 for treatment of
deep partial-thickness burn or skin graft donor sites was investigated by a randomized,
multicenter, double-blind, and placebo-controlled clinical trial [125]. Results showed that the
healing of burn wounds and skin graft donor sites treated by rh-FGF1 was significantly higher
than that observed in the placebo. Also, the mean healing time of burn wounds and skin graft
donor sites in the rh-FGF1 group was significantly shorter than that observed in the placebo
group. FGF1 has been used as a potential therapeutic to treat spinal cord injury and to assist
healing of deep burns or skin graft donor sites [125]. Several pharmacological and in vitro
studies have suggested that FGF1 maintains the integrity/function of the myocardium by acting
on the cardiomyocytes. Several pre-clinical studies have demonstrated that FGF1 is a promising
therapeutic strategy to improve myocardial survival and cardiac function, but there are several
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issues that complicate the clinical application of FGFs for acute myocardial infarction. One of
the issues is its interaction with heparin; exogenous heparin treatment, either with unfractionated
or low molecular weight (enoxaparin), is standard medical practice for patients with acute
myocardial infarction (MI). Thus, findings by Huang et al., demonstrate that FGF1 mutant with
reduced heparin binding affinity may be a promising strategy for acute treatment of MI; yet,
future studies are needed to address its long-term effects, post-MI [126]. FGF1 is also known to
act as an anti-diabetic agent. High-calorie diet might lead to an increase in insulin resistance, and
cause metabolic syndrome, obesity, type 2 diabetes mellitus (DM), and hypertension. However,
aggravating metabolic conditions reduce the neurogenic potential of hypothalamic neuro
progenitor cells, which contribute to a decreased central glucose sensing and peripheral glucose
clearance. Potentially, FGF1 remedies the debilitated hypothalamic state in DM by restoring the
number of glucose-sensing neurons, inducing neurogenesis, suppressing reactive astrocytes and
restoring synaptic functionality, which ultimately leads to the observed restoration of
normoglycemia. FGF1 with low mitogenic variants came up as an important candidate in
restoring euglycemia and did not lead to any side effects. The peripheral administration of FGF1
need hours to reach the normal glucose levels without facing hypoglycemic risk [127].
FGFs are modified either by adsorption or encapsulation within materials to ensure elevated
biological activity in a well-regulated manner. Several materials have been formulated to carry
the FGF drug and reduce their therapeutic ability and bioavailability, still, there is an immense
need to develop a more sustained and targeted drug delivery system.
Focus of this project
hFGF1 uniquely binds to all the four types of FGFRs and therefore it is often referred to
as a universal ligand. hFGF1 enhances proliferation of fibroblasts and embryonic cells, thereby
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regulating wound healing and angiogenesis. However, one of the disadvantages in using hFGF1
as a therapeutic agent is its low thermodynamic stability and short half-life in vivo. It is known
that specific binding to negatively charged heparin sulfate proteoglycans (HSPGs) increases the
stability of hFGF1. Nevertheless, the role of heparin in stabilization of hFGF1 and activation of
FGF-FGFR induced cell signaling has been a subject of debate. There have been reports which
show that heparin is essential for the cell proliferation activity of hFGF1 [26-29]. In marked
contrast, there are studies which show that the role of heparin is only restricted to conferring
stability to the growth factor. In this context, this project is divided into four distinct aims: 1)
overexpression, purification and characterization of the hFGF1 variants leading to the design of a
hyperstable and bioactive acidic fibroblast growth factor 2) design of a heparin independent
human acidic fibroblast growth factor variant 3) characterization of the structural forces
governing the reversibility of the unfolding of the human acidic fibroblast growth factor 4)
stability of sFGF1 with respect to the fluctuating pH conditions, aliphatic alcohols, and cell
culture media.
The first and second studies aim to enhance the inherent thermal stability, resistance to
proteases, and mitogenic activity of wtFGF1 using site directed mutagenesis. These mutations
were made on wtFGF1 as single, double, triple, quadruple, and penta mutants at positions 136,
126, 54, 61, and 107 (R136E, K126N, Q54P, S61L, and H107S). Two of these mutations
(R136E and K126N) belong to the heparin binding pocket so it was predicted that introduction of
negative charges in the heparin binding pocket would reduce the electrostatic interaction between
the dense cluster of positive charges and lead us to better understand of the role of heparin in
hFGF1 activation and cell signaling. Isothermal titration calorimetry and bioactivity assay results
have concluded that heparin binding is not mandatory for hFGF1 to perform its biological
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function. Heparin only aids in stabilization of the growth factor. These two studies lead to
generation of a hyper stable and heparin independent hFGF1 variant (sFGF1). sFGF1 is
anticipated to be more effective in treating variety of biomedical conditions, including wound
healing.
The third study aims at comprehending the effects of single, double and triple variants
(R136E, K126N, Q54P) on the conformational stability and reversible unfolding of hFGF1.
Equilibrium unfolding process of hFGF1 is irreversible and is known to exist in partially
unfolded state(s) close to physiological pH and temperature. This specific aim involves the use
of biophysical techniques like circular dichroism and fluorescence spectroscopy, nuclear
magnetic resonance, and molecular dynamics simulations to characterize the structural
determinants involved in refolding of the triple variant of hFGF1. The results obtained from
these studies could provide valuable clues in designing drugs against large number of amyloid
diseases.
The last chapter focusses on studying sFGF1’s ability to sustain conformational
fluctuations at varied pH conditions, resistance to proteases in DMEM cell culture media, and
stability in different aliphatic alcohols (ethanol, 2,2,2- trifluoroethanol (TFE), and acetonitrile).
Results of these studies might be useful for many biomedical applications, including drug
delivery and tissue engineering.

36

REFERENCES
[1] Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in
development, metabolism and disease. The Journal of Biochemistry. 2011 Feb
1;149(2):121-30.
[2] Hui Q, Jin Z, Li X, Liu C, Wang X. FGF family: from drug development to clinical
application. International journal of molecular sciences. 2018 Jul;19(7):1875.
[3] Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. TRENDS in Genetics.
2004 Nov 1;20(11):563-9.
[4] The Universal Protein Resource. The Universal Protein Resource for fibroblast growth
factor-15 in mouse. Available at: https://www.uniprot.org/uniprot/O35622.
[5] Kerr R, Agrawal S, Maity S, Koppolu B, et al. Design of a thrombin resistant human
acidic fibroblast growth factor (hFGF1) variant that exhibits enhanced cell proliferation
activity. Biochemical and biophysical research communications. 2019 Oct
15;518(2):191-6.
[6] Davis JE, Alghanmi A, Gundampati RK, et al. Probing the role of proline− 135 on the
structure, stability, and cell proliferation activity of human acidic fibroblast growth
factor. Archives of biochemistry and biophysics. 2018 Sep 15;654:115-25.
[7] Ornitz DM, Itoh N. Fibroblast growth factors. Genome biology. 2001
Mar;2(3):reviews3005-1.
[8] Wang YC, Peterson SE, Loring JF. Protein post-translational modifications and
regulation of pluripotency in human stem cells. Cell research. 2014 Feb;24(2):143-60.
[9] Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley
Interdisciplinary Reviews: Developmental Biology. 2015 May;4(3):215-66.
[10] Olsnes S, Klingenberg O, Wie˛ dłocha A. Transport of exogenous growth factors and
cytokines to the cytosol and to the nucleus. Physiological reviews. 2003 Jan 1;83(1):16382.
[11] Planque N. Nuclear trafficking of secreted factors and cell-surface receptors: new
pathways to regulate cell proliferation and differentiation, and involvement in cancers.
Cell Communication and Signaling. 2006 Dec 1;4(1):7.
[12] Bouleau S, Grimal H, Rincheval V, Godefroy N, Mignotte B, Vayssiere JL, Renaud F.
FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway.
Oncogene. 2005 Nov;24(53):7839-49.
[13] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy.
Nature reviews Drug discovery. 2009 Mar;8(3):235-53.

37

[14] Li Y, Sun C, Yates EA, Jiang C, Wilkinson MC, Fernig DG. Heparin binding preference
and structures in the fibroblast growth factor family parallel their evolutionary
diversification. Open biology. 2016 Mar 1;6(3):150275.
[15] Thallapuranam SK, Agarwal S, Gindampati RK, Jayanthi S, Wang T, Jones J, Kolenc O,
Lam N, Niyonshuti I, Balachandran K, Quinn K, inventors. Engineered fgf1 and fgf2
compositions and methods of use thereof. United States patent application US
16/356,872. 2019 Sep 19.
[16] Abraham JA, Whang JL, Tumolo A, et al. Human basic fibroblast growth factor:
nucleotide sequence and genomic organization. The EMBO Journal. 1986 Oct
1;5(10):2523-8.
[17] Bing M, Da‐Sheng C, Zhao‐Fan X, et al. Randomized, multicenter, double‐blind, and
placebo‐controlled trial using topical recombinant human acidic fibroblast growth factor
for deep partial‐thickness burns and skin graft donor site. Wound repair and regeneration.
2007 Nov;15(6):795-9.
[18] Higgins CA, Petukhova L, Harel S, Ho YY, Drill E, Shapiro L, Wajid M, Christiano AM.
FGF5 is a crucial regulator of hair length in humans. Proceedings of the National
Academy of Sciences. 2014 Jul 22;111(29):10648-53.
[19] Kook SH, Jeon YM, Lim SS, Jang MJ, Cho ES, Lee SY, Choi KC, Kim JG, Lee JC.
Fibroblast growth factor-4 enhances proliferation of mouse embryonic stem cells via
activation of c-Jun signaling. PloS one. 2013 Aug 13;8(8):e71641.
[20] Suzuki S, Ota Y, Ozawa K, Imamura T. Dual-mode regulation of hair growth cycle by
two Fgf-5 gene products. Journal of investigative dermatology. 2000 Mar 1;114(3):45663.
[21] Armand AS, Laziz I, Chanoine C. FGF6 in myogenesis. Biochimica et Biophysica Acta
(BBA)-Molecular Cell Research. 2006 Aug 1;1763(8):773-8.
[22] Zinkle A, Mohammadi M. Structural biology of the FGF7 subfamily. Frontiers in
Genetics. 2019 Feb 12;10:102.
[23] Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family.
Developmental dynamics: an official publication of the American Association of
Anatomists. 2008 Jan;237(1):18-27.
[24] Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nürnberg G, Lew ED, Dobbie A,
Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG. Mutations in different
components of FGF signaling in LADD syndrome. Nature genetics. 2006 Apr;38(4):4147.

38

[25] Osslund TD, Syed R, Singer E, Hsu EW, Nybo R, Harvey T, Arakawa T, Narhi LO,
Chirino A, Morris CF, Chen BL. Correlation between the 1.6 Å crystal structure and
mutational analysis of keratinocyte growth factor. Protein Science. 1998 Aug;7(8):168190.
[26] Friedl A, Chang Z, Tierney A, Rapraeger AC. Differential binding of fibroblast growth
factor-2 and-7 to basement membrane heparan sulfate: comparison of normal and
abnormal human tissues. The American journal of pathology. 1997 Apr;150(4):1443.
[27] Tsai SM, Wang WP. Expression and function of fibroblast growth factor (FGF) 7 during
liver regeneration. Cellular Physiology and Biochemistry. 2011;27(6):641-52.
[28] Kim N, Yamamoto H, Pauling MH, Lorizio W, Vu TH. Ablation of lung epithelial cells
deregulates FGF‐10 expression and impairs lung branching morphogenesis. The
Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology:
Advances in Integrative Anatomy and Evolutionary Biology. 2009 Jan;292(1):123-30.
[29] Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in
lung development, inflammation, and repair. American Journal of Physiology-Lung
Cellular and Molecular Physiology. 2002 May 1;282(5):L924-40.
[30] Tong L, Zhou J, Rong L, et al. Fibroblast growth factor-10 (FGF-10) mobilizes lungresident mesenchymal stem cells and protects against acute lung injury. Scientific reports.
2016 Feb 12;6(1):1-2.
[31] Terauchi A, Johnson-Venkatesh EM, Bullock B, Lehtinen MK, Umemori H. Retrograde
fibroblast growth factor 22 (FGF22) signaling regulates insulin-like growth factor 2
(IGF2) expression for activity-dependent synapse stabilization in the mammalian brain.
Elife. 2016 Apr 15;5:e12151.
[32] Boylan M, Anderson MJ, Ornitz DM, Lewandoski M. The Fgf8 subfamily (Fgf8, Fgf17
and Fgf18) is required for closure of the embryonic ventral body wall. Development.
2020 Nov 1;147(21).
[33] Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, Jacobson-Dickman
EE, Eliseenkova AV, Ma J, Dwyer A, Quinton R. Decreased FGF8 signaling causes
deficiency of gonadotropin-releasing hormone in humans and mice. The Journal of
clinical investigation. 2008 Aug 1;118(8):2822-31.
[34] Sunmonu NA, Li K, Li JY. Numerous isoforms of Fgf8 reflect its multiple roles in the
developing brain. Journal of cellular physiology. 2011 Jul;226(7):1722-6.
[35] Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, Zhang F, Linhardt
RJ, Joyner AL, Mohammadi M. Structural basis by which alternative splicing modulates
the organizer activity of FGF8 in the brain. Genes & development. 2006 Jan
15;20(2):185-98.

39

[36] Lewandoski M, Meyers EN, Martin GR. Analysis of Fgf8 gene function in vertebrate
development. InCold Spring Harbor symposia on quantitative biology 1997 Jan 1 (Vol.
62, pp. 159-168). Cold Spring Harbor Laboratory Press.
[37] Cholfin JA, Rubenstein JL. Patterning of frontal cortex subdivisions by Fgf17.
Proceedings of the National Academy of Sciences. 2007 May 1;104(18):7652-7.
[38] Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N, Takada S.
FGF18 is required for normal cell proliferation and differentiation during osteogenesis
and chondrogenesis. Genes & development. 2002 Apr 1;16(7):870-9.
[39] Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi
M, Kuro-o M, Mangelsdorf DJ, Kliewer SA. Research resource: comprehensive
expression atlas of the fibroblast growth factor system in adult mouse. Molecular
endocrinology. 2010 Oct 1;24(10):2050-64.
[40] Hotta Y, Sasaki S, Konishi M, Kinoshita H, Kuwahara K, Nakao K, Itoh N. Fgf16 is
required for cardiomyocyte proliferation in the mouse embryonic heart. Developmental
Dynamics. 2008 Oct;237(10):2947-54.
[41] Itoh N, Ohta H. Roles of FGF20 in dopaminergic neurons and Parkinson's disease.
Frontiers in molecular neuroscience. 2013 May 31;6:15.
[42] Liu Y, Ma J, Beenken A, Srinivasan L, Eliseenkova AV, Mohammadi M. Regulation of
receptor binding specificity of FGF9 by an autoinhibitory homodimerization. Structure.
2017 Sep 5;25(9):1325-36.
[43] Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova AV, Larochelle WJ,
Dhanabal M, Blais S, Ornitz DM, Day LA, Neubert TA. Homodimerization controls the
fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent
diffusion in the extracellular matrix. Molecular and cellular biology. 2009 Sep
1;29(17):4663-78.
[44] Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic
regulator. The Journal of clinical investigation. 2005 Jun 1;115(6):1627-35.
[45] Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21,
preferentially expressed in the liver. Biochimica et Biophysica Acta (BBA)-Gene
Structure and Expression. 2000 Jun 21;1492(1):203-6.
[46] Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in
mice. Endocrinology. 2008 Dec 1;149(12):6018-27.
[47] Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis
controls energy expenditure and insulin action in mice. Cell metabolism. 2013 May
7;17(5):790-7.

40

[48] Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE,
Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by
induction of FGF21. Molecular medicine. 2011 Jul;17(7):736-40.
[49] Hanssen MJ, Broeders E, Samms RJ, et al. Serum FGF21 levels are associated with
brown adipose tissue activity in humans. Scientific reports. 2015 May 18;5:10275.
[50] Itoh N. FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases.
Frontiers in endocrinology. 2014 Jul 7;5:107.
[51] Staiger H, Keuper M, Berti L, Hrabě de Angelis M, Häring HU. Fibroblast growth factor
21—metabolic role in mice and men. Endocrine Reviews. 2017 Oct 1;38(5):468-88.
[52] Giralt M, Gavaldà-Navarro A, Villarroya F. Fibroblast growth factor-21, energy balance
and obesity. Molecular and cellular endocrinology. 2015 Dec 15;418:66-73.
[53] Kilkenny DM, Rocheleau JV. The FGF21 receptor signaling complex: Klothoβ, FGFR1c,
and other regulatory interactions. InVitamins & Hormones 2016 Jan 1 (Vol. 101, pp. 1758). Academic Press.
[54] Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annual review of
physiology. 2016 Feb 10;78:223-41.
[55] Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney
disease–associated hyperparathyroidism yet increases mortality. The Journal of clinical
investigation. 2012 Jul 2;122(7):2543-53.
[56] Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a
causative factor of tumor-induced osteomalacia. Proceedings of the National Academy of
Sciences. 2001 May 22;98(11):6500-5.
[57] Shimada T, Hasegawa H, Yamazaki Y, et al. FGF‐23 is a potent regulator of vitamin D
metabolism and phosphate homeostasis. Journal of Bone and Mineral Research. 2004
Mar;19(3):429-35.
[58] Fukumoto S. Targeting fibroblast growth factor 23 signaling with antibodies and
inhibitors, is there a rationale? Frontiers in endocrinology. 2018 Feb 20;9:48.
[59] Bernett MJ, Somasundaram T, Blaber M. An atomic resolution structure for human
fibroblast growth factor 1. PROTEINS: Structure, Function, and Bioinformatics. 2004
Nov 15;57(3):626-34.
[60] Zhu X, Komiya H, Chirino A, Faham S, Fox GM, Arakawa T, Hsu BT, Rees DC. Threedimensional structures of acidic and basic fibroblast growth factors. Science. 1991 Jan
4;251(4989):90-3.

41

[61] Sweet RM, Wright HT, Janin J, Chothia CH, Blow DA. Crystal structure of the complex
of porcine trypsin with soybean trypsin inhibitor (Kunitz) at 2.6 Å resolution.
Biochemistry. 1974 Sep 1;13(20):4212-28.
[62] Brych SR, Blaber SI, Logan TM, Blaber M. Structure and stability effects of mutations
designed to increase the primary sequence symmetry within the core region of a β‐trefoil.
Protein Science. 2001 Dec;10(12):2587-99.
[63] Häcker U, Nybakken K, Perrimon N. Heparan sulphate proteoglycans: the sweet side of
development. Nature reviews Molecular cell biology. 2005 Jul;6(7):530-41.
[64] Schlessinger J, Plotnikov AN, Ibrahimi OA, et al. Crystal structure of a ternary FGFFGFR-heparin complex reveals a dual role for heparin in FGFR binding and
dimerization. Molecular cell. 2000 Sep 1;6(3):743-50.
[65] Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of
fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature. 2000
Oct;407(6807):1029-34.
[66] DiGabriele AD, Lax I, Chen DI, Svahn CM, Jaye M, Schlessinger J, Hendrickson WA.
Structure of a heparin-linked biologically active dimer of fibroblast growth factor.
Nature. 1998 Jun;393(6687):812-7.
[67] Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R. Structural
specificity of heparin binding in the fibroblast growth factor family of proteins.
Proceedings of the National Academy of Sciences. 2003 Mar 4;100(5):2357-62.
[68] Harmer NJ. Insights into the role of heparan sulphate in fibroblast growth factor
signalling. Biochemical Society Transactions. 2006 Jun 1;34(3):442-5.
[69] Arunkumar AI, Kumar TK, Kathir KM, Srisailam S, Wang HM, Leena PS, Chi YH,
Chen HC, Wu CH, Wu RT, Chang GG. Oligomerization of acidic fibroblast growth
factor is not a prerequisite for its cell proliferation activity. Protein science. 2002
May;11(5):1050-61.
[70] Angulo J, Hricovíni M, Gairi M, Guerrini M, De Paz JL, Ojeda R, Martín-Lomas M,
Nieto PM. Dynamic properties of biologically active synthetic heparin-like
hexasaccharides. Glycobiology. 2005 Oct 1;15(10):1008-15.
[71] Canales A, Lozano R, López‐Méndez B, Angulo J, Ojeda R, Nieto PM, Martín‐Lomas
M, Giménez‐Gallego G, Jiménez‐Barbero J. Solution NMR structure of a human FGF‐1
monomer, activated by a hexasaccharide heparin‐analogue. The FEBS journal. 2006
Oct;273(20):4716-27.

42

[72] Chi YH, Kumar TK, Wang HM, Ho MC, Chiu IM, Yu C. Thermodynamic
characterization of the human acidic fibroblast growth factor: Evidence for cold
denaturation. Biochemistry. 2001 Jun 26;40(25):7746-53.
[73] Culajay JF, Blaber SI, Khurana A, Blaber M. Thermodynamic characterization of
mutants of human fibroblast growth factor 1 with an increased physiological half-life.
Biochemistry. 2000 Jun 20;39(24):7153-8.
[74] Zakrzewska M, Krowarsch D, Wiedlocha A, Otlewski J. Design of fully active FGF-1
variants with increased stability. Protein Engineering Design and Selection. 2004 Aug
1;17(8):603-11.
[75] Zakrzewska M, Krowarsch D, Wiedlocha A, Olsnes S, Otlewski J. Highly stable mutants
of human fibroblast growth factor-1 exhibit prolonged biological action. Journal of
molecular biology. 2005 Sep 30;352(4):860-75.
[76] Wong P, Hampton B, Szylobryt E, Gallagher AM, Jaye M, Burgess WH. Analysis of
putative heparin-binding domains of fibroblast growth factor-1 using site-directed
mutagenesis and peptide analogues. Journal of Biological Chemistry. 1995 Oct
27;270(43):25805-11.
[77] Zakrzewska M, Wiedlocha A, Szlachcic A, Krowarsch D, Otlewski J, Olsnes S.
Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.
Journal of Biological Chemistry. 2009 Sep 11;284(37):25388-403.
[78] Dubey VK, Lee J, Somasundaram T, Blaber S, Blaber M. Spackling the crack: stabilizing
human fibroblast growth factor-1 by targeting the N and C terminus β-strand interactions.
Journal of molecular biology. 2007 Aug 3;371(1):256-68.
[79] Szlachcic, A., et al., Structure of a highly stable mutant of human fibroblast growth factor
1, Acta Cryst, 2009. D65: p. 67-73.
[80] Ortega, S., et al., Conversion of Cysteine to Serine Residues Alters the Activity, Stability,
and Heparin Dependence of Acidic Fibroblast Growth Factor, J Biol Chem, 1991. 266(9):
p. 5842-5846.
[81] Huang, Z., Tan, Y., Gu, J., Liu, Y., Song, L., Niu, J., Zhao, L., Srinivasan, L., Lin, Q.,
Deng, J. and Li, Y., 2017. Uncoupling the Mitogenic and Metabolic Functions of FGF1
by Tuning FGF1-FGF Receptor Dimer Stability. Cell reports, 20(7), pp.1717- 1728.
[82] Xia, X., Kumru, O. S., Blaber, S. I., Middaugh, C. R., Li, L., Ornitz, D. M., Suh, J. M.,
Atkins, A. R., Downes, M., Evans, R. M., Tenorio, C. A., Bienkiewicz, E., & Blaber, M.
(2016). An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1
Differentially Affects Mitogenic and Glucose-Lowering Activities. Journal of
pharmaceutical sciences, 105(12), 3507–3519.

43

[83] Lew ED, Furdui CM, Anderson KS, Schlessinger J. The precise sequence of FGF
receptor autophosphorylation is kinetically driven and is disrupted by oncogenic
mutations. Sci. Signal. 2009 Feb 17;2(58):ra6.
[84] Brewer JR, Mazot P, Soriano P. Genetic insights into the mechanisms of Fgf signaling.
Genes & development. 2016 Apr 1;30(7):751-71.
[85] Bae JH, Boggon TJ, Tomé F, Mandiyan V, Lax I, Schlessinger J. Asymmetric receptor
contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor
in living cells. Proceedings of the National Academy of Sciences. 2010 Feb
16;107(7):2866-71.
[86] Stauber DJ, DiGabriele AD, Hendrickson WA. Structural interactions of fibroblast
growth factor receptor with its ligands. Proceedings of the National Academy of
Sciences. 2000 Jan 4;97(1):49-54.
[87] Lin X, Zhang Y, Liu L, et al. FRS2α is essential for the fibroblast growth factor to
regulate the mTOR pathway and autophagy in mouse embryonic fibroblasts. International
journal of biological sciences. 2011;7(8):1114.
[88] Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor
receptors in carcinogenesis. Molecular Cancer Research. 2010 Nov 1;8(11):1439-52.
[89] Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007 Jun
29;129(7):1261-74.
[90] Lonic A, Barry EF, Quach C, Kobe B, Saunders N, Guthridge MA. Fibroblast growth
factor receptor 2 phosphorylation on serine 779 couples to 14-3-3 and regulates cell
survival and proliferation. Molecular and cellular biology. 2008 May 15;28(10):3372-85.
[91] Ahmed Z, Lin CC, Suen KM, et al. Grb2 controls phosphorylation of FGFR2 by
inhibiting receptor kinase and Shp2 phosphatase activity. Journal of Cell Biology. 2013
Feb 18;200(4):493-504.
[92] Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in
constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat
activation, and phosphatidylinositol 3-kinase activation. Molecular biology of the cell.
2001 Apr 1;12(4):931-42.
[93] Kong M, Wang CS, Donoghue DJ. Interaction of Fibroblast Growth Factor Receptor 3
and the Adapter Protein SH2-B a role in stat5 activation. Journal of Biological
Chemistry. 2002 May 3;277(18):15962-70.
[94] Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review.
Human pathology. 2010 Apr 1;41(4):461-76.

44

[95] Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, Van Etten
RA. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer cell. 2004 Mar
1;5(3):287-98.
[96] Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P,
Wang R, Lin SF, Cheng AJ. Identification of targetable FGFR gene fusions in diverse
cancers. Cancer discovery. 2013 Jun 1;3(6):636-47.
[97] Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in
human glioblastoma. Science. 2012 Sep 7;337(6099):1231-5.
[98] Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder
cancer. Human molecular genetics. 2013 Feb 15;22(4):795-803.
[99] Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell
carcinoma of the lung. Journal of thoracic oncology. 2012 Dec 1;7(12):1775-80.
[100] Xian W, Pappas L, Pandya D, et al. Fibroblast growth factor receptor 1–transformed
mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer
research. 2009 Mar 15;69(6):2244-51.
[101] Sobhani N, Ianza A, D’Angelo A, et al. Current status of fibroblast growth factor
receptor-targeted therapies in breast cancer. Cells. 2018 Jul;7(7):76.
[102] André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258):
preclinical and clinical data in breast cancer. Clinical cancer research. 2013 Jul
1;19(13):3693-702.
[103] Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy
resistance and is a therapeutic target in breast cancer. Cancer research. 2010 Mar
1;70(5):2085-94.
[104] Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene amplification and
clinicopathological features in gastric cancer. British journal of cancer. 2012
Feb;106(4):727-32.
[105] Li SQ, Cheuk AT, Shern JF, et al. Targeting wild-type and mutationally activated FGFR4
in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One. 2013;8(10)
e76551.
[106] Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor
receptor (FGFR) pathway: the current landscape and barriers to clinical application.
Oncotarget. 2017 Feb 28;8(9):16052.

45

[107] Catalogue of Somatic Mutations in Cancer. Available at:
http://cancer.sanger.ac.uk/cosmic.
[108] Dodé C, Levilliers J, Dupont JM, et al. Loss-of-function mutations in FGFR1 cause
autosomal dominant Kallmann syndrome. Nature genetics. 2003 Apr;33(4):463-5.
[109] NIH Survillance epidemiology. Available at:
https://seer.cancer.gov/statfacts/html/breast.html.
[110] Snyder-Warwick AK, Perlyn CA, Pan J, Yu K, Zhang L, Ornitz DM. Analysis of a gainof-function FGFR2 Crouzon mutation provides evidence of loss of function activity in the
etiology of cleft palate. Proceedings of the National Academy of Sciences. 2010 Feb
9;107(6):2515-20.
[111] Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor
receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature
genetics. 1996 Jun;13(2):233-7.
[112] Chen L, Li C, Qiao W, Xu X, Deng C. A Ser365→ Cys mutation of fibroblast growth
factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe
achondroplasia. Human molecular genetics. 2001 Mar 1;10(5):457-66.
[113] Adar R, Monsonego‐Ornan E, David PE, Yayon A. Differential activation of cysteine‐
substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine
localization. Journal of Bone and Mineral Research. 2002 May;17(5):860-8.
[114] Di Martino E, L'hôte CG, Kennedy W, Tomlinson DC, Knowles MA. Mutant fibroblast
growth factor receptor 3 induces intracellular signaling and cellular transformation in a
cell type-and mutation-specific manner. Oncogene. 2009 Dec;28(48):4306-16.
[115] Ahmad I, Singh LB, Foth M, Morris CA, Taketo MM, Wu XR, Leung HY, Sansom OJ,
Iwata T. K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to
promote tumorigenesis in the skin and lung, but not in the bladder. Disease models &
mechanisms. 2011 Jul 1;4(4):548-55.
[116] Munro NP, Knowles MA. Fibroblast growth factors and their receptors in transitional cell
carcinoma. The Journal of urology. 2003 Feb 1;169(2):675-82.
[117] Vi JG, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in
human rhabdomyosarcomas that promote metastasis in xenotransplanted models. The
Journal of clinical investigation. 2009 Nov 2;119(11):3395-407.
[118] Zhang J, Li Y. Therapeutic uses of FGFs. InSeminars in cell & developmental biology
2016 May 1 (Vol. 53, pp. 144-154). Academic Press.

46

[119] Maddaluno L, Urwyler C, Werner S. Fibroblast growth factors: key players in
regeneration and tissue repair. Development. 2017 Nov 15;144(22):4047-60.
[120] Tanaka EM. The molecular and cellular choreography of appendage regeneration. Cell.
2016 Jun 16;165(7):1598-608.
[121] Miller DL, Ortega S, Bashayan O, Basch R, Basilico C. Compensation by fibroblast
growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in
FGF2 null mice. Molecular and cellular biology. 2000 Mar 15;20(6):2260-8.
[122] Abraham JA, Whang JL, Tumolo A, et al. Human basic fibroblast growth factor:
nucleotide sequence and genomic organization. The EMBO Journal. 1986 Oct
1;5(10):2523-8.
[123] Weich HA, Iberg N, Klagsbrun M, Folkman J. Expression of acidic and basic fibroblast
growth factors in human and bovine vascular smooth muscle cells. Growth Factors. 1990
Jan 1;2(4):313-20.
[124] Feige JJ, Baird A. Glycosylation of the basic fibroblast growth factor receptor. The
contribution of carbohydrate to receptor function. Journal of Biological Chemistry. 1988
Oct 5;263(28):14023-9.
[125] Bing M, Da‐Sheng C, Zhao‐Fan X, et al. Randomized, multicenter, double‐blind, and
placebo‐controlled trial using topical recombinant human acidic fibroblast growth factor
for deep partial‐thickness burns and skin graft donor site. Wound repair and regeneration.
2007 Nov;15(6):795-9.
[126] Huang C, Liu Y, Beenken A, et al. A novel fibroblast growth factor-1 ligand with
reduced heparin binding protects the heart against ischemia-reperfusion injury in the
presence of heparin co-administration. Cardiovascular research. 2017 Nov
1;113(13):1585-602.
[127] Gasser E, Moutos CP, Downes M, Evans RM. FGF1—a new weapon to control type 2
diabetes mellitus. Nature Reviews Endocrinology. 2017 Oct;13(10):599-609.

47

CHAPTER II
Overexpression, Purification and Characterization of the hFGF1 Variants Leading to the
Design of a Hyperstable and Bioactive Acidic Fibroblast Growth Factor (sFGF1)
Abstract
Human acidic fibroblast growth factor (hFGF1) regulates key cellular processes such as
cell proliferation, cell differentiation, angiogenesis, and tumor growth. hFGF1 is known to have
low in vivo half-life and low melting temperature in the physiological range (Tm -37˚C). Binding
of heparin to hFGF1 increases the stability of the growth factor. Moreover, it is believed that
heparin is mandatory for the activation of FGF-FGFR complex formation and signaling. Thus,
the main objective of this study is to build a hFGF1 variant which is entirely heparin independent
yet possess elevated biological activity. In this context, successful expression, production, and
purification of single, double, triple, and quadruple variants leading to the highly stable variant,
superFGF1 (sFGF1) is achieved by introduction of mutations in wtFGF1. After obtaining the
pure protein(s), all the variants are characterized using biophysical methods to monitor the
overall structure, conformational stability, and backbone flexibility. The bioactivities of the
designed variants are monitored using cell proliferation assay. The results of this study show that
no major structural changes are caused due to the mutations leading to sFGF1. Additionally,
limited enzymatic digestion and ANS binding experiments reveal that the mutations leading to
sFGF1 render the growth factor more resistance to proteolytic enzymes and also results in
decreasing the flexibility than the wtFGF1 molecule. Isothermal titration calorimetry data
suggest that the heparin binding affinity is significantly decreased due to the introduction of
R136E/K126N mutation. Thermal equilibrium unfolding data demonstrate that all mutations
exhibit higher Tm in comparison to wtFGF1. Overall, the results of this study indicate that
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introduction of specific mutations of R136E, K126N, S61L, H107S and Q54P into wtFGF1
causes hFGF1 variants (R136E/K126N, R136E/K126N/Q54P, R136E/K126N/S61L,
R136E/K126N/H107S, R136E/K126N/Q54P/S61L, and R136E/K126N/Q54P/H107S) to lose its
heparin binding affinity, enhance its thermal, chemical, and proteolytic stability, and gain
mitogenic activity.
Introduction
Growth factors are a large class of biomolecules that promote cell growth, development,
and differentiation. Fibroblast growth factors (FGFs) are a family of twenty-two related proteins
that are involved in mitogenic and cell-survival activities. All members of the FGF family show
strong mitogenic properties that are essential for proper growth and development [1-3]. FGFs
play a vital role in many biological processes, including cell proliferation and angiogenesis [4].
One member of this family is the protein known as acidic fibroblast growth factor (FGF1). The
human FGF1 (hFGF1) is a ~16kDa, positively charged, heparin-binding monomeric protein. The
wild-type hFGF1 has a relatively short half-life of 5 minutes and low thermal stability in the
body, with a melting temperature (Tm - 41°C) close to the physiological range [5].
The stability of hFGF1 increases as a consequence of binding to heparin, which also
protects the protein against proteolytic digestion and denaturation via heat. Heparin is a
negatively charged glycosaminoglycan of repeating disaccharide chains of L-iduronic acid and
D-glucosamine, which binds to the cluster of positively charged amino acids on hFGF1, known
as the heparin binding region [6]. It has been long debated whether heparin is essential for
hFGF1 to bind to fibroblast growth factor receptors (FGFRs) since it plays an important role in
stabilizing the protein. This added stability allows hFGF1 to have more time to interact with
FGFRs, a family of receptor tyrosine kinases (RTKs), on the surface of cell membranes,
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stimulating intracellular signaling pathways that lead to processes such as cell proliferation, cell
differentiation, and cell migration. hFGF1’s inherent instability stems from the repulsive
electrostatic forces of positively charged amino acid residues in the heparin-binding region
making hFGF1 to be more susceptible to proteolytic cleavage and degradation. The threedimensional solution structure of hFGF1, determined using multidimensional nuclear magnetic
resonance (NMR) technique demonstrates that hFGF1 consists of twelve β-strands arranged in an
antiparallel fashion into a β-barrel structure [7-10].
One of the wild-type hFGF1 (wtFGF1) variant called R136E has been found to gain
stability and enhanced bioactivity, which appears to be beneficial for potential pharmaceutical
use in wound healing medications [11-15].
Most of these hFGF1 variants have been constructed based on the introduction of point
mutations into the receptor binding site and heparin binding pocket of hFGF1; thus, increasing
its stability. Prior work conducted in our lab demonstrated that mutations in the heparin binding
pocket can modulate the stability and mitogenic activity, which is the basis of this project [1619]. This chapter is focused on generating double, triple, and quadruple variant(s) of hFGF1 with
four more mutations on R136E-FGF1 using site directed mutagenesis. The four mutations made
on R136E are K126N, S61L, Q54P, and H107S (Fig. 1).

50

wtFGF1:
MFNLPPGNYK KPKLLYCSNG GHFLRILPDG TVDGTRDRSD QHIQLQLSAE SVGEVYIKST
ETGQYLAMDT DGLLYGSQTP NEECLFLERL EENHYNTYIS KKHAEKNWFV GLKKNGSCKR
GPRTHYGQKA ILFLPLPVSS D
sFGF1:
MFNLPPGNYK KPKLLYCSNG GHFLRILPDG TVDGTRDRSD PHIQLQLLAE SVGEVYIKST
ETGQYLAMDT DGLLYGSQTP NEECLFLERL EENSYNTYIS KKHAEKNWFV GLNKNGSCKR
GPETHYGQKA ILFLPLPVSS D

Fig. 1: Amino acid sequence of wtFGF1. The residues highlighted in green represent the amino
acids that are mutated to construct sFGF1. Correspondingly, the residues in red represent the
mutated residues in wtFGF1 (R136E, K126N, Q54P, S61L, and H107S).
R136E and K126N mutations were chosen because they are both located in hFGF1’s
heparin-binding region (Fig. 2). The R136E mutation replaced a polar positively charged amino
acid with a polar negatively charged one [20]. The K126N mutation replaced a polar positively
charged amino acid with a polar neutral amino acid. Replacement of the lysine residue with
another negatively charged residue can potentially cause repulsion between the two negatively
charged residues; therefore, we replaced lysine with a neutral amino acid (Asn). Since, trypsin
cleaves at the C-terminal of arginine and lysine residues, mutating an Arg to Glu and a Lys to
Asn will increase the variant hFGF1’s resistance to trypsin digestion. Moreover, R136 is the
secondary thrombin cleavage site in hFGF1. Mutating R136 to Glu will significantly reduce the
chances of hFGF1 being cleaved by thrombin. There will also be less repulsion between the
positively charged amino acid residues in the heparin-binding region, which can plausibly lead to
increase the inherent stability of the hFGF1. Histidine at position 107 plays an important role in
receptor binding and interacts with R251 and R255 of D2 and D3 domain of the FGFR. Both the
positively charged amino acids (Arg and His) might repel at the receptor binding site; therefore,
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we have substituted histidine with serine. S61 lies close to the hydrophobic pocket in the
structure of hFGF1. So, the mutation of Ser, a polar amino acid to Leu, a non-polar amino acid is
expected to increase the stability of hFGF1 by rendering it more compact [21-23]. Lastly, it has
already been known that Pro rearranges the β-turn geometry and forms a short 310- helix [13].
This 310- helix is expected to form two continuous overlapping type I β-turns. Thus, substitution
of Gln to Pro might provide more stability to hFGF1 by increasing the β-strand interactions.

Fig. 2: Ribbon representation of hFGF-1 structure (PDB ID: 1RG8) showing the location of
mutated residues.
The objective of this chapter is to shed light on the structural forces that contribute to
high stability of these mutations. As altering the primary amino acid sequence can potentially
alter the secondary and tertiary structure of the protein, measures were taken to ensure that the
three-dimensional structure of the variants is not significantly altered. Structural analyses were
conducted to study the role of the amino acid mutations on hFGF1 variants contributing to its
higher stability and enhanced biological function. In summary, all the single, double, triple and
quadruple variants have been found to have a higher inherent stability and a reduced affinity for
heparin as compared to wtFGF1.
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Results and discussion
Human acidic fibroblast growth factor (hFGF1) is a 155-amino acid, an all 𝛽-sheet
protein. The heparin binding pocket (HBP) on hFGF1 constitutes the region between residues
124 and 140 (Fig. 2). The heparin binding site carries net positive charge attributed by the six
polar, basic amino acids at physiological pH [24]. Previous studies on hFGF1 have shown that
due to the repulsion between these positive residues in HBP, hFGF1 is unstable and it is unlikely
that hFGF1 will complex with the FGF receptor. Therefore, binding of hFGF1 to the negatively
charged heparin provides stability to the growth factor [25].
Construction and purification of pure wtFGF1 and its variants
The single (R136E), double (R136E/K126N), (R136E/S61L), (R136E/H107S),
(R136E/Q54P), triple (R136E/K126N/S61L), (R136E/K126N/Q54P), (R136E/K126N/H107S),
and quadruple (R136E/K126N/Q54P/S61L), (R136E/K126N/Q54P/H107S) variants were
designed and transformed into the multiple cloning site of pET-20b vector. wtFGF1 and the
variants were overexpressed in BL21-plysS cells in lysogeny broth (LB) media. As hFGF1 is a
heparin binding protein, wtFGF1 and the designed variants were purified by heparin sepharose
affinity column chromatography. The proteins were eluted using a stepwise salt (sodium
chloride) gradient. Pure wtFGF1 was eluted with 1.5M sodium chloride concentration, whereas,
R136E single variant and double variants (R136E/Q54P, R136E/S61L, and R136E/H107S) were
eluted with 0.8M sodium chloride. However, R136E/K126N variant, and the triple and quadruple
variants were eluted from the column using 10 mM phosphate buffer with 0 mM NaCl,
suggesting no heparin binding affinity for hFGF1 (Fig. 3). Correspondingly, the binding affinity
of the R136E/K126N variant, and the triple and quadruple variants is weaker than that of the
non-heparin binding E. coli proteins, which non-specifically bind to the heparin beads.
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Fig. 3: SDS-PAGE analysis of proteins (A - wtFGF1 and B - R136E/K126N) eluted upon
heparin sepharose chromatography at different concentrations of NaCl. Panel-A: Pure wtFGF1
(Lane-1); Supernatant (Lane-2); 10 mM PB + 0 mM NaCl (Lane-3); 10 mM PB + 100mM
NaCl (Lane-4); 10 mM PB + 300 mM NaCl (Lane-5); 10 mM PB + 500 mM NaCl (Lane-6); 10
mM PB + 800 mM NaCl (Lane-7); 10 mM PB + 1500 mM NaCl (Lane-8). Panel-B: Supernatant
(Lane-1); 10 mM PB + 0 mM NaCl (Lanes 2-5); 10 mM PB + 300 mM NaCl (Lane-6); 10 mM
PB + 800 mM NaCl (Lane-7); Marker-pure wtFGF1 (Lane-8).
To remove minor bacterial impurities, R136E/K126N variant, the triple variants and
quadruple variants were further subjected to S-75 size-exclusion column chromatography. The
revealed three peaks – the first major peak comprised of high molecular weight E.coli
contaminants followed by a middle peak corresponding to the molecular weight of hFGF1
variant, and a third peak corresponding to low molecular weight E.coli contaminants (Figs. 4 and
5).

54

mAU

R136E/K126N
variant
Higher
molecular
weight
contaminants

Lower
molecular
weight
contaminants

Volume (milliliters)

Fig. 4: Elution profile of the R136E/K126N variant (M.W- 15.9 kDa) from a S-75 size-exclusion
column.
The yields of purified wtFGF1 and the variants were in the range of 25-30 mg/L of the
bacterial culture (Table 1). The results of purification suggest a positive co-relation between the
salt concentration at which hFGF1 elutes out of the heparin sepharose column and heparin
binding affinity of hFGF1.

Fig. 5: Analysis of size-exclusion chromatographic profile by SDS-PAGE. wtFGF1 (Lane-1);
sFGF1 (Lane-2); R136E (Lane-3); R136E/K126N (Lane-4); R136E/Q54P (Lane-5);
R136E/S61L (Lane-6); R136E/H107S (Lane-7); R136E/K126N/Q54P (Lane-8);
R136E/K126N/S61L (Lane-9); R136E/K126N/H107S (Lane-10); R136E/K126N/Q54P/S61L
(Lane-11); 136E/K126N/Q54P/H107S (Lane-12).
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Table 1: Protein yield of wtFGF1 and the variants.
hFGF1 variants
wtFGF1
R136E
R136E/K126N
R136E/H107S
R136E/S61L
R136E/Q54P
R136E/K126N/Q54P
R136E/K126N/S61L
R136E/K126N/H107S
R136E/K126N/Q54P/S61L
R136E/K126N/Q54P/H107S

Protein yield (mg/L)
29 ± 0.408
29.2 ± 0.510
27.14 ± 0.914
26.8 ± 1.54
27.6 ± 1.60
27.93 ± 1.36
25.8 ± 0.618
28.2 ± 0.338
27.7 ± 0.74
26.81 ± 0.702
27.92 ± 0.654

Mutations in hFGF1 does not cause significant structural change
wtFGF1 is known to contain one tryptophan (W121) and eight tyrosine residues. The
fluorescence spectrum is analyzed by examining the presence or absence of peaks at 305 nm and
350 nm. hFGF-1’s lone tryptophan residue is typically quenched by adjacent proline and lysine
resides in the native state. Therefore, wtFGF1 shows an emission maximum at 305 nm
corresponding to the eight tyrosine residues in the native protein. These quenching effects are
completely relieved in the denatured state(s) of the protein, resulting in a significant increase in
the fluorescence at 350 nm characteristic for tryptophan residues. Fig. 6 displays the overlay of
intrinsic fluorescence spectra of wtFGF1 and its variants. The presence of tyrosine peak at 305
nm and absence of tryptophan peak at 350 nm indicates that the mutations did not alter the
tertiary structure of wtFGF1. The broadening of peak at 340 nm corresponds to the emission of
the previously quenched tryptophan residues.
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Fig. 6: Overlay of the Fluorescence spectra showing the similarity in the tertiary structure of
wtFGF1 and the designed variants. wtFGF1 (pink), R136E (orange), K126N-DM (gray), Q54PDM (yellow), S61L-DM (purple), H107S-DM (green), Q54P-TM (blue), S61L-TM (red),
H107S-TM (dark green), H107S-QM (teal), and S61L-QM (brown).
Far-UV CD spectra is a valuable technique for examining the secondary structure of
proteins in solution. The overlay of far-UV CD spectra of wtFGF1 and the variants shows no
apparent changes in the overall secondary structure of the variant protein (Fig. 7). The negative
peak at 210 nm (class II β‐protein structure) and the positive peak at 228 nm (β‐turns, loops and
aromatic side chains) show that the characteristic secondary (β -trefoil) structure of wtFGF1 is
preserved in all the variants.
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Fig. 7: Overlay of the Circular dichroism (CD) spectra of wtFGF1 and its variants. wtFGF1
(pink), R136E (orange), K126N-DM (gray), Q54P-DM (yellow), S61L-DM (purple), H107SDM (green), Q54P-TM (blue), S61L-TM (red), H107S-TM (dark green), H107S-QM (teal), and
S61L-QM (brown).
Introduction of the R136E mutation renders the hFGF1 molecule more compact
8-anilino-1-nathalenesulfonate (ANS) is a non-polar fluorescent dye that is widely used
to determine the presence of solvent-exposed hydrophobic surfaces in proteins [26]. The data in
Fig. 8 (Panel - A and B) depicts the binding of ANS to wtFGF1. The relative fluorescent
intensity is directly proportional to the number of ANS molecules bound to the protein.
Normally, hydrophobic residues are buried inside the protein core. Therefore, increase in the
ANS fluorescence suggests exposure of these hydrophobic residues towards the surface of the
protein. The plot from the ANS binding assay (Fig. 8) indicates that the solvent-exposure of nonpolar surfaces in the structures of wtFGF1 and the variants do not vary significantly from each
other. Also, this data indicates that the maximum solvent exposure of hydrophobic surface(s) is
seen in wildtype in the absence of heparin. This suggests that wtFGF1, when not bound to
heparin, is more flexible. On the other hand, R136E, R136E/S61L, R136E/Q54P, and
R136E/H107S variants exhibit decreased flexibility and increased compactness compared to
R136E/K126N, the triple variants and quadruple variants. The ANS fluorescence decreases for
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R136E, R136E/S61L, R136E/Q54P, and R136E/H107S when exposed to heparin whereas,
R136E/K126N, the triple variants and the quadruple variants do not show any difference in the
ANS fluorescence when bound to heparin which infers that R136E, R136E/S61L, R136E/Q54P,
and R136E/H107S variants are more stable upon binding to heparin. Overall, the results of ANS
binding experiments suggest that R136E/K126N variant, the triple variants and quadruple
variants possess fewer solvent-accessible non-polar surfaces as compared to wtFGF1.

A

B

Fig. 8: ANS binding curves of wtFGF1 and the variants in the, absence (Panel-A) and presence
of heparin (Panel-B). The presence of solvent-exposed hydrophobic regions in the proteins were
monitored by changes in relative fluorescence intensity at 510 nm. wtFGF1 (blue), R136E
(orange), K126N-DM (gray), Q54P-DM (yellow), S61L-DM (purple), H107S-DM (green),
Q54P-TM (pink), S61L-TM (red), H107S-TM (dark green), H107S-QM (teal), and S61L-QM
(brown).
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Introduction of the R136E mutation makes the hFGF1 molecule resistant to the proteolytic
action
Trypsin, a serine protease, specifically cleaves polypeptides at the carboxyl end of
positively charged amino acids - lysine and arginine [27]. wtFGF1 contains three arginine and
nine lysine residues. Therefore, limited trypsin cleavage is performed to understand if the
conformational flexibility of the arginine and lysine residues are altered due to introduction of
the mutations in wtFGF1; thereby, monitoring the conformational flexibility of the protein. It can
be inferred from Fig. 9 that wtFGF1 (Panel-A) is susceptible to trypsin digestion and gets
completely degraded in the first 20 minutes, whereas the R136E/K126N variant is resistant to the
action of trypsin (Panel-B).

A

B

Fig. 9: SDS-PAGE analysis of limited trypsin digestion of wtFGF1 (Panel – A) and
R136E/K126N (Panel-B) variant. 0.5 mg/mL of proteins (Lane-1); 4 minutes (Lane-2); 6
minutes (Lane-3); 10 minutes (Lane-4); 15 minutes (Lane-5); 30 minutes (Lane-6); 45 minutes
(Lane-7); 60 minutes (Lane-8); 5 mg/mL of trypsin (Lane-9).

The densitometric analysis results suggest that all the variants (R136E, R136E/S61L,
R136E/Q54P, R136E/H107S, R136E/K126N, R136E/K126N/S61L, R136E/K126N/Q54P,
R136E/K126N/H107S, R136E/K126N/Q54P/S61L, and R136E/K126N/Q54P/H107S) showed
complete resistance against trypsin whereas wtFGF1 was digested by 80% in the first 20 minutes
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(Fig. 10). These results clearly indicate that the variants resulting from the manipulation of
wtFGF1 decrease the backbone flexibility and consequently increase the resistance of protein to
proteolytic digestion. This result corroborates the inference drawn from the ANS binding
experiment.
A

B

Fig. 10: Densitometric analysis of limited trypsin digestion of wtFGF1 and the designed variants
as monitored by SDS-PAGE in the absence of heparin (Panel-A) and presence of heparin (PanelB). wtFGF1 (blue), R136E (orange), K126N-DM (gray), Q54P-DM (yellow), S61L-DM
(purple), H107S-DM (green), Q54P-TM (pink), S61L-TM (red), H107S-TM (dark green),
H107S-QM (teal), and S61L-QM (brown).
Besides being present at the wound site to help in blood clot formation, thrombin is also
known to cleave hFGF1 at R136 and make it biologically inactive. In this regard, resistance of
hFGF1 to thrombin is imperative [28]. Limited thrombin experiment was performed to examine
subtle changes in the flexibility of the protein backbone caused by the introduction of mutations
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in wtFGF1. The data in Fig. 11 depicts the undigested proteins (wtFGF1 and the hFGF1 variants)
after 72 hours of thrombin exposure. The densitometric analysis results elucidate that all the
variants- R136E, R136E/S61L, R136E/Q54P, R136E/H107S, R136E/K126N,
R136E/K126N/S61L, R136E/K126N/Q54P, R136E/K126N/H107S, R136E/K126N/Q54P/S61L,
and R136E/K126N/Q54P/H107S show complete resistance against thrombin whereas wtFGF1 is
completely degraded within the first 24 hours.
A

B

Fig. 11: Densitometric analysis of the limited thrombin digestion of R136E and the double
variants (Panel - A), the triple and quadruple variants (Panel – B) over 72 hours at protein
concentrations of 33 µM and 165 µM of thrombin. Panel – A: wtFGF1 (blue), R136E (brown),
K126N-DM (red), Q54P-DM (teal), S61L-DM (green), H107S-DM (golden). Panel – B:
wtFGF1 (blue), Q54P-TM (yellow), S61L-TM (red), H107S-TM (green), H107S-QM (teal), and
S61L-QM (gray).
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ANS binding and limited enzymatic digestion experiments lead us to an understanding
that the designed variants of hFGF1 render decreased flexibility to the growth factor. The
reversal of charge at position 136 (R136E) produces a counter-ion effect and aids in the partial
nullification of the repulsions experienced by closely placed positive charges in the heparin
binding pocket. The counterion effect introduced in the heparin binding pocket due to the
introduction of R136E mutation not only decreases the flexibility of the heparin binding pocket,
but also renders the FGF1 molecule more compact [12]. This aspect appears to make the
potential trypsin cleavage sites in hFGF1 less accessible to the enzyme. Another reason for the
increased resistance of the designed hFGF1 mutations might be due to the substitution of one of
the three arginine residues to glutamic acid (arginine is one of the trypsin cleavage site).
However, it is highly unlikely that substitution of just one Arg to Glu could decrease the
susceptibility of the protein to trypsin so predominantly in hFGF1 variant than wtFGF1. So, it
appears that the substitution of Arg to Glu changes the conformation flexibility by rendering the
molecule more compact due to the plausible introduction of a new electrostatic interaction
between E136 with a neighboring positively charged amino acid in the heparin binding pocket.
On the other hand, reduced susceptibility of the R136E variant to the action of thrombin could be
primarily because of the removal of secondary thrombin cleavage site (R136) caused by the
replacement of arginine to glutamic acid. Therefore, out of the other four mutations (K126N,
Q54P, S61L, H107S), R136E was chosen as the basis of the project. K126N mutation also lies in
the heparin binding pocket. It appears that substitution of Lys with Asn at position 126 led to
introduction of two new hydrogen bonds (N126-S130 and G129-N126). Thus, introduction of
new interactions happens to make the potential trypsin cleavage site in hFGF1 less accessible to
trypsin [29].
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Introduction of R136E/K126N/Q54P/S61L mutation increases the thermal stability of
hFGF1
The unfolding of the proteins under increasing temperature were monitored by the change
in intrinsic fluorescence intensity at 305 nm/350 nm. The intrinsic fluorescence spectrum of
properly folded wtFGF1 shows an emission maximum at around 305 nm, characteristic for the
eight tyrosine residues. The signal from the single tryptophan residue (Trp121) is completely
quenched by the surrounding lysine and proline residues. Upon unfolding, the tertiary structure
becomes more relaxed and the quenching effect is weakened (the nearby proline and lysine
residues move away from the indole ring or Trp), resulting in a significant increase in the
fluorescence at 350 nm, characteristic for tryptophan residues.

Fig. 12: Thermal stability analysis of the R136E (Panel – A) and double variants (Panel – B) in
the presence and absence of heparin. Panel – A: wtFGF1 with hep (orange), wtFGF1 without hep
(gray), R136E with hep (green), and R136E without hep (blue). Panel – B: wtFGF1 with hep
(red), wtFGF1 without hep (gray), H107S-DM with hep (dark green), H107S-DM without hep
(blue), S61L-DM with hep (orange), S61L-DM without hep (graphite), Q54P-DM with hep
(teal), Q54P-DM without hep (yellow), K126N-DM without hep (aqua), and K126N-DM with
hep (light green).
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The thermal stability data reveal that the R136E/K126N/Q54P/S61L mutation is the most
stable design of all the hFGF1 variants, with the Tm being 62 ± 0.23˚C in the absence of heparin
and 63 ± 0.36˚C in the presence of heparin (Fig. 13D).
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Fig. 13: Thermal stability analysis of the triple variants (Panel -A) and quadruple variants (Panel
– B) in the presence and absence of heparin. Panel – A: wtFGF1 without hep (red), wtFGF1 with
hep (blue), Q54P-TM with hep (teal), Q54P-TM without hep (green), H107S-TM with hep
(aqua), H107S-TM without hep (orange), S61L-TM with hep (gray), and S61L-TM without hep
(yellow). Panel – B: S61L-QM with hep (blue), S61L-QM without hep (orange), H107S-QM
with hep (gray), and H107S-QM without hep (yellow).
It has also been shown in Table 2 that unlike the other variants tested, the thermal
stability of R136E/K126N (ΔTm - 2 ± 0.16˚C), the triple [R136E/K126N/S61L (ΔTm - 1 ±
0.02˚C), R136E/K126N/Q54P (ΔTm - 1 ± 0.15˚C), and R136E/K126N/H107S (ΔTm - 1 ±
0.05˚C)] and the quadruple variants [R136E/K126N/Q54P/S61L (ΔTm - 1 ± 0.13˚C),
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R136E/K126N/Q54P/H107S (ΔTm - 2 ± 0.04˚C)], is independent of heparin whereas the thermal
stability of the other double variants [R136E/S61L (ΔTm - 17 ± 0.05 ˚C), R136E/H107S (ΔTm 12 ± 0.23 ˚C), and R136E/Q54P (ΔTm - 10 ± 0.11 ˚C)] and the R136E variant (ΔTm - 9 ± 0.18
˚C) still depends on heparin, in fact, it increases in the presence of heparin (Figs. 12 and 13).
Tm is the denaturation temperature at which 50% of the protein population exists in the
denatured state(s). ΔTm (Tm with heparin - Tm without heparin) analysis of wtFGF1 shows that
heparin protects wtFGF1 from degrading at higher temperatures. Higher ΔTm value indicates
higher dependency of the growth factor on heparin. Of the four double variants (R136E/S61L,
R136E/H107S, R136E/Q54P, and R136E/K126N), R136E/K126N is the only variant, wherein
the ΔTm value was observed to drop by ~ 2˚C. This implies that the R136E/K126N variant of
hFGF1 has a higher inherent stability than the wtFGF1 alone. As R136E/K126N double variant
was the basis for the triple and the quadruple variant, it is reasonable to expect that these variants
do not exhibit heparin binding affinity.
Table 2: Comparison of the thermal stability of the wtFGF1 and the designed variants.
Δ Tm (Celsius)

42 ± 0.05

Tm with
heparin
(Celsius)
63 ± 0.08

R136E

52 ± 0.60

61 ± 0.42

9 ± 0.18

R136E/K126N

49 ± 0.25

51 ± 0.41

2 ± 0.16

R136E/H107S

46 ± 0.59

58 ± 0.82

12 ± 0.23

R136E/S61L

43 ± 0.04

60 ± 0.09

17 ± 0.05

R136E/Q54P

52.5 ± 0.12

62.5 ± 0.23

10 ± 0.11

R136E/K126N/Q54P

58.5 ± 0.17

59.5 ± 0.32

1 ± 0.15

R136E/K126N/S61L

63 ± 0.6

64 ± 0.62

1 ± 0.02

R136E/K126N/H107S

55 ± 0.26

56 ± 0.31

1 ± 0.05

R136E/K126N/Q54P/S61L

62 ± 0.23

63 ± 0.36

1 ± 0.13

R136E/K126N/Q54P/H107S

58 ± 0.17

60 ± 0.21

2 ± 0.04

hFGF1 variants

Tm without
heparin (Celsius)

wtFGF1

21 ± 0.03
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Overall, the thermal equilibrium unfolding data indicate that substituting Arg with Glu at
position 136, Lys by Asn at position 126, Gln by Pro at position 54, Ser by Leu at position 61,
and His by Ser at position 107 helped in stabilizing the growth factor. Out of all the variant
combinations, the highest thermal stability is exhibited by the quadruple variant
(R136E/K126N/Q54P/S61L) where the Tm without heparin is 62˚C, which is nearly 67% more
when compared to wtFGF1 in the absence of heparin (Tm - 42˚C). The thermal stability has a
positive relation with the half-life of a protein. It appears that K126N eliminates the heparin
binding affinity and S61L mutation confers higher thermal stability because replacement of
serine, a polar amino acid with leucine, a non-polar amino acid appears make the hFGF1
structure more compact. This compactness might strengthen the interactions (H-bond and salt
bridges) inside the protein core and stabilize the protein against thermal and enzymatic
degradation. These conclusions are consistent with the conclusions drawn from the limited
proteolytic digestion data.
The R136E/K126N variant causes complete loss of heparin binding affinity
Isothermal titration calorimetry (ITC) was used to directly determine the heparin binding
affinity of wtFGF1 and its variants. The binding affinities, reported as Kd values, are derived
from the ITC data (Fig. 14). A small Kd value indicates a high binding affinity, while a large Kd
value indicates a low binding affinity. Fig 14 depicts that the heparin binding affinity of R136E
(Kd - 4.2 µM), R136E/S61L (Kd - 4.5 µM), R136E/H107S (Kd - 4.6 µM), R136E/Q54P (Kd - 3.1
µM) is lower than that of wtFGF-1 (Kd - 1.6 µM). This infers that the hFGF1 variants exhibit
weaker heparin binding affinity than wtFGF1. Contrastingly, the R136E/K126N (Kd - could not
be determined) variant lacks the ability to bind to heparin suggesting that R136 and K126 are
critical for the heparin binding of hFGF1. The unusual heat changes in the isothermograms are

67

due to the electrostatic interactions between the charged heparin molecules and some of the
charged components present in the buffer. Furthermore, as R136E/K126N was the basis for the
third mutation, all the triple and quadruple variants lacked heparin binding affinity as shown in
Table 3. This data clearly suggests that the charge reversal at position 136 (R136E) and charge
neutralization at position 126 (K126N) are important residues for the heparin interaction.

Fig 14: Isothermograms representing titration of wtFGF1 and all the designed variants with
heparin.
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Table 3: Heparin binding affinity of wtFGF1 and its variants.
hFGF1 variants

Kd (µM)

wtFGF1

1.6

R136E

4.2

R136E/K126N

No binding

R136E/H107S

4.6

R136E/S61L

3.1

R136E/Q54P

4.5

R136E/K126N/Q54P

No binding

R136E/K126N/S61L

No binding

R136E/K126N/H107S

No binding

R136E/K126N/Q54P/
S61L
R136E/K126N/Q54P/
H107S

No binding
No binding

The complete loss of heparin binding affinity observed for the R136E/K126N variant but
not for R136E variant is probably due to the knockout of two positively charges residues in the
heparin binding region (Table 3). Examination of the X-ray crystal structure of acidic hFGF
shows that the region from residues 105-128 contains eight basic amino acids, making it
conducive for heparin binding. Perhaps, most significantly, the crystal structure of hFGF1
suggests that heparin interacts with K132, K126, and R136 [31]. Therefore, R136E variant
appears to decrease the heparin binding affinity by 2.5 times but could not knock down the
ability of hFGF1 to bind to heparin completely. On the other hand, substitution of two of the
three residues (K126N and R136E) located in the core heparin binding triad (K132, K126, and
R136) might lead to the complete knock down of hFGF1’s ability to bind to heparin. This is
expected because introduction of a negative charge and a neutral amino acid in the heparin
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binding pocket of hFGF1 could plausibly reduce the repulsion between the positively charged
amino acids. The reduction in the charge-charge repulsion in the heparin binding region might
have led to a heparin independent hFGF1 variant (R136E/K126N). The distance between the Cα
atoms of R136 from Cα atom of R133 (located in the middle of the heparin binding pocket) in
the absence of heparin is 7.15 Å and the distance between the Cα atoms of K126 from Cα atom
of R133 is 13.24 Å. In the presence of heparin, R136 and K126 shift moderately closer to R133
(~5.15 Å and 9.57 Å, respectively). Surprisingly, the distance of residues E136 and N126,
irrespective of the presence of heparin, is quite similar to the wtFGF1 in the presence of heparin
(E136 - 9.68 Å and N126 - 5.16 Å). This indicates that introduction of these two mutations
(R136E and K126N) bring conformational changes in the heparin binding region making the
hFGF1 molecule more compact and heparin independent.
Introduction of R136E variant enhances the bioactivity of hFGF1
hFGF1 is a heparin binding protein capable of stimulating mitogenic and angiogenic
responses in a variety of cell types. There have been several studies which suggest that heparin is
mandatory for the activation of the FGF receptor. In this context, decrease in heparin binding
affinity of hFGF1 variants to heparin can be expected to decrease the ability of the growth factor
variants to promote cell proliferation activity. However, comparison of the cell proliferation
activity of wtFGF1 with those observed for the different variants clearly show that lack of
heparin binding affinity of hFGF1 does not significantly affect their cell proliferation activity.
Out of all, only R136E, R136E/H107S, R136E/S61L, and R136E/Q54P are the hFGF1 variants
which exhibit reduced heparin binding affinity. The other variants (R136E/K126N,
R136E/K126N/Q54P, R136E/K126N/S61L, R136E/K126N/H107S, R136E/K126N/Q54P/S61L,
and R136E/K126N/Q54P/H107S) do not bind to heparin. Fig. 15A indicates that at all the
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concentrations of hFGF1, R136E exhibits higher cell proliferation activity than wtFGF1
although, the heparin binding affinity is lower than that of wtFGF1. Figs. 15 and 16 shows that
all the hFGF1 variants display higher mitogenic activity than wtFGF1 irrespective of their
heparin binding affinity.
A

B

Fig. 15: Cell proliferation activity of NIH 3T3 cells treated with wtFGF1 and R136E (Panel – A)
and wtFGF1 and double variants (Panel – B). 50 ng/mL (blue), 10 ng/mL (red), 2 ng/mL (green),
0.4 ng/mL (purple), and 0 ng/mL (aqua).
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Overall, this data suggests that there is no positive correlation between the heparin
binding affinity and the cell proliferation activity. There have been several reports which suggest
that heparin dependent hFGF1 activity is necessary for the receptor activation. Contrastingly,
there are other groups which demonstrate that the former is not true. Moscatelli et al., have
reported in their study that human FGF2 interacts with its receptor even when hFGF2 is not
bound to heparin [32]. Several site-directed mutagenesis reports on hFGF1 are working on
improving the proteolytic and enzymatic stability. A study by Ortega et al., where they substitute
the cysteine residues by serine (C30S, C131S, C97S) led to decreased heparin binding affinity,
yet the variants exhibited longer physiological half-life and increased mitogenic activity [14].
Similar observation was made by other groups, which showed that heparin binding is not
essential for the FGFR activation and inducing downstream signaling pathways [15, 33]. The
K132E mutation was observed to exhibit significantly lower heparin dependency as compared to
that of wthFGF1 [18, 33]. Additionally, Brych et al., reported that higher stability is directly
related to the higher bioactivity irrespective of heparin binding [15].

Fig. 16: Cell proliferation activity of NIH 3T3 cells treated with wtFGF1, triple and quadruple
variants. 50 ng/mL (blue), 10 ng/mL (red), 2 ng/mL (green), 0.4 ng/mL (purple), and 0 ng/mL
(aqua).
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Zakrzewska et al., examined the biological and biophysical properties of 17 variants of
hFGF1 which include single mutation of lysine residues (at positions 126 and 132), double
mutations of the same lysine residues and a few multiple variants where in along with lysine
mutation they included different combinations of Q54P, S61I, and H107G [13, 29]. It was
observed that the single mutation (K126N and K132E) exhibit reduced heparin affinity but yet
displayed higher mitogenic activity than wtFGF1. In case of the double substitution
(K132E/K126N), the variant exhibits strongly reduced affinity for heparin but did not show any
difference in the mitogenic activity in the presence or absence of heparin. However,
K126N/Q54P/S61I/H107G, a quadruple variant exhibited reduced heparin binding ability and
showed two-folds higher mitogenic activity than wtFGF1 in absence of heparin [16, 29]. In
conclusion, almost all the mutations exhibited reduced heparin binding affinity and prolonged
mitogenic activity in comparison to wtFGF1 [16, 17]. Most of the mutations were known to
increase the Tm up to 64°C. Thus, our results are in good agreement with many hFGF1 and
hFGF2 studies, which states that the FGF-FGFR complex can still be formed in the absence of
heparin and can lead to activation of the signaling complex.
Conclusions
The hFGF1-heparin complex is the most extensively studied protein-glycosaminoglycan
complex. There have been two opposing arguments regarding the role of heparin in the
biological function of hFGF1. X-ray crystal structure studies have established the fact that
heparin plays a critical role in the receptor activation of hFGF1. On the contrary, there have been
reports that demonstrate that heparin only improves the stability of hFGF1 through electrostatic
interactions. The results of the current study show that heparin appears to influence the stability
of the growth factor but has very little effect on the cell proliferation activity of the protein.
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Isothermal titration calorimetric results from this study show that the R136 and K126 positions
are critical for the heparin binding ability of hFGF1. The cell proliferation assay results were one
of the most important outcomes for the future application of this research, which concluded that
all the heparin-independent variants of hFGF1 show higher mitogenic activity than wtFGF1.
Overall, the results obtained in the current chapter suggest that introduction of specific mutations
of R136E, K126N, S61L, H107S and Q54P into wtFGF1 causes hFGF1 to lose its heparin
binding affinity, gain cell proliferation activity and enhance its thermal, chemical, and
proteolytic stability when compared to wtFGF1.

Materials and methods
Materials
Agilent was the producer for the site directed mutagenesis kit and the competent cells (XL-gold,
BL 21 plysS, BL 21 star). The plasmid isolation kit was obtained from Qiagen Inc., USA.
Lysogeny broth was purchased from IBI Scientific, USA. Heparin sepharose resin was obtained
from GE Healthcare, USA. VWR Scientific., USA supplied the buffer components (Na2HPO4,
NaH2PO4, NaCl). Low molecular weight (~3000 Da) heparin sodium salt was obtained from
Sigma and MP Biomedicals LLC. NIH 3T3 cells were obtained from ATCC and all the cell
culture reagents including, DMEM media, fetal bovine serum (FBS) and penicillin streptomycin
were purchased from Thermo Fisher Scientific (Waltham, MA). All other chemicals and
materials were of high-quality analytical grade. Due to the polydisperse nature of high molecular
weight of heparin, we have used low molecular weight heparin (M.wt ~ 3000 Da) for this study.
Unless otherwise stated, samples were made in 10 mM phosphate buffer saline (pH 7.2) and
incubated at 37 ºC.
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Construction and Purification of hFGF1 and the variants
Site-directed mutagenesis was employed to construct the mutations (R136E, K126N, Q54P,
S61L, and H107S) (Fig. 17, Table 4). For expression of hFGF1, BL-21star cells were grown to
an Optical Density of 0.6–8.0 at Abs of 600 and incubated with 1 mM isopropyl β-Dthiogalactoside for 2.5 hours. Cells were harvested and resuspended in 10 mM phosphate buffer
(PB). Cells were sonicated for 30 cycles with 20 second on/off pulses. Supernatant was separated
from the cell debris using centrifugation at 19,000 rpm for 30 minutes and subsequently passed
over heparin Sepharose affinity column that was then washed extensively with equilibration
buffer (10 mM phosphate buffer). The proteins were purified using step-wise sodium chloride
gradient. Certain variants were further purified using gel filtration chromatography. The hFGF1
variants were loaded onto a Superdex 75(S-75) column (GE Healthcare, Pittsburgh, PA)
equilibrated in 10 mM phosphate buffer and 100 mM NaCl, pH 7.2 on an AKTA FPLC and ran
at a flow rate of 1 milliliter per minute. The elution volume was monitored by absorbance at 280
nm. Fractions were collected and the purity of proteins were verified using 15% Sodium Dodecyl
Sulfate Poly Acrylamide Gel Electrophoresis (SDS-PAGE) followed by staining with Coomasie
brilliant blue. The concentration of the protein was quantified using the Bradford method
[24,25].

Fig. 17: pET20 expression vector with recombinant wtFGF1 gene and ampicillin resistant gene.

75

Table 4: Codon changes in E.coli corresponding to the mutations.
Amino acid change

Codon present in wtFGF1

Codon present in sFGF1

Arg to Glu

CGG

GAG

Lys to Asn

AAG

AAC

Ser to Leu

AGT

CTT

Gln to Pro

CAG

CCG

His to Ser

CAT

AGT

Circular Dichroism and fluorescence spectroscopy
Using a combo circular dichroism / fluorescence Jasco J-1500 Spectrophotometer dual
results of the CD and fluorescence spectra were obtained to determine the secondary and tertiary
structural changes of wtFGF1 and hFGF1 in the presence and absence of heparin. Circular
dichroism is used to determine the secondary structural changes in the protein. For analysis,
13µM of protein was added to 10 mM PB + 100 mM NaCl and loaded into a 0.1 cm path length
quartz cell. The wavelength of the spectrophotometer was set in a range of 190 - 250nm at 25ºC,
and the scanning speed was 20 nm/min. The data of CD was collected as an average of three
scans. The resultant CD data was expressed in terms of molar ellipticity.
Intrinsic fluorescence spectroscopy was used to examine any alternation in the tertiary
structure and folding of protein by combining 13 µM protein with 10 mM phosphate buffer (PB).
The excitation wavelength for the fluorescence measurements was 280 nm and the emission
were recorded from 300 – 450 nm. Intrinsic fluorescence was done at these wavelengths to study
if there were any changes among tyrosine and tryptophan residues, which fluoresce at 308 and
340 nm, respectively. A buffer subtraction was made to correct any background noise.
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8-Anilino-1-napthalenesulfonic acid (ANS) binding assay
ANS binding assay measurements were made using a Fluorescence Spectrophotometer F-2500
(Hitachi) with a slit width set to 2.5nm. Protein concentrations of 33 µM in phosphate buffer
containing 100 mM NaCl, pH 7.2 were placed in a quartz cuvette. Titrations using an ANS stock
were made by addition of 10 µM increments of ANS followed with mixing and incubation for 2
minutes preceding each reading at 25⁰C. Fluorescence intensity was determined with an
excitation at 380nm and emission intensity was recorded at 510nm.
Limited Trypsin and thrombin digestion
Limited trypsin digestion of hFGF1 and the variants was performed in phosphate buffer
containing 100 mM NaCl, pH 7.2. The initial reaction tube contained 50 µM of protein and 0.5
µg of enzyme. The trypsin and thrombin containing samples were incubated at room temperature
(25 °C) and 37 °C respectively. Digested samples were removed at specific intervals as noted in
the results section and then the reaction was stopped by the addition of 10% trichloroacetic acid
and the samples were resolved on a 15% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS− PAGE) gel and subsequently stained using Coomassie brilliant blue. The
percentage of enzymatic digestion was identified from the band intensity, on the SDS PAGE gel,
using UN-ScanIT densiometric software (Silk Scientiﬁc Inc.). hFGF1 samples which were not
subjected to the enzymatic digestion was considered as the control representing 100% undigested
hFGF1.
Equilibrium unfolding
Intrinsic fluorescence using the Jasco J-1500 Spectrophotometer was used to monitor the
unfolding nature of hFGF1 and the variants at increasing thermal intervals. The protein
concentration used was 50 µM in 10 mM phosphate buffer and 100 mM NaCl (pH 7.2). A
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temperature probe was inserted into the sample cell to heat the sample. Fraction of protein
unfolded was calculated from the ratio of the wavelength of emission maxima (305/350 nm)
observed during chemical denaturant titration. Thermal denaturation as probed by fluorescence
was carried by heating of samples at 5-degree increments for 5 minutes.
Isothermal titration calorimetry
The binding affinity of hFGF1 and the variants with heparin were measured using a Microcal
VP-ITC Micro Calorimeter. The wtFGF1 and the designed variants were prepared at a
concentration of 100 mM. Heparin in the syringe was at a concentration of 1000 mM (to
maintain a 1:10 protein: ligand ratio). All samples were degassed before loading. The volume of
heparin injections was 6 mL and a total of 49 titrations were performed at 25 °C. The data was
analyzed using Origin scientific plotting software.
Bioactivity Assay
3T3 fibroblast cells obtained from ATCC (Manassas, VA) were cultured in media consisting of
DMEM supplemented with 10% bovine calf serum. Cells were grown and were incubated
overnight at 37 C. The bioactivity of FGF1 was determined by quantifying the cell number
increase after the cells were incubated with hFGF1. Starved 3T3 fibroblasts were collected and
seeded in a well plate at a seeding density of 10,000 cells/well. The bioactivity assays were
performed five times under the same condition. 3T3 cell proliferation was assessed by the Cell
Titer-Glo (Promega, Madison, WI) cell proliferation assay after 24 hours.
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CHAPTER III
Design of a Human Acidic Fibroblast Growth Factor (hFGF1) Variant that has no Heparin
Binding Affinity
Abstract
Human acidic fibroblast growth factor (hFGF1) is a member of a family of polypeptides
that are involved in cell proliferation, cell differentiation, angiogenesis and wound healing.
hFGF1 is known to exhibit low half-life in vivo and has poor thermal and proteolytic stability
(Tm -37˚C). Binding of heparan sulfate, a glycosaminoglycan, stabilizes the protein and aids in
activation of the biological response. However, heparin binding affinity of hFGF1 can be a
significant disadvantage in healing topical wounds. In general, it is believed that high binding
affinity of both hFGF1 and thrombin to heparin potentially increases the probability of thrombin
to gain access to hFGF1 and render it inactive. In this context, generation of a bioactive hFGF1
variant that exhibits poor heparin binding may significantly decrease its susceptibility to
thrombin cleavage. Surprisingly, results of the current study show that super FGF1 (sFGF1)
exhibits enhanced cell proliferation activity, lacks heparin binding affinity, and shows an
increased activation of Erk and Akt pathways when compared to wtFGF1. Limited enzymatic
digestion and ANS binding experiments show that in comparison to wtFGF1, sFGF1 render less
flexibility and less susceptibility of hFGF1 to the action of trypsin and thrombin. Thermal and
urea equilibrium unfolding data suggest that sFGF1 exhibits significantly higher Tm (68˚C) and
Cm (3.6 M) when compared to wtFGF1 (Tm -37˚C and Cm -1.2 M). Isothermal titration
calorimetry data reveal that sFGF1 is the only known mutation till date which completely lacks
heparin binding affinity. Overall, the results for hyperthermal stability, resistance to the action of
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proteases, and enhanced heparin-independent bioactivity infer that sFGF1 can be used as a viable
target for wound healing.
Introduction
Human acidic fibroblast growth factor (hFGF1) is a 16kDa mitogen that is characterized
by its high affinity for heparin. It is one of the twenty-three different types of FGFs, all of which
are involved in crucial cell-survival activities [1-3]. FGFs are vital for embryonic and fetal
development, wound healing, bone fracture healing, neuroprotection, and tumor development
and progression [4,5]. Fibroblast growth factor (FGF) signals cellular processes by activating the
specific tyrosine kinase fibroblast growth factor receptors (FGFRs). Activated FGFRs in-turn
induce downstream signaling through some common pathways such as: mitogen activated
protein kinase (MAPK), phosphoinositide-3-kinase/AKT, and phospholipase-C pathways [6].
hFGF1 uniquely binds to all the four types of FGFRs; therefore, it is often referred to as a
universal ligand [7].
hFGF1 has an intrinsically low thermodynamic stability, and almost half of the wild type
hFGF1 population is unfolded at physiological pH and temperature [8-10]. FGFs have high
affinity for cell-surface proteoglycans, such as heparin sulfate (HSPGs) HSPGs are essential for
the protein regulation especially in signal transmission and chemical recruitment [11]. HeparinhFGF1 interaction mediates specific binding to the cell surface tyrosine kinase receptors,
fibroblast growth factor receptors (FGFRs) and as a result mediates FGFs’ biological response
[12]. Heparin is a highly sulfated glycosaminoglycan made up of 2-O-sulfated iduronic acid and
6-O-sulfated, N-sulfated glucosamine, IdoA(2S)-GlcNS(6S), linked by α‐(1→4) glycosidic
linkages. Binding of heparin to hFGF1 ensures stability and confers better interaction of hFGF1
to its receptor [13-15]. X-ray crystal and solution NMR structures of heparin-hFGF1 complex
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shows that the negatively charged heparin binds to the positively charged heparin binding region
located at the C-terminal of hFGF1 [20]. Heparin-binding site (HBS) in hFGF1 spans residues
between ß strands 1/2 and extends from the loop between β strands 9/10 to the loop between β
strands 11/12 [21]. Crystal structure data on FGF-FGFR-HS ternary complex revealed that
heparin promotes FGF signaling through the formation of a 2:2:2 or 2:2:1 (FGF: FGFR: HS)
complexes [22]. The cluster of positively charged amino acids in the heparin binding region is
accountable for the thermal and proteolytic instability of hFGF1 [9, 23, 24]. Therefore, it is
believed that the binding of heparin to hFGF1 increases the stability of the protein [25].
However, there is significant debate whether or not heparin is mandatory for effective
functioning of hFGF1. There have been reports which show that heparin is essential for the cell
proliferation activity of hFGF1 [26-29]. In marked contrast, there are also studies which show
that the role of heparin is only restricted to conferring stability to the growth factor [4, 8, 9-11,
30]. Interestingly, K132E mutation, in the heparin binding region has been shown to diminish the
heparin binding affinity of hFGF1 and exhibit significant loss of cell proliferation activity [39].
hFGF1 has also been shown to be susceptible to thrombin cleavage [16,1]. Although
hFGF1 lacks the primary thrombin cleavage site (-LVPRGS-), the enzyme has been known to
specifically cleave hFGF1 at position R136 and render it biologically inactive. In this context,
there have been several attempts to design hFGF1 variants that exhibit increased resistance to the
action of thrombin [17]. Thus, all the three molecules, (hFGF1 (for its cell proliferation activity),
thrombin (aid in blood clot formation), and heparin (to stabilize hFGF1 and act as an
anticoagulant) are present at wound site. Studies have shown that the relationship of heparin with
thrombin and hFGF1 at the wound site is competitive. Therefore, design of a heparin
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independent hFGF1 variant might decrease the competition and consequently increase the wound
healing potential of hFGF1 [1, 18].
Kerr et al., has designed an hFGF1 variant, R136E, which has higher thermal stability, is
more resistant to proteolytic degradation, and enhanced cell proliferation activity when compared
to wtFGF1. However, R136E variant exhibits heparin binding affinity. In this context, the main
objective of this chapter is to introduce mutations on R136E variant to further enhance its
stability and cell proliferation activity in a heparin independent manner. This study also aims to
understand the structural basis for the extraordinary properties introduced due to four additional
mutations (K126N, S61L, H107S, and Q54P) on R136E (Fig. 1) [19]. In this context, due to its
extraordinary stability and cell proliferation activity, we believe that it would be apt to name the
penta mutant of hFGF1 as super-hFGF1 (sFGF1).

wtFGF1:
MFNLPPGNYK KPKLLYCSNG GHFLRILPDG TVDGTRDRSD QHIQLQLSAE SVGEVYIKST
ETGQYLAMDT DGLLYGSQTP NEECLFLERL EENHYNTYIS KKHAEKNWFV GLKKNGSCKR
GPRTHYGQKA ILFLPLPVSS D
sFGF1:
MFNLPPGNYK KPKLLYCSNG GHFLRILPDG TVDGTRDRSD PHIQLQLLAE SVGEVYIKST
ETGQYLAMDT DGLLYGSQTP NEECLFLERL EENSYNTYIS KKHAEKNWFV GLNKNGSCKR
GPETHYGQKA ILFLPLPVSS D

Fig. 1: Amino acid sequence of wtFGF1. The residues highlighted in red represent the mutated
residues in wtFGF1 (R136E, K126N, Q54P, S61L, and H107S).
In order to accomplish this, mutational studies as well as various biophysical techniques
and molecular dynamic simulations have been performed. Results of this study indicate that in
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spite of significant differences in the stability, resistance to proteases, and enhanced cell
proliferation activity, overall structure of hFGF1 was not found to be substantially perturbed due
to introduction of the mutations. Amongst all other hFGF1 variants known so far,
R136E/K126N/Q54P/S61L/H107S variant demonstrates zero heparin binding affinity. Results of
the current study also indicate that introduction of five mutations led to formation of new
electrostatic interactions and hydrogen bonds that are plausibly responsible for higher stability
and enhanced cell proliferation activity of hFGF1.
Results and discussion
Spatial proximity of the penta mutations (Q54P, S61L, H107S, K126N, and R136E) in the
structure of hFGF1
The crystal structure analysis of heparin-hFGF1 binary complex reveals that heparin is
sandwiched between two FGF1 monomers. Heparin binding pocket (HBP) spans from residue
N120 to H138 towards the C-terminal domain of hFGF1 [20,33]. Basic and polar amino acids of
HBP (N32, K126, K127, N128, K132, Q141, K142) bind to the negatively charged heparin
decasaccharide through electrostatic interactions [1]. These positively charged residues are
primarily located in the flexible loops between beta strands X, XI, and XII. K127, K132, G134,
and R136 are well conserved among different isoforms of FGF. Interestingly, alignment of
amino acid sequences of FGF1 isolated from different species shows that residues in the heparinbinding pocket, including residues 132 to 137, are highly conserved. The well-conserved R136
and K126 residues are located in the heparin binding region. As mentioned above, HBP consists
of positively charged residues, therefore, mutating a polar positively charged amino acid with a
polar negatively charged residue (R136E) and substituting a polar positively charged amino acid
with a polar neutral residue (K126N) can potentially decrease the repulsion between the closely
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packed positively charged residues [1, 19]. Additionally, thrombin cleaves hFGF1 at R136,
hence mutating Arg to Glu at position 136 will reduce the probability of thrombin induced FGF1
degradation [1]. Q54 is located within a turn between β-strands III and IV. Studies have shown
that presence of proline in a β-turn rearranges the β-turn geometry and forms a short 310- helix.
Therefore, Gln was mutated to Pro [19, 24]. H107 is located in the turn spanning β8/ β9 and is
also involved in receptor binding. At the receptor binding site, His interacts with Arg at positions
251 and 255 of the D2 and D3 domain of the receptor [24]. To prevent the repulsion between
His107 and Arg251 and 255, His was replaced with Ser. S61 is located in the middle of β-strand
IV, which is close to the hydrophobic pocket in the hFGF1 structure. Thus, mutation of Ser to
Leu (S61L) is predicted to increase the stability of the growth factor by rendering it more
compact (Fig. 2) [1, 30].

Fig. 2: Ribbon representation of wtFGF1 illustrating mutation sites and electrostatic potential
map showing that the heparin binding region in wtFGF1 is flexible and extends outwards (Top
panel). Ribbon representation and electrostatic potential map of sFGF1 showing that the heparin
binding region is less flexible upon introduction of mutations (Bottom panel).
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Construction and purification of pure wtFGF1 and super FGF1 (sFGF1)
wtFGF1 and sFGF1 were overexpressed in BL21-PlysS cells in LB medium. They were
purified to homogeneity on a heparin sepharose matrix using affinity column chromatography.
The proteins were eluted using a stepwise sodium chloride gradient. wtFGF1 exhibited strong
heparin binding affinity and was eluted in 1.5 M sodium chloride concentration. In contrast,
sFGF1 eluted from the column, along with some bacterial contaminants, in 10mM phosphate
buffer with 0 mM NaCl. These results suggest that sFGF1, unlike wtFGF1, has no or very
insignificant heparin binding affinity. sFGF1 was re-purified using gel filtration chromatography
to obtain the pure protein (approximately 98% pure). The yields of purified wtFGF1 and sFGF1
were in the range of 35-40 mg/L of the bacterial culture. SDS-PAGE gels were analyzed using
pure wtFGF1, purified and characterized previously, as a protein marker. Analysis of the results
of SDS PAGE data shows that wtFGF1 elutes out in the 1500 mM NaCl fraction whereas sFGF1
elutes in the buffer wash (Fig. 3 A and B).

Fig. 3: SDS-PAGE analysis of protein fractions (A- wtFGF1 and B- sFGF1) eluted upon heparin
sepharose chromatography at different concentrations of NaCl. Panel -A: Supernatant (Lane-1);
10 mM PB + 0 mM NaCl (Lane-2); 10 mM PB + 100mM NaCl (Lane-3); 10 mM PB + 300 mM
NaCl (Lane-4); 10 mM PB + 500 mM NaCl (Lane-5); 10 mM PB + 1500 mM NaCl (Lane-6);
and Pure wtFGF1 as a marker (Lane - 8). Panel-B: Supernatant (Lane-1); 10 mM PB + 0 mM
NaCl (Lanes 2-5); 10 mM PB + 100 mM NaCl (Lanes 6 and 7); Pure wtFGF1 as a marker (Lane8).

88

The sFGF1 fraction obtained from heparin sepharose chromatography was subjected to
S-75 column, size-exclusion chromatography. The size-exclusion chromatography profile
showed 4 peaks (Fig. 4A). The first peak corresponds to high molecular weight E. coli
contaminants, the middle peak represents a fraction that contains pure sFGF1 protein (Fig. 4B),
and the third and fourth peaks comprise of low molecular weight E. coli contaminants.

A

B
1

2

mAU

sFGF1 variant

Higher
molecular
weight
contaminants

Lower
molecular
weight
contaminants

Volume (milliliters)

Fig. 4: Elution profile of sFGF1 (M.W- 15.9 kDa) from a S-75 size-exclusion column (Panel-A).
Analysis of size-exclusion chromatographic profile by SDS-PAGE. wtFGF1 (Lane-1); sFGF1
(Lane-2) (Panel-B).
Mutations in sFGF1 does not cause substantial structural change
wtFGF1 contains eight tyrosine residues and a lone tryptophan at position 121 (Trp121)
[1]. Intrinsic fluorescence spectrum of native wtFGF1 shows only tyrosine fluorescence at 308
nm. In the native state, fluorescence of the tryptophan residue is completely quenched by the
amine/imine groups of lysine and proline residues, which are located in close spatial proximity to
Trp121. However, when exposed to a denaturant, such as chemical or temperature, position of
indole ring of tryptophan is shifted away from the lysine and proline residues, exposing
tryptophan to the polar environment. This is manifested by the fluorescence spectrum which has
an emission maximum at 350 nm. Intrinsic fluorescence spectra of wtFGF1 and sFGF1
completely overlap with the emission maxima at 308 nm (Fig. 5). These results suggest that
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incorporated mutations, in sFGF1, did not significantly perturb the tertiary structure of the
protein.
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Fig. 5: Overlay of the Fluorescence spectra of wtFGF1 (blue) and sFGF1 (orange).
Far-UV circular dichroism (CD) spectra (190 nm – 250 nm) is an excellent technique to
determine alterations in the secondary structures of proteins. Far UV-CD spectrum of wtFGF1
overlays well with that of sFGF1, suggesting no major secondary structural changes occur due to
the mutations in sFGF1 (Fig. 6). These spectral features (characteristic positive ellipticity band in
the wavelength ranging from 220-230 nm and a negative band in the region of 210 ~ 200 nm)
indicate that the protein still maintains its native β-trefoil conformation upon introduction of five
mutations.
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Fig. 6: Overlay of far-UV Circular dichroism (CD) spectra of wtFGF1 (gray) and sFGF1
(orange).
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To investigate the interactions that stabilized the structure of hFGF1, we also performed
molecular dynamic (MD) simulation analyses on wtFGF1 and sFGF1. Molecular dynamics
simulations were performed on wtFGF1 and sFGF1 to supplement the experimental data.
Simulations were run on the crystal structure of protein in the absence (1RG8) and presence of
heparin. Hexasaccharide heparin from a dimeric hFGF1 crystal structure (2AXM) was added to
monomeric hFGF1 to build the heparin-bound systems. Root mean square fluctuations (RMSF)
of the Cα atoms and root mean square deviations (RMSD), in the presence and absence of
heparin, of sFGF1 were compared to wtFGF1.
In the absence of heparin, wtFGF1 remains stable upto 2µs with a RMSD value of 1Å.
However, after 2µs (Fig. 7) the RMSD abruptly changes to and remains around 3Å for the rest of
the simulation, indicating that a conformational transition has occurred. In the contrary, heparinfree and heparin-bound sFGF1 show significant fluctuations in the RMSD value when compared
to wtFGF1. Both the forms of sFGF1 stay stable throughout the 4.8 µs time period. Unlike
wtFGF1, sFGF1 does not undergo any conformational transition. These results suggest that
heparin-free wtFGF1 is more flexible than the heparin-bound wtFGF1. The heparin-bound
wtFGF1 curve overlays well with the curves of both the forms of sFGF1 (heparin-free and
heparin-bound).
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Fig. 7: Overlay of root mean square deviation curves of wtFGF1 and sFGF1 in absence and
presence of heparin.
Heparin stabilizes the structure of hFGF1 by decreasing repulsion(s) between the
positively charged residues located in the heparin binding pocket. The fact that heparin bound
wtFGF1 overlays well with heparin-free and heparin-bound sFGF1 provides insight the
extraordinary stability of sFGF1. This means that introduction of mutations, especially the ones
involved in the heparin binding (R136E and K126N), might have increased electrostatic
interaction in the residues; which in turn, increased the inherent stability of hFGF1. Similar trend
in the fluctuation of the RMSD values were observed for the heparin binding region (Fig. 8).
Heparin-free wtFGF1 showed higher flexibility than heparin bound wtFGF1 and both the forms
of sFGF1.
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Fig. 8: Overlay of root mean square deviation curves of the heparin binding region (residues 127
– 143) of wtFGF1 and sFGF1 in absence and presence of heparin.
RMSD results are further supported by the RMSF results. Heparin bound and heparin
free forms of wtFGF1 and sFGF1 showed similar trends in their fluctuations in the entire protein
except for the heparin binding region (Fig. 9). The heparin binding region of the heparin-free
wtFGF1 is more flexible than in the other systems. The heparin binding region spans residues
126-142 in hFGF1. This data along with the RMSD measurements support the conclusions
drawn from structural flexibility experiments that sFGF1 renders more compactness to hFGF1.

Fig. 9: Overlay of root mean square fluctuation curves of wtFGF1 and sFGF1 in absence and
presence of heparin.
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Introductions of mutations leads to electrostatic interactions in the structure of hFGF1
Analysis of the salt bridge interactions revealed two additional salt bridges which are not
found in wtFGF1. One salt bridge that is observed is between the carboxylic acid group of E136
and epsilon amino group of K132 (Fig. 10). This interaction occurs within the heparin binding
region and stays stable at around 6Å (weak salt bridge) for 4.8µs. Another salt bridge occurs
between the carboxylate group of E136 and guanidinium head group of R133 (Fig. 11). This
interaction is also present in the heparin binding region. Both salt bridges are observed in the
sFGF1 in the presence and absence of heparin but not in wtFGF1. Thus, extra stability of sFGF1
over wtFGF1 appears to be due to these additional salt bridges. The introduction of the mutations
plausibly promotes these new salt bridges in the heparin binding region (R136E and K126N).
These mutations also could have lowered the repulsion between closely packed basic amino
acids in the heparin binding region. The salt bridges present exclusively in wtFGF1 in the
absence of heparin have been described in Chapter-IV.

Fig. 10: Time series of the E136-K132 donor-acceptor salt bridge distance in the sFGF1
structure.
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Fig. 11: Time series of the E136-R133 donor-acceptor salt bridge distance in the sFGF1 structure
The number of transient H-bond interactions (including those that do not satisfy the
occupancy criteria; mentioned in the methods section) over the course of the simulation is nearly
same for wtFGF1 and sFGF1. In heparin-free wtFGF1, only 1 out of 65 H-bonds (that satisfy the
occupancy criteria) involves the heparin binding region (L145-K142 which is a backbonebackbone H-bond). All the 65 interactions observed in wtFGF1 also occur in sFGF1 with similar
occupancies. 7 stable hydrogen bonds were identified in the heparin binding region of
sFGF1(Table 1) that do not qualify as hydrogen bonds in heparin-free wtFGF1 (Table 1) based
on the occupancy criteria defined in the methods section. Five of these interactions involved
variant residues (N126 and E136) and are unique to sFGF1 (Table 1). It should be noted that
equivalent interactions in both sFGF1 models and heparin-bound wtFGF1 have similar
occupancies (Table 1), thus recapitulating the results of the RMSD and RMSF analyses.
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Table 1: Comparison of electrostatic interactions involved in the heparin-binding region of
wtFGF1 and sFGF1.
Donor

Acceptor

K126 (B)
Q141 (S)
G129 (B)
R136 (B)
T137 (S)

S130 (B)
R136 (B)
K126 (B)
R133 (B)
G134 (B)
Q141 (S)
N126 (B)
S130 (B)
E136 (B)

H138 (B)
G129 (B)
N126 (B)
Q141 (S)
E136 (B) R133 (B)
R133 (S) E136 (S)

wtFGF1 w/o
hep
44
31
33
37
35
22
N/A
N/A
N/A
N/A
N/A

wtFGF1 with
hep
97
80
79
76
70
54
N/A
N/A
N/A
N/A
N/A

sFGF1 with
hep
N/A
N/A
N/A
N/A
67
55
74
98
62
68
150

sFGF1 w/o
hep
N/A
N/A
N/A
N/A
67
51
72
97
57
64
158

Introduction of the mutations did not significantly perturb the hFGF1 structure
Changes in the structure of wtFGF1 and sFGF1 were determined using 1H 15N HSQC
multidimensional NMR spectroscopy. NMR structure of wtFGF1 has been solved earlier and a
complete set of assigned resonances is available. 1H 15N chemical shift perturbations were
monitored based on chemical shifts assignments published by our group and others [17, 38]. The
1

H 15N chemical shift perturbation of individual residues were calculated using the formula, (√

[(2ΔδNH)2 + (ΔδN)2]). Our results are in good agreement with the published assignments.
Superimposition of 1H 15N HSQC spectra of wtFGF1 and sFGF1 reveals modest chemical shift
perturbations. The calculated 1H 15N chemical shift perturbations indicate that there were
significant perturbations in the position of amino acids which are in proximity to the mutation
sites (E136, G134, K132, and S107). E136, G134, and K132 are located in the heparin binding
region. Spatially, S107 is positioned very close to the heparin binding pocket. E136 and S107 are
the mutated residues. G134 is located very close to E136, and R133 and is involved in an
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electrostatic interaction with the hydroxyl side chain of Thr at position 137 in wtFGF1 as well as
sFGF1.

Fig. 13: Overlay of the 1H 15N HSQC of the wtFGF1 (yellow) and sFGF1 (red). The blue circles
represent the amino acids in the wtFGF1 (R136, K126, Q54, S61, and H107). The green circles
are predicted location of the amino acid after the mutation.
Introductions of mutations renders hFGF1 to be more compact, thus increasing the
thermal, chemical and proteolytic stability of hFGF1. It also leads to complete loss of heparin
binding affinity of hFGF1. Overall, results of the 1H 15N HSQC data suggest that engineered
mutations, generating sFGF1, did not significantly alter the gross three-dimensional structure of
the protein (Fig. 13).
Introduction of the mutations renders the hFGF1 molecule more compact
8-anilinonaphthalene-1-sulfonate (ANS) is a non-polar dye that is widely used to detect
the presence of solvent-exposed hydrophobic region(s) in proteins. Results of ANS binding
experiments shed light on the structural flexibility of the proteins. As hydrophobic residues are
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typically buried in the interior of the protein core, an increase in ANS fluorescence suggests
greater exposure of solvent-accessible hydrophobic region(s) [2]. Hydrophobic properties of
proteins can be crucial as a driving force towards proper folding as well as protein-protein
interactions. ANS binding curve for sFGF1 is quite similar to that of wtFGF1 (Fig. 14),
indicating that the mutations did not lead to any significant tertiary structural changes. wtFGF1
without heparin exhibits maximum relative fluorescence intensity which indicates that wtFGF1
is structurally more flexible than sFGF1 with/without heparin and wtFGF1 with heparin. Unlike
wtFGF1, sFGF1 does not show any difference in the ANS fluorescence in presence of heparin
which indicates that heparin does not significantly affect the tertiary structure of sFGF1. On the
other hand, the structure of wtFGF1 becomes more compact upon binding to heparin.
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Fig. 14: ANS binding curves of wtFGF1 and sFGF1 in the presence and absence of heparin.
wtFGF1 without heparin (gray), wtFGF1 with heparin (orange), sFGF1 without heparin (blue),
and sFGF1 with heparin (yellow).
sFGF1 mutations is more resistant to the action of proteolytic enzymes
Trypsin, a serine protease, specifically cleaves proteins at the C-terminal end of lysine
and arginine residues. hFGF1 contains three arginine and nine lysine residues. We performed
limited trypsin digestion (LTD) assay on wtFGF1 and sFGF1, to determine effects of the
mutations on the conformational flexibility of hFGF1. The percentage of hFGF1 digested after
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different time periods of incubation with trypsin was measured by densitometric analysis based
on the change(s) in intensity of the ~16 kDa hFGF1 band on Coomassie blue stained SDS-PAGE
gels (Fig. 15).
A

B

Fig. 15: SDS-PAGE analysis of limited trypsin digestion of wtFGF1 (Panel – A) and sFGF1
(Panel-B). 0.5 mg/mL of proteins (Lane-1); 4 minutes (Lane-2); 6 minutes (Lane-3); 10 minutes
(Lane-4); 15 minutes (Lane-5); 30 minutes (Lane-6); 45 minutes (Lane-7); 60 minutes (Lane-8);
5 mg/mL of trypsin (Lane-9).
Densitometric analysis of SDS PAGE gels reveal the rate of digestion of wtFGF1 and
sFGF1 by trypsin. Fig. 16 showed that after 20 minutes of incubation with the enzyme,
approximately 80% of wtFGF1 was digested. Contrastingly, sFGF1, after 20 minutes of
incubation with trypsin, remains almost completely undigested. In fact, sFGF1 remains stable for
24 hours when treated with trypsin (Fig. 16 B). These results indicate that sFGF1 is a highly
compact molecule with significantly diminished backbone flexibility. In addition, results of the
LTD experiments corroborate well with ANS binding data.
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Fig. 16: Densitometric analysis of limited trypsin digestion of wtFGF1 and sFGF1 as monitored
by SDS-PAGE (Panel-A). SDS-PAGE analysis of limited trypsin digestion of sFGF1 (Panel-B).
0.5 mg/mL of proteins (Lane-1); 1 hour (Lane-2); 4 hours (Lane-3); 8 hours (Lane-4); 16 hours
(Lane-5); 24 hours (Lane-6).
Thrombin is another serine protease which is mainly present at the wound site and
converts fibrinogen to fibrin. This conversion creates a matrix which includes cytokines (growth
factor) and heparin. The primary thrombin cleavage site is -LVPRGS-. Slowly, the matrix is
dissolved, and growth factors including hFGF1 are released at the site of wound. hFGF1 has a
secondary thrombin cleavage site between R136 and T137. It has been reported earlier that
thrombin degrades wtFGF1 at the wound site and renders it biologically inactive [40, 41]. In this
context, limited thrombin experiments were performed to examine if substitution of secondary
cleavage site (Arg at position 136 by Glu) in the structure of hFGF1 can enable thrombin
resistant hFGF1 variant. Densitometric analysis of the rate of digestion of wtFGF1 and sFGF1 by
thrombin shows that intensity of the 16 kDa band does not change for sFGF1 after 48 hours. On
the contrary, the 16 kDa band intensity is completely lost/faded for wtFGF1 in about 24 hours
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(Figs. 17 and 18). Thus, it can be inferred that sFGF1 is resistant to the action of thrombin for 48
hours whereas wtFGF1 is completely degraded within the first 24 hours (Fig. 17).
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Fig. 17: SDS-PAGE analysis of limited thrombin digestion of wtFGF1 (Panel-A) and sFGF1
(Panel-B). 33 µM of proteins (Lane-1); 12 hours (Lane-2); 24 hours (Lane-3); 36 hours (Lane-4);
48 hours (Lane-5); 60 hours (Lane-6); 165 µM of thrombin (Lane-7).
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Fig. 18: Densitometric analysis of limited thrombin digestion of wtFGF1 and sFGF1 as
monitored by SDS-PAGE.
Introduction of the mutations increases the stability of hFGF1
The thermal stability of wtFGF1 and sFGF1 were examined by monitoring the changes in
the intrinsic fluorescence intensity ratio at 308 nm and 350 nm. The data in Fig. 19 depicts
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unfolding curves of wtFGF1 and sFGF1 when exposed to increasing temperature, with and
without heparin in solution.
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Fig. 19: Thermal stability analysis of wtFGF1 and sFGF1 in the presence and absence of heparin.
Table 2. Comparison of the thermal stability of wtFGF1 and sFGF1.
Tm Values (°C)

sFGF1

wtFGF1

With Heparin

68 ± 0.012

62 ± 0.012

Without Heparin

67 ± 0.023

41 ± 0.047

∆Tm

1 ± 0.026

21 ± 0.049

Analysis of the denaturation temperature, Tm (the temperature at which 50% of the
protein population exists in unfolded state(s)), revealed that presence of heparin significantly
increases ability of wtFGF1 to resist the denaturation by increase in temperature. The presence of
heparin accounts for 21°C of thermal resistance by wtFGF1. Also, heparin independent nature of
sFGF1 is evident from the data, Tm remains 67.5˚C for sFGF1 with and without heparin, thus
showing that addition of heparin doesn’t significantly affect the thermal stability of sFGF1
(Table 2).
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Unfolding of the proteins under increasing urea concentration was also monitored by the
change in intrinsic fluorescence intensity at 305 nm/350 nm. Urea-induced unfolding curves of
wtFGF1 and sFGF1 shows that both the forms of sFGF1 (with and without heparin), is more
stable at higher urea concentrations than wtFGF1 without heparin, as shown in Fig 20. wtFGF1
has Cm value (the concentration value where 50% of the protein population remains in unfolded
state (s)) of 3.8 ± 0.051 M and 1.2 ± 0.02 M with and without heparin, respectively.
Contrastingly, sFGF1 exhibits Cm values of 3.65 ± 0.12 M with heparin and 3.66 ± 0.054 M
without heparin. Cm values displayed by sFGF1 are approximately three times higher than that
exhibited by wtFGF1 without heparin. Thus, data from the urea denaturation experiment suggest
that sFGF1 has a higher inherent stability than wtFGF1.
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Fig. 20: Urea stability analysis of wtFGF1 and sFGF1 in the presence and absence of heparin.
Table 3. Comparison of urea stability of wtFGF1 and sFGF1.
Cm Values (M)

sFGF1

wtFGF1

With Heparin

3.65 ± 0.12

3.8 ± 0.02

Without Heparin

3.66 ± 0.054

1.2 ± 0.051

∆Cm

0.01 ± 0.087

2.6 ± 0.0355
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Overall, the thermal and urea equilibrium unfolding data indicate that introduction of
mutations aid in stabilizing the growth factor. Stability against temperature and urea can be
directly related to half-life of the protein, hence molecules exhibiting higher Tm and Cm values
are expected to exhibit higher biological activity at physiological temperature for an extended
period of time. sFGF1 exhibited much higher thermal stability (Tm~ 68°C) in comparison to
wtFGF1, both in absence and presence of heparin. A similar trend was observed even in case of
urea-induced denaturation. This may be due to the reduction of charge-charge repulsion in the
heparin binding pocket caused because of the substitution of Lys by Asn and Arg by Glu at
positions 126 and 136, respectively. Furthermore, Q54P and S61L mutations might have led to
increase in β-sheet propensity and decrease in entropy, consequently enhancing the stability of
sFGF1. Additionally, introduction of H107S mutation appears to significantly increase the
hydrogen bonding network (G129-N126, N126-S130, Q141-E136, and E136-R133) in the
vicinity of heparin binding site. These conclusions are in good agreement with the conclusions
drawn from the structural flexibility data.
Introduction of a negative and a neutral charge in the heparin binding pocket leads to
complete loss of heparin binding affinity
Isothermal titration calorimetry (ITC) is a valuable technique to determine the
thermodynamic binding parameters of interactions in solution. The dissociation constant, Kd, has
an inverse relationship with the binding affinity. Thus, more the Kd, less is the binding affinity of
the protein to the ligand. Comparison of the Kd values between wtFGF1 (Kd = 1.6M) and
sFGF1 (Kd value can’t be determined) reveals that wtFGF1 exhibits significantly more heparin
binding affinity than sFGF1. The unusual heat changes in the isothermograms are due to the
electrostatic interactions between the charged heparin molecules and some of the charged
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components present in the buffer. From Fig. 21 and table 4, it can be concluded that sFGF1
clearly exhibits zero heparin binding affinity indicating that integrity of the heparin binding
pocket is reliant on the presence of the positively charges residues.

B

A

No binding

Kd = 1.6M

Fig. 21: Isothermograms representing titration of wtFGF1 (Panel - A) and sFGF1 (Panel - B)
with heparin.
Table 4: Heparin binding affinity of wtFGF1 and sFGF1.
hFGF1 variants

Kd (µM)

wtFGF1

1.6

sFGF1

No binding

X-ray crystal structure of hFGF1 indicates that R136, K132, and K126 form a triad
and facilitate binding of hFGF1 to heparin. Mutating two of these three residues might lead to
significant reduction in the repulsion between positively charged amino acids in the heparin
binding pocket. Using the crystal structures of hFGF1 in presence (PDB 2ERM) and absence of
heparin (PDB 1RG8), distance of all the mutated residues were measured with respect to R133
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(which lies in the middle of the heparin binding pocket) [20, 33]. The distance between the two
residues was calculated using a combination of the following commands in VMD – measure
center, vecsub, and veclength. In absence of heparin, the residues in wtFGF1 (R136, K126, Q54,
S61, and H107) are located ~7.15 Å, ~13.24 Å, ~27.75 Å, ~26.32 Å, and ~25.6 Å, respectively,
away from the critical heparin binding residue R133 (PDB 1RG8) whereas in the presence of
hexasaccharide heparin (PDB 2ERM), R136 is shifted significantly closer to R133 (~9.57 Å)
whereas K126, Q54, S61, and H107 are moderately positioned ~9.57 Å, ~24.41 Å, ~24.17 Å,
and ~24.8 Å near R133. On the contrary, the distance between the mutated residues and R133 in
sFGF1 (E136, N126, P54, L61, and S107) remains nearly the same, irrespective of the presence
of heparin (Table 5). Thus, modification of Arg with Glu at position 136, Lys with Asn at
position 126, Gln with Pro at position 54, Ser with Leu at position 61, and His with Ser at
position 107 seems to compact the overall hFGF1 structure including the heparin binding pocket
(HBP). Although out of all the five substitutions, R136E and K126N appears to bring drastic
conformational changes in the heparin binding region making sFGF1 heparin independent.
Table 5: Distance of residues in wtFGF1 and sFGF1 from the middle of the heparin
binding pocket (R133).
Distance between (Å)
Proteins
wtFGF1 w/o
heparin
wtFGF1 with
heparin
sFGF1 w/o
heparin
sFGF1 with
heparin

K/N126 R133
13.24

R/E136 R133
7.15

S/L61 –
R133
26.32

Q/P54 R133
27.75

H/S107 R133
25.6

9.57

5.15

24.17

24.41

24.8

9.7

5.16

23.46

23.97

23.9

9.68

5.18

23

25

23.78
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Introduction of the mutations enhances the mitogenic activity of hFGF1
The final step in analysis of viability of sFGF1 in a clinical setting is the
understanding of its proliferative activity. Heparin is considered to be a crucial player in the
hFGF1-FGFR interaction and activation. On that basis, decrease in the heparin binding affinity
of the growth factor would lead to decrease in the mitogenic activity. In this context, cell
proliferation assay was conducted using different concentrations of wtFGF1 and sFGF1. Fig. 22
displays that sFGF1 enhances the cell proliferation activity of the FGF1 protein as compared to
wtFGF1. This result is nearly 70% more effective than wtFGF1 at the highest concentration (Fig.
22). Increased mitogenic activity is possibly due to the increased structural stability as measured
by the equilibrium unfolding experiments. Isothermal titration calorimetric results suggest that
sFGF1 is a heparin independent protein. Since sFGF1 is shown to demonstrate high cell
proliferative ability despite having no heparin binding affinity, the data here shows that heparin
binding is not mandatory to initiate cell proliferation.
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Fig. 22: Cell proliferation activity of NIH 3T3 cells treated with wtFGF1 and sFGF1
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The notion that heparin is not mandatory for hFGF1 activation of cell surface receptors
has been previously reported [4,8,10,11]. Culajay et al., reported that substitution of the three
cysteine residues (C30S, C131S, C97S) with serine decreased the heparin binding affinity of
hFGF1 but increased the physiological half-life of hFGF1 and also enhanced the mitogenic
activity of hFGF1 [9]. Additionally, combination of mutations L58F, H35Y, H116Y, and F122Y
demonstrated an increase in the thermal stability, even in the absence of heparin, without causing
significant loss in the bio activity of hFGF1 [9]. Further introduction of mutations at multiple
sites on the quadruple mutant (L58F/H35Y/H116Y/F122Y) led to generation of a septuplet
mutant (H35Y/Q54P/L58F/S61I/H107G/H116Y/F122Y). Surprisingly, this septuplet mutant was
found to exhibit six-fold higher cell proliferation activity than wtFGF1 in the absence of heparin
[24]. In this context, results of this study clearly show that heparin is not a pre-requisite for the
cell proliferation activity of hFGF1. Heparin, present on the cell surface, possibly regulates the
FGF protein level in the extracellular matrix (ECM), and also confers protection to FGFs against
thermal denaturation and proteolytic degradation. In addition to facilitating the FGF-FGFR
binding, HS also acts as a storage reservoir for ligand and determines the radius of ligand
diffusion by controlling the gradients of paracrine FGFs in ECM [38].
Introduction of mutations enhances the ability of sFGF1 to activate ERK and Akt
pathways
FGF ligands carry out their diverse functions by binding and activating the FGFR family
of tyrosine kinase receptors in an HSGAG-dependent manner. FGFs exert their physiological
roles through binding to the FGFR and regulate downstream signaling pathways such as,
RAS/MAPK, PI3K/AKT, and PLCγ pathways. In this context, receptor activation assay was
conducted to study the effects of wtFGF1 and sFGF1 on Valve interstitial cells (VICs). We used

108

western blotting to detect the expression of phosphorylated Erk1/2 and Akt in cultured valve
interstitial cells treated with different doses of wtFGF1 and sFGF1. Results in Fig. 23 indicate
that sFGF1 significant increases the activation of both these pathways (Erk1/2 and Akt)
specifically, that of Erk1/2 pathway when compared to wtFGF1.
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Fig. 23: Receptor activation assay of serum starved valve interstitial cells (VICs) treated with
different concentrations of wtFGF1 and sFGF1. Cell lysates were resolved on SDS-PAGE
followed with western blotting to detect ability of wtFGF1 and sFGF1 to activate ERK and Akt
signaling pathways.
In spite of many years of research, the role of heparin in hFGF1-induced cell signalling is
still controversial. Several studies have demonstrated that presence of heparin on the cell surface
is mandatory for the receptor dimerization and augments the mitogenic response stimulated by
hFGF1. In contrast, there have been reports indicating that heparin is not mandatory for the
activation of FGF-FGFR cell signaling. In this context, results of this study show that sFGF1 can
interact with the FGFR and trigger phosphorylation of Erk and Akt pathways even in the absence
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of heparin. This is an important finding since activation of the Erk 1/2 pathway is known to be
involved in wound healing mechanism [42].
Conclusions
Amino acid sequence of the FGFs, including hFGF1, folds into a β-trefoil conformation.
This group of cytokines exhibits a wide array of activities such as, mitogenic activity, angiogenic
activity, wound healing, and bone growth. There has been a long-standing debate on the role of
heparin in determining the biological function of hFGF1. Initially there existed a general belief
within literature that heparin is critical for binding of hFGF1 to its receptors. In contrast, there
have been studies which demonstrated that heparin is not mandatory for the cell proliferation
activity of hFGF1. In this study, we were able to demonstrate that heparin only stabilizes the
structure of hFGF1 by decreasing the repulsion(s) between the positively charged residues
located in the heparin binding pocket. Limited enzymatic digestion data suggest that sFGF1
substantially increases the resistance of hFGF1 to trypsin and thrombin. Thermal and urea
induced unfolding results demonstrate that sFGF1 is significantly more stable than wtFGF1 with
a Tm of around 68 °C and Cm of approximately 3.6 M. Isothermal titration calorimetry data
indicate that the positively charged residues (K126 and R136) are significant in determining
affinity of hFGF1 to heparin. Molecular dynamic (MD) simulation analyses suggest the
introduced mutations in sFGF1 lowers the flexibility to the heparin binding region and
consequently increases the stability of the growth factor by forming stable electrostatic
interactions (salt bridges and hydrogen bonds). 1H-15N HSQC NMR experiment show that
sFGF1 does not significantly affect the three-dimensional structure of the growth factor. Cell
proliferation experiments indicate that sFGF1 exhibits a heparin-independent cell proliferation
activity which is higher than that exhibited by wtFGF1. Receptor activation assay demonstrates
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that sFGF1 exhibits substantial increase in activation of Erk and Akt pathways, which is known
to be crucial for the wound healing. In conclusion, the hyperstability, resistance to the action of
proteases, and enhanced heparin-independent bioactivity and activation of FGFR qualifies
sFGF1 as a promising biotherapeutic to promote wound healing.
Materials and methods
Materials
The Quikchange lightning multi-site directed mutagenesis kit was from Agilent and the DNA
plasmid isolation kit was from Qiagen Inc., USA. XL-Gold, PlysS, and BL-21(DE3) competent
cells were obtained from Agilent and Novagen Inc., USA respectively. Lysogeny broth was
purchased from IBI Scientific, USA. Heparin sepharose resin was from GE Healthcare, USA.
Buffer components (Na2HPO4, NaH2PO4, NaCl) were supplied from VWR Scientific., USA.
Low molecular weight (~3000 Da) heparin sodium salt was obtained from Sigma and MP
Biomedicals LLC. NIH 3T3 cells were obtained from ATCC and all the cell culture reagents
including, DMEM media, fetal bovine serum (FBS) and penicillin streptomycin were purchased
from Thermo Fisher Scientific (Waltham, MA). All other chemicals and materials were of highquality analytical grade. Unless otherwise stated, samples were made in 10 mM phosphate buffer
saline (pH 7.2) and incubated at 37 ºC.
In this study, we have used low molecular weight heparin (M.wt~ 3000 Da) because the
high molecular weight heparin is a polydispersed glycosaminoglycan. The high polydispersity
imposes a serious challenge to accurately determine the binding affinity of the ligand to the
growth factor [32]. Furthermore, the low molecular weight (M.wt~ 3000 Da) heparin used has
been estimated to be 8 to 12 units long and multiple studies have shown that heparin with a chain
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length of 8-units has been shown to be sufficient to facilitate optimal FGF-1 induced cell
signaling [33, 34].

Construction and purification of pure wtFGF1 and sFGF1
For all the experiments, a truncated version of hFGF1 (residue number, 15-154) was
inserted into a pET20b expression vector. Primers were designed using an online agilent primer
design program and were ordered from IDT DNA Inc., USA. Site-directed mutagenesis (SDM)
was performed using a QuickChange lightning kit followed by polymerase chain reaction (PCR)
as per the protocol provided by the manufacturer. This project specifically utilizes Escherichia
coli cells (BL21 E. coli). The plasmid was then transformed into XL-gold competent cells and
sequencing of the plasmid was performed at the University of Arkansas Medical Science
(UAMS) – DNA core sequencing facility. After verification of the plasmid sequence, sFGF1 was
overexpressed in BL-21(pLysS) Escherichia coli cells cultured in lysogeny broth (LB) and then
placed in New Brunswick Science Innova 4330 Refrigerated Incubator Shaker at 37 °C with
agitation speed of 250 rpm. All transfers and inoculations were done in a Labconco Purifier
Class II Biosafety Cabinet rinsed with 70% ethanol prior to work. After the overexpression,
bacterial cells were lysed via ultra-sonication using a Branson Sonifier 150 at a 32% amplitude
and the released proteins were separated from the cell debris by centrifugation for 20 minutes at
19,000 rpm. wtFGF1 and sFGF1 were then purified on a pre-equilibrated heparin-sepharose
column with increasing sodium chloride gradient in 10 mM PB at speed of approximately 1.5
mL/min. SDS-PAGE was then used to determine the purity of the protein. The protein bands
were visualized by staining the gels with Coomassie brilliant blue and the protein concentrations
were determined by Bradford assay using a Hitachi F-2500 fluorimeter.
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Fluorescence and Circular Dichroism Spectroscopy
Circular dichroism and intrinsic fluorescence data were acquired using a Jasco J-1500
Spectrophotometer. 33 µM protein was added to 10 mM PB + 100 mM NaCl and loaded into a
0.1 cm path length quartz cuvette. CD machine was kept at a constant temperature at 25⁰C. The
wavelength of the spectrophotometer was set over the range of 190-250 nm and the spectrum
were scanned at 20nm/min speed. To obtain the intrinsic fluorescence spectrum, the excitation
wavelength was set to 280 nm and the emission spectra was set for a range of 300 to 450 nm.
The fluorescence data sheds light on the tertiary folding of the protein based on the naturally
fluorescent tryptophan and tyrosine residues, which have an emission wavelength of
approximately at around 350 nm and 305 nm, respectively.
1H 15N

HSQC multidimensional NMR spectroscopy
1

H-15N HSQC experiments were conducted on a Bruker Avance DMX-700 MHz

spectrometer equipped with a 5 mm inverse cryoprobe at 25°C. wtFGF1 and the sFGF1 were
grown in M9 medium with 15NH4Cl used as the sole nitrogen source. 15N labeled protein samples
(1 mM) were prepared in 90% H2O + 10% D2O solution containing 10 mM phosphate buffer
containing 100 mM NaCl and 25 mM (NH4)2SO4 (pH 6.5). Data were analyzed using
XWINNMR 3.5 software supplied by Bruker.
ANS Binding
ANS (8-anilinonaphthalene-1-sulfonate) binding experiments were performed to provide
further information regarding the protein’s tertiary structure. ANSs an extrinsic fluorophore that
fluoresces when it binds to solvent exposed hydrophobic regions of a protein. ANS binding
experiments were performed by addition of increasing concentrations (10 μM addition) of ANS
to 33 µM of wtFGF1. Relative fluorescence intensity was determined with an excitation at 380
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nm and emission intensity was recorded at 510 nm. These experiments were repeated with
sFGF1 samples in the presence and absence of heparin.

Limited Trypsin Digestion
Proteolytic trypsin digestion was performed to determine the structural flexibility of the
wild-type and sFGF1. Trypsin is a proteolytic enzyme that cleaves peptide bonds at the Cterminal end of lysine and arginine amino acids, except when either are followed by a proline.10
µL of 330 mM trypsin was added to 10 µL of 33 µM of protein and 90 µL of 10 mM PB + 100
mM NaCl. The samples were immediately incubated in a hot water bath at 37⁰C for 0, 4, 6, 10,
15, 30, 45, and 60 minutes. TCA preparation was performed on each sample immediately after
being removed from the hot water bath to stop the trypsin reaction. The results were assessed
using SDS-PAGE analysis along with UN-SCAN-IT gel software. The intensity of the bands in
the gel was compared to control bands containing only wtFGF1. This study was repeated with
sFGF1 samples.
Limited Thrombin Digestion
Proteolytic thrombin digestion was performed to determine the structural flexibility of the
wild-type and the mutant protein. Thrombin recognizes the specific amino acid sequence
LVPRGS and cleaves between the arginine (R) and glycine (G) residues. In hFGF1, thrombin
cleaves between the Arg at position 136 and Thr at position 137. Thrombin cleavage was
performed using 33 µM of wtFGF1 and sFGF1 protein, 165 µM of bovine thrombin, and 10 mM
PB + 100 mM NaCl. The samples were incubated at 37⁰ C in a rotator and collected at 3, 6, 18,
24, 36, and 48 hours. TCA preparation was performed on each sample immediately after being
removed from the rotator to stop the thrombin reaction. The results were assessed using SDS
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PAGE analysis along with UN-SCAN-IT gel software. The intensity of the bands in the gel was
compared to control bands containing only protein.

Equilibrium unfolding experiments
Thermal denaturation studies were performed on the JASCO-1500 spectrofluorometer
using intrinsic fluorescence emission scans to reveal how temperature affects the stability of
wtFGF1 and sFGF1 with and without heparin. 33 µM protein in 10 mM PB + 100 mM NaCl
were added to a cuvette and a temperature probe was inserted to monitor the temperature. Data
on the samples were collected at 5⁰ C intervals over a temperature range of 25 ⁰C – 90 ⁰C. The
fraction of the unfolded protein was calculated using the ratio of tyrosine to tryptophan emission
fluorescence measurements at 305 nm and 340 nm, respectively.
For the chemical denaturation studies, 8 M urea was used to induce protein denaturation.
This process was monitored using intrinsic fluorescence emission scans using a JASCO-1500
spectrophotometer. Data of samples of 33 µM protein in 10 mM PB + 100 mM NaCl (wtFGF1
and sFGF1) were each collected over a urea concentration of 0-6 M. The fraction of unfolded
protein was calculated using the ratio of tyrosine to tryptophan emission fluorescence
measurements at 305 and 340 nm.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was used to calculate the binding affinity of
wtFGF1 and sFGF1 to heparin. ITC measures the molar ratio of bound ligand to protein at
specified aliquots of titrant, which in this case is heparin. Within an adiabatic chamber, a series
of 30 titrations were performed at 25°C with a stir speed of 750 rpm. Protein samples were
prepared with 10 mM sodium phosphate buffer containing 100 mM NaCl and 25 mM (NH4)2SO4
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pH 7.2. A 1:10 ratio of protein to ligand (100 μM protein: 1 mM heparin) was used on a GE
MicroCal iTC-200 in which heparin was titrated into hFGF1 samples. The detected thermal
change from the binding of heparin to hFGF1 is then measured by a small sensor and compared
to a reference cell. The data for wtFGF1 and sFGF1 were best-fit to one set of sites and any
excess heats of dilution given from heparin were appropriately subtracted out.
Cell Proliferation Activity
The cell proliferation assay measures the biological activity of a growth factor. 3T3
fibroblast cells obtained from ATCC (Manassas, VA) were cultured in complete media
consisting of DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were
grown to 80-90% confluency and were incubated overnight at 37°C with 5% CO2 in serum free
media before further use. The cell proliferation activity of hFGF1 was determined by quantifying
the increase in cell number after the cells had been incubated with wtFGF1/sFGF1 at varying
concentrations. Starved 3T3 fibroblasts were collected and seeded in a 96-well plate at a seeding
density of 10,000 cells/well. Cells were then co-incubated individually with wild type and sFGF1
at concentrations of 0, 0.4, 2, 10, and 50 ng/mL. After 24 hours of incubation, 3T3 cell
proliferation was assessed by the CellTiter-Glo (Promega, Madison, WI) cell proliferation assay.
Receptor activation assay
Valve interstitial cells (VICs) were isolated from porcine heart and used at passage 2-7.
VICs were allowed to reach about 80% confluence before they were serum starved for 24 hours
prior to treatment. 6 different doses of wild-type (WT) and super (S) FGF were used, including
3ng/ml, 30ng/ml 250ng/ml, 300ng/ml, 450ng/ml and 600ng/ml. 10 minutes after treatment, cells
were lysed with RIPA lysis buffer (Santa Cruz Biotech). Cell lysate was centrifuged at 10,000
rpm, 40C and the supernatant was collected and quantified by BCA assay (Thermo Scientific).
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Control samples had VICs only, no treatment with either wild-type or mutant FGF. For western
blotting, cell lysate was mixed with 4X Laemmli buffer (Bio-Rad) in the presence of reducing
condition β-mercaptoethanol (Bio-Rad) and equally loaded to each lane of 4-15%
polyacrylamide gel (Bio-Rad). Electrophoresis was run for 1 hour at room temperature before the
protein was transferred to polyvinyldifluoride (PVDF) membrane (Immobilon-FL), blocked in
Licor blocking buffer (Li-Cor, Lincoln NE) for 1 hour before probing with total mouse ERK1/2
(Cell signaling 1:50) and rabbit p-ERK1/2 (Cell signaling 1:500). For Akt detection, membranes
were probed with rabbit p-Akt (Cell signaling 1:100) prior to stripping and reprobing with rabbit
Akt (Cell signaling, 1:200). The membranes were kept at 40C overnight. The next day,
appropriate secondary antibodies (Li-Cor, 1:15,000) were added to the membranes and incubated
for 1 hour before the membranes were washed and scanned using a Licor Odyssey scanner.
Relative expression of p-ERK1/2 and p-Akt were quantified by comparing the band intensity
obtained for the phosphorylated proteins and normalizing it with the intensity obtained for the
corresponding total proteins.
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CHAPTER IV
Characterization of the Structural Forces Governing the Reversibility of the Thermal
Unfolding of the Human Acidic Fibroblast Growth Factor

Abstract
Human acidic fibroblast growth factor (hFGF1) ~16 kDa is an all beta-sheet protein that is
involved in the regulation of key cellular processes including cell proliferation, cell
differentiation, angiogenesis, and wound healing. hFGF1 is known to be an unstable protein and
has been shown to aggregate when subjected to thermal unfolding. In this study, we investigate
the equilibrium unfolding of hFGF1 using a wide array of biophysical and biochemical
techniques including multidimensional NMR spectroscopy. Systematic analyses of the thermal
and chemical denaturation data on seven different designed variants (Q54P, K126N, R136E,
K126N/R136E, Q54P/K126N, Q54P/R136E, and Q54P/K126N/R136E) of hFGF1 indicate that
nullification of charges in the heparin binding pocket can significantly increase the thermal
stability of the protein. The triple variant (Q54P/K126N/R136E) was found to be the most stable
of all the hFGF1 variants studied. Its Tm value is about ~ 20C higher than the wild type protein.
GdnHCl/urea-induced equilibrium unfolding of wtFGF1 and the other designed variants of
hFGF1 are reversible. However, with the exception of the triple variant, the thermal unfolding of
wtFGF1 and the other designed hFGF1 is irreversible. However, renaturation of the triple variant
from its thermal denatured state(s) shows hysteresis behavior. Two-dimensional 1H-15N HSQC
and cell proliferation data clearly show that the triple variant of hFGF1 regains its biologically
active conformation upon refolding from its thermal denatured state(s). Results from
microsecond-level molecular dynamics (MD) simulations show that a network of hydrogen
bonds and salt bridges linked to the Q54P, K126N, and R136E mutations, are responsible for the
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high thermal stability and reversibility of the thermal unfolding of the triple variant of hFGF1. In
our opinion, the findings of the study provide valuable clues for the rational design of a stable
hFGF1 variant that exhibits potent wound healing properties.
Introduction
Protein folding is a fascinating puzzle that has attracted the attention of researchers for a
long time [1]. The mechanism by which a nascent polypeptide chain folds into a unique threedimensional structure has largely remained enigmatic. However, useful knowledge about the
plausible structural events that occur during the folding of proteins from their denatured state(s)
has been gained [2,3]. Stable intermediate state(s) that populate the equilibrium/kinetic
folding/unfolding pathways of several proteins have been characterized and their significance in
directing a protein to fold to its native conformation have been reported [4,5]. It is widely
believed that the folding polypeptide is partitioned between productive intra-chain interactions
leading to the formation of the native conformation and non-productive inter-chain interactions
that result in misfolding and consequently aggregation of the protein [6,7]. Aggregates formed
can range from amorphous structures without order to highly structured fibrils as observed in
dilapidating amyloid diseases such as Alzheimer’s disease, Parkinson’s disease, serum amyloidA (SAA), dialysis-related amyloidosis, cystic fibrosis, Creutzfeldt-Jakob disease, Huntington
disease, and type-II diabetes [8-10]. In several cases, the propensity to aggregate is attributed to
inter-chain interactions between solvent-exposed hydrophobic surfaces present in obligatory and
non-obligatory partially structured intermediates that populate the kinetic or equilibrium
folding/unfolding pathways of proteins [11]. In this context, understanding the structural
determinants governing protein aggregation is critical for the rational design of drugs against the
multitude of amyloid diseases [12].
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The folding/unfolding pathways of single and multidomain proteins have been
extensively studied [13,14]. However, most of these proteins are predominantly helical [15].
Studies examining the kinetics of all helical proteins such as myoglobin and cytochrome-c have
indicated that -helical proteins refold from their denatured state(s) very rapidly on a millisecond
timescale [16]. The higher rate of refolding of all-helical single domain proteins is believed to be
due to the ease of formation of intra-strand backbone hydrogen bonds in helical conformations.
Interestingly, very little information exists on the kinetics of folding of all beta-sheet proteins. A
detailed knowledge of the kinetic events in the folding of all-beta-sheet proteins will likely
provide valuable information on the structural forces that trigger aggregation or fibril formation
which mostly involves organization of the polypeptide backbone into an array of beta-sheets
[17,18].
Human acidic fibroblast growth factor (hFGF1) is a ~16 kDa heparin binding protein.
hFGF1 is an all beta-sheet protein and its backbone is organized into a beta-trefoil architecture
[19, 20]. hFGF1 plays crucial role(s) in the regulation of key cellular processes such as cell
proliferation, cell differentiation, angiogenesis, tumor metastasis, and wound healing [21-23].
hFGF1 has a low half -life in vivo [24]. Interestingly, a significant population of hFGF1 has been
shown to exist in partially unfolded states at temperatures which are marginally higher than the
physiological temperature [25]. Previous studies have demonstrated that the denaturant-induced
equilibrium unfolding/refolding of hFGF1 does not occur via a two-state mechanism. Samuel et
al., showed that guanidium hydrochloride (GdnHCl)-induced equilibrium unfolding of hFGF1
proceeds through the formation of an obligatory intermediate [26]. Similarly, Alsenaidy et al.,
have shown that hFGF1 is highly prone to aggregation when subjected to heat beyond its Tm (<
40C) value or when subjected to minor changes in pH or ionic strength [27]. Blaber and
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coworkers elucidated that the thermal unfolding of hFGF1 can only be reversed by the addition
of low concentrations of GdnHCl [28]. It is believed that addition of low concentrations of the
denaturant potentially destabilizes the stable obligatory intermediate that accumulates in the
GdnHCl-induced equilibrium unfolding pathway of hFGF1 [26]. The propensity of hFGF1 to
heavily aggregate has been a significant impediment in realizing its strong wound healing
potential. In this context, there has been an increased interest in devising new wound healing
formulations that could stabilize hFGF1 against heat-induced aggregation. In this context, in this
study, we have designed a novel triple variant (TM) (Fig.1, Q54P, K126N, R136E) of hFGF1
that not only exhibits significantly higher thermal stability but also exhibits reversible thermal
unfolding by resisting the formation of aggregates. We believe that the findings of this study
provide valuable insights into the interplay of structural forces that confer reversible unfolding
behavior to the protein and also provide useful clues for the rational design of hFGF1-based
therapeutics to manage chronic wounds.
Results and discussion
Rationale for the designed mutations
As mentioned previously, hFGF1 is an all beta sheet protein with 12 beta strands
organized into a β-trefoil structure. The flexible heparin binding pocket contains a high density
of positively charged residues and is located between β-strands 10 and 12 (Fig. 1). We recently
demonstrated that a charge reversal mutation (R136E) in the heparin binding pocket marginally
decreases the heparin binding affinity but enhances both the thermodynamic stability and cell
proliferation activity of hFGF1 [19]. hFGF1 is known to be inherently unstable molecule at
temperatures just above the physiological temperature [20]. It is believed that the instability of
hFGF1 largely stems from the charge repulsions between the closely placed positively charged
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residues in the heparin binding pocket [19]. In this context, introduction of a negative charge in
the heparin binding pocket is postulated to provide a counter-ion effect and consequently
stabilize the growth factor molecule. K126 is located in the periphery of the heparin binding
pocket and has been shown to contribute significantly to the heparin binding affinity [19].
Therefore, we expect that neutralization of the charge via the K126N mutation would not only
decrease the heparin binding affinity but also increase the stability of hFGF1. Contribution of
two negative charges in the cationic heparin binding pocket is expected to significantly stabilize
the structure of hFGF1. Thus, introduction of Glu, Asn, and Pro residues at positions 54, 126,
and 136, could plausibly induce a stable conformation by improving the interactions (salt
bridges) in the protein core and stabilize the growth factor against temperature and chemical
denaturants. Q54 is lodged on the loop connecting beta-strands -3 and 4. This β-turn falls under
the category of type I or type IV turns. In either of these β-turns, proline is 4.3 times more
favored than Gln [40]. In this context, substitution of Q54 with proline is expected to make the
molecule more compact and consequently promote and stabilize additional interactions in the
protein core. Zakrzewska et al., showed that Q54P mutation significantly increases both the
stability and cell proliferation activity of hFGF1 [40]. Substitution of glutamine with proline is
believed to significantly decrease the local backbone flexibility and render the hFGF1 molecule
more compact [40]. In addition, secondary structural analyses of wtFGF1 also revealed presence
of short 310-helices. Again, Pro is a favored amino acid in 310-helix type of secondary structure.
Matthews et al., and Mateos et al., observed that proline mutations decrease the conformational
entropy of the unfolded state of proteins [41,42]. Thus, introduction of Q54P, K126N, and
R136E plausibly aids in minimizing the exposure of hydrophobic regions to the surface and
restricts the conformational fluctuations occurring in the heparin binding region, thereby leading
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to refolding and higher stability of the growth factor. In this context, seven (Q54P, K126N,
R136E, Q54P/R136E, Q54P/K126N, K126N/R136E and Q54P/K126N/R136E) different
variants were designed to specifically delineate their effects on the structure, stability, heparin
binding affinity, and cell proliferation activity of hFGF1.

A

Triple mutant (R136E/K126N/Q54P)

B

E136
P54

N126

Fig. 1: Amino acid sequence of the triple variant of hFGF1. The residues highlighted in red
represent the mutated residues in wtFGF1 (Q54P, K126N, and R136E) (Panel – A). Cartoon
representation of hFGF1 structure (PDB ID: 1RG8) showing the mutation sites (Panel – B).
Mutations do not alter the structure of hFGF1
Human acidic fibroblast growth factor (wtFGF1) and the designed variants (R136E, K126N,
Q54P, Q54P/R136E, Q54P/K126N, K126N/R136E and Q54P/K126N/R136E) were purified to
homogeneity using affinity and gel filtration column chromatography (Fig. 2).
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2 345
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Fig. 2: SDS-PAGE analysis of proteins eluted upon heparin sepharose and gel filtration
chromatography. wtFGF1 (Lane - 1), R136E (Lane – 2), K126N (Lane – 3), Q54P (Lane – 4),
R136E/K126N (Lane – 5), R136E/Q54P (Lane – 6), and K126N/Q54P (Lane - 7).
It is important to verify if the introduction of mutations in the seven different variants
significantly perturbed the structure of hFGF1. In this context, we used far-UV circular
dichroism (CD) spectroscopy and intrinsic fluorescence spectroscopy to monitor the structural
changes that could potentially occur as a consequence of the introduced mutations. Far-UV CD
spectrum (190 nm – 250 nm) of the wtFGF1 shows positive and negative ellipticity bands
centered at around 228 nm and 205 nm, respectively (Fig. 3A). These structural features are
consistent with the β-trefoil structure of hFGF1. Interestingly, the far-UV CD spectra of the 7
designed hFGF1 variants superimpose quite well with that of the wild type protein suggesting
that the secondary structure of the protein is not perturbed due to the designed mutations.
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Fig. 3: Overlay of the far-UV CD spectra of wtFGF1 and the designed variants (Panel – A).
Overlay of the fluorescence spectra showing the similarity in the tertiary structure of wtFGF1
and the designed variants (Panel – B). The inset figures represent a cartoon representation of the
intrinsic fluorescence spectra of hFGF1 in its native and denatured state(s). Concentration of
protein used was 0.5 mg/mL in 10mM phosphate buffer, pH 7.2 containing 100mM NaCl.
wtFGF1 (pink), R136E (orange), K126N (gray), Q54P (yellow), K126N/R136E (purple),
Q54P/R136E (green), Q54P/K126N (blue), and Q54P/K126N/R136E (brown).
hFGF1 contains eight tyrosine residues and a lone tryptophan residue (Trp121, Fig. 1A).
Intrinsic fluorescence of a single tryptophan residue in the properly folded conformation is
significantly quenched by the surrounding amine groups of lysine and proline residues [19]. As a
consequence, intrinsic fluorescence spectrum of wtFGF1 in its native state shows an emission
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maximum at 308 nm corresponding to the tyrosine fluorescence (Fig. 3B). However, the
quenching effect of tryptophan is completely relieved in the unfolded state(s) and shows a
characteristic emission maximum at around 350 nm (Fig. 3B, inset). Therefore, monitoring
changes in the intrinsic fluorescence provides a reliable measure of the tertiary structural changes
that could plausibly occur in the protein. Overlay of the intrinsic fluorescence spectra of the
designed variants of hFGF1 revealed little or no significant differences indicating that the tertiary
structural contacts in the protein mostly remain unperturbed after the introduction of the
designed mutations in the protein (Fig. 3B). Results of intrinsic fluorescence and far-UV CD data
analyzed in conjunction conclusively suggest that the designed mutations did not significantly
perturb the native three-dimensional structure of wtFGF1.
Effect (s) of mutation on the thermal stability of hFGF1 variants
As mentioned previously, hFGF1 is an unstable molecule [Tm ~ 41 C, Tm is the
temperature at which 50% of the protein population exists in denatured state(s)] and is known to
exist in partially folded state(s) around physiological temperatures (Table-1) [28]. The protein is
known to aggregate when subjected to thermal unfolding at temperatures above its Tm [43]. In
addition, thermal unfolding of hFGF1 is known to be irreversible and consequently the
calculated Tm (apparent) value is only a qualitative measure of the thermal stability of the protein
[43]. More recently, Blaber and coworkers showed that the thermal unfolding of hFGF1 can be
reversed in the presence of low concentrations of GdnHCl [28]. The low thermal stability and the
problems associated with irreversibility of the thermal unfolding have significantly impeded the
development of hFGF1 based therapeutics for chronic wound care. In this context, we investigate
the stability of wtFGF1 and its designed 7 variants by monitoring the changes in the intrinsic
fluorescence intensity ratio at 308 nm and 350 nm (Fig. 4).
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Table 1: Comparison of the stability of wtFGF1 and the designed variants.
Proteins
wtFGF1
R136E
K126N
Q54P
Q54P/R136E
Q54P/K126N
K126N/R136E
Q54P/K126N/R136E

Tm value (°C)
41.5 ± 0.1
52 ± 0.2
54 ± 0.1
43 ± 0.1
53 ± 0.1
56 ± 0.5
49 ± 0.1
60 ± 0.1

Cm value (M Urea)
1.9 ± 0.4
2.25 ± 0.1
2.3 ± 0.3
1.52 ± 0.3
1.53 ± 0.2
1.55 ± 0.1
1.70 ± 0.1
3.97 ± 0.1

Cm value (M GdnHCl)
1.0 ± 0.8
1.82 ± 0.4
1.87 ± 0.3
1.44 ± 0.5
1.53 ± 0.6
1.43 ± 0.1
1.74 ± 0.2
2.35 ± 0.1
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Fig. 4: Intrinsic fluorescence spectra of thermal unfolding of wtFGF1 (Panel – A) and triple
variant of hFGF1 (Panel – B).
The thermal unfolding data suggests that wtFGF1 (Tm (apparent) - 41 °C) exhibits the lowest
thermal stability (Table-1). Replacement of Q54 with proline appears to have a marginal effect
(Tm (apparent) = ~ 43 C, Fig. 5, Table-1)) on the stability of the protein. Interestingly, single point
mutations (K126N and R136E) in the heparin binding pocket appear to have a more profound
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effect (~ 10 C – 12C) on the thermal stability of the protein (Table-1 & Fig. 5). These results
suggest that the charge repulsions between the closely placed residues in the heparin binding
pocket are primarily responsible for the inherent instability of hFGF1. The K126N mutation not
only decreases the repulsions between positively charged residues in the heparin binding pocket
but also appears to facilitate forging of a backbone to side-chain hydrogen bonding between
N126 and S130. It is believed that introduction of a negative charge via the R136E mutation
induces a counter-ion effect in the heparin binding pocket which consequently partially screens
the charge repulsions between the cationic residues located in the heparin binding pocket.
Surprisingly, the double mutation (K126N/R136E) in the heparin binding pocket shows a
noticeably lower (Tm (apparent) ~ 49 C, Table-1 & Fig. 6) stability than the corresponding
individual single-point mutations (K126N and R136E).

Fig. 5: Thermal unfolding and refolding curves of wtFGF1 (Panel-A; unfolding- blue, refoldingorange), R136E hFGF1 variant (Panel-B; unfolding- blue, refolding- orange), and TM-variant of
hFGF1 (Panel-C; unfolding- blue, refolding- orange). The thermal unfolding and refolding of
wtFGF1 and its variants was monitored by changes in the ratio of intrinsic fluorescence
intensities at 308 nm to 350 nm. Insert figure in Panel-A depicts the intrinsic fluorescence
spectra of hFGF1 in its native and denatured states. Concentration of protein used was 0.5
mg/mL in 10mM phosphate buffer, pH 7.2 containing 100mM NaCl.
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Although it is not clear why simultaneous replacement of both K126 and R136 causes the
observed decrease in stability, this is interesting considering the fact that these individual
mutations distinctly stabilize the protein. It appears that the individual stabilizing forces that
come into play in the heparin binding pocket (due to the incorporation of K126N and R136E
mutations) mutually weaken each other leading to a net decrease in the stability of the protein.
On the other hand, the K126N and R136E mutations when individually combined with the Q54P
mutation, to yield the double variants (Q54P/K126N and Q54P/R136E), confers significant
stability to the protein (Fig. 6, Table -1). These results once again confirm that maximum effects
on the stability of the protein are caused by nullification or reversal of charges in the heparin
binding pocket. Very interestingly, the Q54P mutation appears to compensate for the mutually
destabilizing effects of the K126N and R136E mutations. This is obvious from the high
Tm(apparent) value of the triple variant, Q54P/K126N/R136E (Fig. 6, Table-1). Although the Q54P
site is located remotely from the mutation sites in the heparin binding pocket, the structural kink
introduced by proline appears to be transmitted through a network of interactions to the heparin
binding pocket and consequently enables the two mutations (K126N and R136E) to
synergistically produce a stabilizing effect on the protein.
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Fig. 6: Thermal unfolding and refolding curves of wtFGF1 (Panel-A; unfolding- blue, refoldingorange), K126N hFGF1 variant (Panel-B; unfolding- blue, refolding- orange), Q54P hFGF1
variant (Panel-C; unfolding- blue, refolding- orange), Q54P/R136E hFGF1 variant (Panel-D;
unfolding- blue, refolding- orange), K126N/R136E hFGF1 variant (Panel-E; unfolding- blue,
refolding- orange), and Q54P/K126N hFGF1 variant (Panel-F; unfolding- blue, refoldingorange). The thermal unfolding of wtFGF1 and its variants was monitored by changes in the ratio
of intrinsic fluorescence intensities at 308 nm to 350 nm.
Mutations in the heparin binding pocket also affect stability of hFGF1 to chemical
denaturants
Chemical denaturant–induced isothermic equilibrium unfolding of hFGF1 was examined
to study the effects of the designed mutations on the stability of hFGF1 using intrinsic
fluorescence spectroscopy (Figs. 7 and 8). Urea-induced equilibrium unfolding of wtFGF1 at pH
7.2 (Fig. 7) shows that it is a relatively unstable molecule [Cm ~ 1.9 M, Cm is the concentration of
the denaturant wherein 50% of the protein population exists in the denatured state(s)] (Table-1).

134

Similar to the thermal unfolding data, single point mutations (K126N and R136E) in the heparin
binding pocket increase the resistance of the protein to the denaturation induced by urea.
However, unlike the thermal denaturation data, urea-induced unfolding data suggests that Q54P
does not contribute to the stability of the protein. In fact, the Q54P mutation marginally
decreases the Cm (Cm ~1.5 M). Interestingly, the double variants (Q54P/K126N and
Q54P/R136E) which increased the thermal stability of the protein, did not confer extra stability
against urea denaturation. In fact, the Cm (Cm ~1.5 M) values of these double variants were in the
similar range to that of wtFGF1. However, the triple variant (Q54P/K126N/R136E) was most
resistant to urea-induce equilibrium unfolding. These results clearly indicate that the interplay of
structural forces during thermal unfolding is subtly different than thin urea-induced unfolding of
the protein. The results discussed above also suggest that caution needs to be exercised when
designing proteins based on denaturation data obtained from one-set of conditions.
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Fig. 7: Urea-induced equilibrium unfolding and refolding curves of wtFGF1 (Panel-A; unfolding
– blue, refolding - orange), R136E hFGF1 variant (Panel-B; unfolding – orange, refolding- blue),
and TM-variant of hFGF1 (Panel-C; unfolding – yellow, refolding - orange). The urea-induced
equilibrium unfolding/refolding of wtFGF1 and its variants was monitored by changes in the
ratio of intrinsic fluorescence intensities at 308 nm to 350 nm. Concentration of protein used was
0.5 mg/mL in 10mM phosphate buffer, pH 7.2 containing 100mM NaCl.
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GdnHCl is an ionic denaturant and is known to efficiently disrupt both hydrogen bonds
and electrostatic interactions in proteins. We examined the GdnHCl-induced equilibrium
unfolding of hFGF1 to understand if the trend in the relative stability of the different designed
variants is similar to that observed in the presence of a neutral denaturant such as urea. GdnHClinduced equilibrium unfolding of hFGF1 was studied previously under different buffer
conditions and a stable obligate intermediate was found to be populated at around 0.96 M
GdnHCl29. The partially folded obligatory intermediate was shown to have characteristics
resembling that of a molten-globule-like state. In this study, we find that the Cm of wtFGF1 is 1
M (Table-1, Fig. 8) and is very close to the one reported earlier [44]. All the seven variants of
hFGF1 investigated herein showed higher stability than the wild type protein. This trend in the
Cm values is slightly different from those calculated from the urea-induced unfolding profiles.
Interestingly, the double mutants (Q54P/K126N, Q54P/R136E and K126N/R136E) seem to
exhibit slightly lower stability than the single point mutants (Table-2). These results once again
emphasize that the relative stabilities of hFGF1 appear to vary depending on the nature of the
denaturant used. However, one aspect that can be consistently inferred from all the denaturation
experiments is the extremely high stability of the triple (Q54P/K126N/R136E) variant of hFGF1.
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Fig. 8: GdnHCl-induced equilibrium unfolding and refolding curves of wtFGF1 (Panel-A;
unfolding- yellow, refolding- gray), R136E hFGF1 variant (Panel-B; unfolding- orange,
refolding- blue), and TM-variant of hFGF1 (Panel-C; unfolding- orange, refolding- blue). The
GdnHCl-induced equilibrium unfolding/refolding of wtFGF1 and its variants was monitored by
changes in the ratio of intrinsic fluorescence intensities at 308 nm to 350 nm. Concentration of
protein used was 1 mg/mL in 10mM phosphate buffer, pH 7.2 containing 100mM NaCl.
Reversibility of the thermal unfolding of hFGF1
The thermal unfolding of hFGF1 is not reversible. Heating hFGF1 beyond its Tm causes
aggregation of the protein. In fact, several reports show that wtFGF1 aggregates at temperatures
beyond 50C (Fig. 5) [19]. There has been increased interest in designing novel variants of
hFGF1 which show increased stability and enhanced cell proliferation activity. In this context,
we examined the reversibility of the temperature-induced unfolding of hFGF1 and its variants by
monitoring intrinsic fluorescence changes at 308 nm and 350 nm. wtFGF1 completely unfolds at
temperatures beyond 50C. Refolding of the protein was attempted by slow cooling from 75C to
25C and the results clearly show that the protein remained in the unfolded state(s) (Fig. 5). This
is obvious from the low 308 nm /350 nm intrinsic ratio. Attempts to refold wtFGF1 and its
variants from a lower temperature (55C to 25C) also did not help the proteins regain their
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native conformations. hFGF1 variants, which showed significantly higher Tm(apparent) (K126N,
R136E, Q54P/K126N, and Q54P/R136E) than the wild type protein, also did not refold to their
native conformations upon cooling from 85C to 25C. Interestingly, heat-induced denaturation
of the triple variant (Q54P/K126N/R136E) is completely reversible (Fig. 5). The intrinsic
fluorescence spectrum of the refolded protein at 25C overlaid quite well with the protein that
was not subjected to thermal denaturation at 75 C (Fig. 9).

Fig. 9: Overlay of the intrinsic fluorescence spectrum of the refolded triple variant at 25C
(orange) and the triple variant during thermal denaturation at 75 C (blue).
1

H-15N HSQC spectrum provides atomic level information on the backbone conformation

of a protein. Each crosspeak in the spectrum represents an amino acid in a particular backbone
conformation. In this context, 1H-15N HSQC spectra of the triple variant (Q54P/K126N/R136E)
were acquired before heat treatment and after refolding upon cooling from its heat denatured
state(s). Superimposition of the 1H-15N HSQC spectra shows that most of the crosspeaks overlap
quite well suggesting that the triple variant is capable of refolding back to its native
conformation from the heat denatured state(s) (Fig. 10).
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hFGF1 is a mitogen and exhibits potent cell proliferation activity. Therefore, the effect(s)
of the untreated and refolded triple variant (Q54P/K126N/R136E) forms on the proliferation of
NIH3T3 cells, were compared to examine if the refolded protein is biologically active. As
expected, wtFGF1 promotes proliferation of NIH3T3 cells and the number of cells almost tripled
compared to the control cells which were not treated with wtFGF1 (Fig. 11). Interestingly, the
triple variant exhibits higher cell proliferation activity than the wild type which is mostly
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consistent with its higher structural stability (Fig. 11). The triple variant which was refolded from
its heat denatured state(s) is also biologically active albeit with a lower potency (Fig. 11). The
moderately lower activity exhibited by the refolded triple variant protein could be either due to
lower stability of the refolded protein in the cell culture medium or due to the presence of a
small population of biologically inactive soluble oligomers. However, it should be mentioned
that no visible aggregates were detected in the refolded triple variant protein. These results
suggest that the triple variant can successfully regain its native conformation from its heatdenatured state(s). To our knowledge, this is the only hFGF1 variant that has been unequivocally
shown to refold to its unique biologically active conformation from its heat denatured state(s).

Fig. 11: Cell proliferation activity of the wtFGF1 and the triple variant (with and without heat
treatment). 50 ng/mL (blue), 10 ng/mL (orange), 2 ng/mL (gray), 0.4 ng/mL (yellow), and 0
ng/mL (red).
The triple variant of hFGF1 exhibits hysteresis during refolding from its heat denatured
state(s)
Thermal unfolding of the triple variant (Q54P/K126N/R136E) of hFGF1 is reversible but
a closer look at the thermal unfolding and refolding curves shows that they don’t superimpose
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well (Fig. 12). The Tm values characterizing the unfolding (60 ± 0.07 °C) and refolding (50 ±
0.09 °C) processes do not match. Typically, if the structural transitions that occur during heatinduced denaturation and renaturation from the heat denatured state(s) to the native conformation
are the same, then one would expect the denaturation and renaturation profiles to superimpose
quite well with nearly similar Tm values. The mismatch in the Tm values, characterizing the
thermal unfolding and refolding processes, is clearly indicative of hystersis. The observation of
hysteresis is rare but not unprecedented [45]. Hysteresis has been observed in multidomain and
multimeric proteins [45-50]. Hysteresis observed in the multidomain proteins is largely attributed
to disparities in the folding transition ensembles, which probably stem from the fact that
unfolding of these proteins is governed by domain transition whereas refolding events occur
more cooperatively [50]. However, hysteresis in single domain proteins such as collagen is
believed to be due to mismatch in the structural events that occur in unfolding and refolding of
the protein. Refolding of collagen is believed to occur via slow structural rearrangement of the
loop regions whereas unfolding has been shown to be more cooperative requiring the disruption
of few structural interactions that are important for stability [47]. Another plausible explanation
for the observed hysteresis in the thermal unfolding and refolding of the triple variant of hFGF1
may be ascribed to slow cis-trans isomeriztion of the proline introduced at position 54 via the
Q54P mutation. Verification of this proposal would require in-depth site–directed mutation
studies which are beyond the scope of this study. In addition, in some cases hysteresis has also
been attributed to transient association between protein molecules during the process of protein
folding/unfolding [51]. As protein association is a multimolecular reaction, the hysteresis
behavior ascribed to protein association should be dependent on the protein concentration. In this
context, we compared the thermal unfolding of the triple variant at two different protein
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concentrations (0.5 mg/mL and 0.2 mg/ml). Thermal unfolding and refolding curves obtained at
these concentrations were nearly identical suggesting that the hysteresis phenomenon observed
in the triple variant of hFGF1 is not related to protein association events (Figs. 12A and 12C). In
some cases, hysteresis observed during thermal unfolding-refolding is believed to be due to steep
temperature gradients used during the renaturation process [49]. To verify this, we examined
thermal unfolding/refolding of the triple variant of hFGF1 under two temperature gradient
conditions, 5C and 2C temperature intervals (Figs. 12A and 12B). The results obtained suggest
that the hysteresis observed during the thermal unfolding-refolding of the hFGF1 triple variant is
independent of the temperature gradients used in the experiment (Fig. 12).
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Fig. 12: Thermal unfolding and refolding curves of the triple variant at a concentration of 0.5
mg/mL and temperature interval of 5°C (Panel – A; unfolding (blue), refolding (orange)), 0.5
mg/mL and temperature interval of 2°C (Panel – B; unfolding (blue), refolding (orange)), and 0.2
mg/mL and temperature interval of 5°C (Panel – C; unfolding (blue), refolding (orange)).
Chemical denaturant-induced equilibrium unfolding-refolding of the triple variant of
hFGF1 was examined to understand if the hysteresis behavior is dependent on the conditions
used for protein unfolding/refolding. Overlay of the urea- and GdnHCl-induced equilibrium
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unfolding/refolding profiles separately shows no signs of hysteresis under these conditions. The
Cm values for the chemical-induced equilibrium unfolding and refolding processes appear to be
in agreement within the limits of experimental error (Figs. 7C and 8C). Interestingly, these
results appear to suggest that hysteresis behavior depends significantly on the conditions used for
protein unfolding/refolding. Hysteresis behavior appears to be discernably controlled by the
nature of structural intermediates that populate a particular unfolding pathway. In the theoretical
sense, it appears that the roughness of the protein folding funnel/terrain is denaturant-dependent.
Structural interactions contribute to the stability and reversible thermal unfolding of the
triple variant
The structural interactions that contribute to the enhanced stability and reversible thermal
unfolding behavior of the triple variant of hFGF1 were investigated using two-dimensional NMR
spectroscopy and MD simulations. Superimposition of the 1H-15N HSQC spectra of
Q54P/K126N/R136E on wtFGF1 and analysis of the 1H-15N chemical shift perturbation plot
(Figs. 13A and B) indicate that introduction of mutations at positions 54, 126, and 136, induces
only a minor shift of the cross peaks corresponding to residues located in the spatial vicinity of
the mutation site (R136, G134, and K132). These three residues are located in the heparinbinding pocket. R136 is one of the mutated sites and K132 and G134 are involved in the
formation of stronger electrostatic interactions (E136-K132, G134-G85) in the triple variant.
G134 is in close proximity to R136 and R133 (located in the center of the heparin binding
pocket). Thus, introduction of Q54P, K126N, and R136E appears to have contributed to
formation of new electrostatic interactions in the heparin binding pocket. These new interactions
could plausibly have increased the compactness of the hFGF1 structure and consequently
decreased the flexibility of the heparin binding loop.
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N chemical shift perturbation observed due to the R136E/K126N/Q54P mutation in hFGF1
(Panel-B). The horizontal line represents the arbitrary threshold above which the 1H–15N
chemical shift perturbation(s) was considered as significant. The 1H–15N chemical shift
perturbation of individual residues were calculated using the formula, (√ [(2ΔδNH)2 + (ΔδN)2]).
We have also performed microsecond-level equilibrium MD simulations of wtFGF138
and the triple variant, based on the X-ray crystal structure of the hFGF1 monomer (PDB ID:
1RG8) [29]. wtFGF1 is fairly stable initially, with RMSD values remaining around 1 Å for
approximately 2 µs [38]. However, it undergoes a conformational change quite abruptly after
about 2 µs and reaches an RMSD value of nearly 3 Å [38]. When compared with wtFGF1, the
triple variant (Q54P/K126N/R136E) does not exhibit any sudden conformational changes and
remains relatively stable for 4.8 µs with an RMSD of around 2 Å (Figure 14B). The differential
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behavior of wtFGF1 and the triple variant is more clearly reflected in the RMSD time series of
the heparin-binding region (residues 126-142), wherein wtFGF1 behaves significantly differently
from the triple variant (Fig. 14C). The heparin-binding region in wtFGF1 is initially stable below
1Å but undergoes an abrupt conformational transition (Fig. 14A, 14C) at around 2 µs and stays
at 3.5Å for the rest of the simulation, whereas the heparin-binding region of the triple variant
remains stable around 2Å for 4.8 µs [38]. A visual inspection of the simulation trajectories
clearly reveals that the heparin-binding region of wtFGF1 moves away from the core of the
protein after the 2 µs timepoint, while no major change is observed for the triple variant (Fig.
14A) [38].
These results are further corroborated by the root-mean-square fluctuation (RMSF)
analysis for wtFGF1 and the triple variant, wherein both systems show similar trends in their
fluctuations for different regions with the exception of the heparin-binding region in wtFGF1
(Fig. 14D) [38]. Experimental results of intrinsic fluorescence and far-UV CD spectroscopy data
are in good agreement with the MD simulation data suggesting that the designed mutations do
not significantly perturb the beta-trefoil core structure of wtFGF1.
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Fig. 14: A) Visual representation of wtFGF1 (red) before and after the conformational change.
The heparin-binding region (gold) moves away from the beta-trefoil core of the protein. No
major conformational change occurs in the triple variant (purple). The heparin-binding region
(gold) maintains the same conformation for 4.8 μs. B) RMSD time series for wtFGF1 (red) and
the triple variant (purple). C) RMSD time series for the heparin-binding region of wtFGF1 (red)
and the triple variant (purple). D) Root mean square fluctuation (RMSF) estimations for the
wtFGF1 (red) and the triple variant (purple).
Based on the criteria defined in the methods section, 65 stable hydrogen bonds were
identified in wtFGF1. Only one interaction out of 65 involves the heparin-binding region –
L145-K142 (84%) which is a backbone-backbone hydrogen bond. All 65 interactions observed
in wtFGF1 also occur in the triple variant with similar occupancies. 6 stable hydrogen bonds
were observed in the triple variant involving the heparin binding region (Table 2) that do not
qualify as stable hydrogen bonds in wtFGF1 based on the criteria defined in the methods section
(Table 2). Two of these six interactions involved variant residues (N126 and E136) (Table 2 in
bold).
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Table 2: Electrostatic interactions involved in the heparin binding region in the triple
variant.
Salt bridge/hydrogen bond
Interaction
R133 – E136
N126 – S130
G134 – G85
T137 – G134
K132 – G124
Y139 – E104

Occupancy (%)
triple variant
98
79
79
62
62
54

wildtype
0
0
35
35
28
13

Both interactions involving variant residues have very high occupancies. R133-E136 is a
strong salt-bridge interaction, indicating that the R136E mutation might play a key role in
conferring stability to the protein and in reversing the unfolding process of wtFGF1 (Fig. 15A).
A weaker salt bridge involving E136 (E136-K132) (Fig. 15B) was also identified. Both these
salt-bridges occur only in the triple variant.
Two unique salt-bridges were also identified in wtFGF1 – D84-K132 (Fig. 15C) and
D46-K127 (Fig. 15D) [38]. Electrostatic interactions between positively charged residues in the
heparin binding region and negatively charged residues in the beta-trefoil core, help stabilize the
heparin-binding region after the conformational change that occurs in wtFGF1 [38]. D84 of the
beta-trefoil core interacts with K132 of the heparin binding region, while D46 of the beta-trefoil
core interacts with K127 of the heparin binding region [38]. The absence of the D84-K132
interaction in the triple variant (Figure 15C) indicates that K132 interacts more favorably with
E136 (Figure 15B) than with D84. Therefore, the R136E mutation potentially causes a transition
from a relatively weak long-range interaction to a stronger short-range interaction, thus
stabilizing the triple variant.
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Fig. 15: A, B) Time series of the E136-R133 (A) and E136-K132 (B) donor-acceptor salt bridge
distance in the triple variant structure. C, D) Time series of the D84-K132 (C) and D46-K127
(D) donor-acceptor salt bridge distances in wtFGF1 (red) and the triple variant (purple).
Two out of the three mutations (K126N and R136E) in the triple variant structure are
located in the heparin binding region. RMSD, RMSF and electrostatic interaction analyses
suggest that these mutations are the driving force behind the relative conformational stability of
the triple variant. These results are further supported by solvent accessible surface area (SASA)
calculations for the heparin binding region. SASA of the wildtype heparin-binding region
increases significantly after 2 µs while there is no significant change during the triple variant
simulation (Figure 16) [38].
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Fig. 16: Comparison of the SASA time series of the heparin-binding region of wtFGF1 and the
triple variant.
The MD simulations reveal that although wtFGF1 is relatively stable within 2 microseconds
(which could be misleading if one uses typical sub-microsecond-level simulations), it undergoes
a rapid conformational transition after 2 microseconds [38]. Absence of this conformational
change in the triple variant indicates that the mutations in the heparin binding region have led to
an increase in stability of the protein. While microsecond-level MD simulations cannot provide a
complete characterization of the unfolding and folding process, they do give us unique insights
into the conformational dynamics of wildtype and triple variant hFGF1. The computational data
is generally in agreement with the experimental data, showing that these mutations contribute to
the structural forces responsible for the reversibility of unfolding of the triple variant.
Conclusions
In the present study, we show that nullification or reversal of charge of amino acids in the
heparin binding pocket of hFGF1, increases protein stability without significant perturbation of
the three-dimensional structure of the protein. The triple variant (Q54P/K126N/R136E) exhibits
~ 20C higher stability than the wild type protein. With the exception of the triple variant, the
thermal unfolding of wt-hFGF1 and designed variants is irreversible. Two-dimensional NMR
149

and cell proliferation activity data clearly show that the thermally denatured triple variant fully
regains its biologically active native conformation upon cooling. The refolding of the triple
mutant, from its thermally denatured state(s), exhibits a hysteresis behavior with a mismatch in
the Tm values of the unfolding and refolding process. In addition, comparison of the thermal-,
urea-, and GdnHCl-induced unfolding data suggest that the relative stabilities of hFGF1 and its
variants vary depending on the nature of the denaturant used. MD simulation studies reveal that
the triple variant mutations reduce the flexibility of the heparin binding region and enhance the
stability of hFGF1 by forming a network of stable electrostatic interactions such as R133-E136
and N126-S130. These interactions in the triple variant also appear to play a critical role in the
reversible thermal unfolding of the protein. To the best of our knowledge, this is the first study
wherein a hFGF1 variant with increased stability and reversible protein folding behavior is
reported. The findings of this study, in our opinion, can be expected to provide valuable leads for
the design of an efficient FGF-based therapy for chronic wound care.
Materials and methods
Materials
DNA plasmid isolation kits were purchased from Qiagen, USA and Quikchange II XL
mutagenesis kits were obtained from Agilent. Competent cells (DH5α and BL-21(DE3)) were
sourced from Novagen Inc., USA. Lysogeny broth (LB) was obtained from EMD Millipore,
USA. Heparin sepharose was obtained from GE Healthcare, USA. VWR Scientific Inc, USA
was the supplier for all buffer components including Na2HPO4, NaH2PO4 and NaCl. NIH 3T3
cells were obtained from ATCC and all the cell culture reagents including, DMEM media, fetal
bovine serum (FBS) and penicillin-streptomycin were purchased from Thermo Fisher Scientific
(Waltham, MA).
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Construction and availability of pure wtFGF1 and hFGF1 variant (s)
For all site-directed mutagenesis experiments, a truncated form of the hFGF1 gene (residue
number, 15-154) was inserted into a pET20b expression vector. Primers were designed using an
Agilent primer design program and were ordered from IDT DNA Inc., USA. Site-directed
mutagenesis (SDM) was performed using a QuikChange lightning kit followed by polymerase
chain reaction (PCR) as per the protocol provided by the vendor (Agilent Technologies). The
plasmid was then transformed into XL-gold competent cells and plasmid sequencing was carried
out by the DNA core sequencing facility at the University of Arkansas Medical Science
(UAMS). Each hFGF1 variant was overexpressed in BL-21(pLysS) Escherichia coli cells
cultured in lysogeny broth (LB) at 37 °C with agitation at 250 rpm. After overexpression,
bacterial cells were lysed by ultra-sonication and the released proteins were separated from the
cell debris by centrifugation for 20 minutes at 19,000 rpm. All the hFGF1 variant proteins were
then purified on a heparin-sepharose column using a stepwise salt gradient (100 – 1500 mM
NaCl) in 10 mM sodium phosphate buffer (pH 7.2). SDS-PAGE was used to determine the
purity of the protein. The protein bands were visualized by staining the gels with Coomassie
brilliant blue and the protein concentrations were determined by Bradford assay using a Hitachi
F-2500 fluorimeter.
Circular dichroism (CD) spectroscopy
Far-UV circular dichroism (CD) measurements were performed on a JASCO-1500
spectropolarimeter using a quartz cell of 1 mm path length. Each spectrum was an average of 3
scans and the wavelength range used was from 190-250 nm. The concentration of the protein
used was 33 μM in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl at 25 °C.
All the data points were normalized using necessary background corrections and smoothened
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using the Savitzky-Golay algorithm. The final spectra were obtained after necessary blank
corrections with 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl.
Fluorescence spectroscopy
All intrinsic fluorescence measurements were performed on a Hitachi F-2500 spectrophotometer
at 25 °C and a 10 mm quartz cuvette. The excitation and emission slit widths were each set at 2.5
nm. All the experiments were performed with protein concentration of 33 μM in 10 mM sodium
phosphate buffer (pH 7.2) containing 100 mM NaCl. wtFGF1 and all the variant proteins were
excited at a wavelength of 280 nm and the emission spectra were recorded from 300 nm to 400
nm.
Equilibrium unfolding
Thermal, urea and GdnHCl unfolding of wtFGF1 and all the hFGF1 variants were performed on
a Jasco-1500 spectrophotometer using the fluorescence and circular dichroism spectroscopy.
Equilibrium unfolding experiments were performed using a protein concentration of 33 μM in 10
mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl. Spectra were collected every 5
degrees from 25 to 90 °C. Each set of data was fit using excel graphing tools. The proteins were
excited at a wavelength of 280 nm and the emission spectra were recorded from 300 nm to 400
nm and the fraction unfolded was plotted as a function of temperature. The denaturation
temperature (Tm) was determined as the temperature at which 50% of the protein population was
denatured. Urea and GdnHCl-induced equilibrium unfolding experiments were conducted at a
protein concentration of 33 μM. Urea and GdnHCl was titrated in consistent volumes into the
sample up to a concentration of 8 M and 6 M, respectively. Protein unfolding was monitored by
fluorescence and the fraction unfolded was determined using the ratio of the fluorescence
308/350 nm intrinsic fluorescence. Spectra were collected as an average of 3 scans.
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Nuclear magnetic spectroscopy
1

H-15N HSQC experiments were conducted on a Bruker Avance DMX-700 MHz spectrometer

equipped with a 5 mm inverse cryoprobe at 25°C. wtFGF1 and the Q54P/K126N/R136E-TM
were grown in M9 medium with 15NH4Cl used as the sole nitrogen source. For the heat treated
Q54P/K126N/R136E-TM NMR sample, the protein was heated to 75°C using the water bath for
3 minutes and then cooled down at room temperature for 5 minutes. The sample was then
centrifuged to remove any visible aggregates. 15N labeled protein samples (1 mM) were prepared
in 90% H2O + 10% D2O solution containing 10 mM sodium phosphate buffer (pH 7.2)
containing 100 mM NaCl and 25 mM (NH4)2SO4. Spectra were recorded using 48 scans and 256
data points in XY dimension. Data were analyzed using XWINNMR 3.5 software supplied by
Bruker.
Cell proliferation activity
3T3 fibroblast cells obtained from ATCC (Manassas, VA) were cultured in complete media
consisting of DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were
grown to 80–90% confluency and were incubated overnight at 37 °C with 5% CO2 in serum free
media. Cells were then centrifuged for 2 min at 6000 rpm and then washed twice with hyclone
buffer to remove any remaining trace of enzyme and were transferred to incomplete media
(DMEM media without 10% FBS). The cell proliferation activity of hFGF1 was determined by
quantifying the increase in cell number after the cells had been incubated with hFGF1 at varying
concentrations. Starved 3T3 fibroblasts were collected and seeded in a 96-well plate at a seeding
density of 10,000 cells/well. Cells were then co-incubated individually with wild type and
variant hFGF1 at concentrations of 0, 0.4, 2, 10, and 50 ng/mL. After 24 h of incubation, 3T3
cell proliferation was assessed by the CellTiter-Glo (Promega, Madison, WI) cell proliferation
assay.
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All-atom equilibrium MD simulation
An all-atom equilibrium MD simulation of the triple variant (Q54P, K126N, R136E) was
performed based on the X-ray crystal structure of the hFGF1 monomer (PDB ID: 1RG8 –
Resolution: 1.1 angstroms) [29]. CHARMM-GUI was used to generate the initial simulation
model [30,31]. Residues 12-137 from the crystal structure correspond to residues 26-151 in the
experimental sequence. The first 12 residues were not used experimentally because they are part
of a random coil. The heparin-binding region spans residues 126-142 (in the experimental
sequence). The initial part of simulation was performed with the NAMD 2.13 simulation
package and the CHARMM36 all-atom additive force field [32,33]. The input files were
generated using CHARMM-GUI’s QuickMD Simulator plugin [31]. The model was solvated in a
rectangular TIP3P water box and 150 mM of NaCl ions were inserted into the system using the
Monte-Carlo ion placing method [31]. The system consisted of approximately 25,000 atoms.
Initially, we energy-minimized the system for 10,000 steps using the conjugate gradient
algorithm [34]. Then, the system was relaxed by releasing the restraints in a stepwise manner
(for a total of ∼1 ns) using the standard CHARMM-GUI equilibration protocol [30,31]. The
initial relaxation was performed in an NVT ensemble while the rest of the simulation was
performed in an NPT ensemble at 300 K using a Langevin integrator with a time step of 2 fs and
damping coefficient of 0.5 ps−1. The pressure was maintained at 1 atm using the Nosé−Hoover
Langevin piston method [34,35]. The smoothed cut-off distance for non-bonded interactions was
set to 10−12 Å, and long-range electrostatic interactions were computed with the particle mesh
Ewald (PME) method [36]. The initial equilibration run lasted 15 nanoseconds. The production
run was then extended on the Anton2 supercomputer for 4.8 microseconds, with a timestep of 2.5
fs. The pressure was maintained at 1 atm semi-isotropically, using the MTK barostat, while the
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temperature was maintained at 300 K, using the Nosé–Hoover thermostat. The long-range
electrostatic interactions were computed using the fast Fourier transform (FFT) method [37].
Conformations were collected every 240 picoseconds. Data from an all-atom equilibrium MD
simulation of wildtype hFGF1 that we had performed previously using identical conditions, was
compared with data from the triple variant simulation described above [38].
The RMSD trajectory tool of VMD was used to calculate the RMSD and Cα atoms were
considered for these calculations [39]. For RMSD calculations, we aligned the region of interest
against its own initial configuration and calculated RMSD with respect to this configuration.
RMSF of individual residues was calculated using the Cα atoms by aligning the trajectory against
the crystal structure. The salt bridge plugin of VMD was used to calculate the distance between
the two salt bridge residues over the course of the simulation, which is the distance between the
oxygen atom of the participating acidic residue and the nitrogen atom of the basic residue.
The VMD HBond plugin was used for hydrogen bond analysis [39]. Salt bridges were defined as
interactions with an oxygen-nitrogen cut-off distance below 4 Angstroms for at least 50% of the
total simulation time [39]. Hydrogen bonds were defined as interactions between two residues
with a hydrogen donor and a hydrogen acceptor with an angle cutoff of 35 degrees between the
donor, hydrogen, and acceptor and a donor-acceptor distance cutoff of 4 angstroms. A stable
hydrogen bond was defined as a hydrogen bond with an occupancy of 50% or more over the
course of the simulation. SASA was calculated using the internal SASA measurement method of
VMD [39].

155

REFERENCES
[1] Englander SW, Mayne L. The case for defined protein folding pathways. Proceedings of
the National Academy of Sciences. 2017 Aug 1;114(31):8253-8.
[2] Cieplak AS. Protein folding, misfolding and aggregation: The importance of two-electron
stabilizing interactions. PloS one. 2017 Sep 18;12(9):e0180905.
[3] Hsieh HC, Kumar TK, Chiu CC, Yu C. Equilibrium unfolding of an oligomeric protein
involves formation of a multimeric intermediate state (s). Biochemical and biophysical
research communications. 2004 Dec 31;326(1):108-14.
[4] Ebo JS, Guthertz N, Radford SE, Brockwell DJ. Using protein engineering to understand
and modulate aggregation. Current opinion in structural biology. 2020 Feb 1;60:157-66.
[5] Wu S, Du L. Protein Aggregation in the Pathogenesis of Ischemic Stroke. Cellular and
Molecular Neurobiology. 2020 Jun 11:1-2.
[6] Díaz-Villanueva JF, Díaz-Molina R, García-González V. Protein folding and mechanisms
of proteostasis. International journal of molecular sciences. 2015 Aug;16(8):17193-230.
[7] Balchin D, Hayer-Hartl M, Hartl FU. In vivo aspects of protein folding and quality
control. Science. 2016 Jul 1;353(6294).
[8] Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in
neurodegenerative diseases. Nature neuroscience. 2018 Oct;21(10):1332-40.
[9] Mukherjee A, Soto C. Prion-like protein aggregates and type 2 diabetes. Cold Spring
Harbor perspectives in medicine. 2017 May 1;7(5):a024315.
[10] Wang W, Khatua P, Hansmann UH. Cleavage, Downregulation, and Aggregation of
Serum Amyloid A. The Journal of Physical Chemistry B. 2020 Jan 20;124(6):1009-19.
[11] Wang W, Roberts CJ. Protein aggregation–mechanisms, detection, and control.
International Journal of Pharmaceutics. 2018 Oct 25;550(1-2):251-68.
[12] Sarkar S, Gulati K, Kairamkonda M, Mishra A, Poluri KM. Elucidating protein-protein
interactions through computational approaches and designing small molecule inhibitors
against them for various diseases. Current topics in medicinal chemistry. 2018 Aug
1;18(20):1719-36.
[13] Guinn EJ, Tian P, Shin M, Best RB, Marqusee S. A small single-domain protein folds
through the same pathway on and off the ribosome. Proceedings of the National Academy
of Sciences. 2018 Nov 27;115(48):12206-11.

156

[14] Kantaev R, Riven I, Goldenzweig A, Barak Y, Dym O, Peleg Y, Albeck S, Fleishman SJ,
Haran G. Manipulating the folding landscape of a multidomain protein. The Journal of
Physical Chemistry B. 2018 Aug 8;122(49):11030-8.
[15] Iglesias-Bexiga M, Szczepaniak M, Sanchez de Medina C, Cobos ES, Godoy-Ruiz R,
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CHAPTER V
Stability of sFGF1 with respect to the Fluctuating pH Conditions, Aliphatic Alcohols, and
Cell Culture Media
Abstract
Human acidic fibroblast growth factor (hFGF1), a 16 kDa heparin binding protein is ubiquitously
expressed and is a powerful mitogen which is involved in various crucial cell-survival activities.
Besides the cell survival activities, this protein is also involved in treatment of disorders such as
diabetes, myocardial infarction, neuroprotection, bone fracture healing, and wound healing. The
major disadvantage of using hFGF1 as a wound healing agent is that the apparent melting
temperature (Tm -37˚C) of the growth factor lies in the physiological range. A negatively charged
glycosaminoglycan, heparin, when bound to wtFGF1 increases the stability of the growth factor.
Using a wide range of biophysical techniques, we determine that super FGF1 (sFGF1)
considerably increases resistance of the growth factor to a broader range of pH range (2.5-11)
and stabilizes hFGF1 in different aliphatic alcohols, and DMEM cell culture media. Intrinsic
fluorescence spectroscopy data suggest that sFGF1 can sustain the conformational fluctuations
over a broader range of pH (2.0 -11), whereas wtFGF1 is only stable from pH 4.0 - 9.5. The
stability of sFGF1 in all the three aliphatic alcohols (ethanol, TFE and acetonitrile) is more than
double of that exhibited by wtFGF1. Results of differential scanning calorimetry experiments
suggest that unlike wtFGF1, sFGF1 is thermally reversible from pH 4.0 - 9.0. Results from SDSPAGE show that sFGF1 increases resistance of the growth factor to the action of proteases
present in DMEM cell culture media. sFGF1 due to its ability to sustain varying pH conditions
and enhanced stability in cell culture media is believed to help in the efficient growth of different
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types of mammalian cells. Further, the stability of sFGF1 under diverse conditions may be useful
to design a more versatile wound healing therapeutic(s).
Introduction
Fibroblast growth factors (FGFs) constitute a family of heparin binding proteins involved
in the regulation of cell growth and differentiation, and angiogenesis [1]. Several fibroblast
growth factors (FGFs) have been found to be vital for embryonic and fetal development, wound
healing, bone fracture healing, neuroprotection, and tumor development and progression, and
they also protect against radiation-induced intestinal damage, myocardial infarction, and diabetes
mellitus [2-9]. Out of all the FGFs, hFGF1 is unique in a way that it can activate all four known
tyrosine kinase fibroblast growth factor receptors (FGFRs) [10]. FGFs’ activities, therefore,
could be harnessed to treat disorders that result from these types of insufficiencies - diseases
characterized by ischemia such as, peripheral arterial disease, coronary ischemia, diabetic ulcers,
and bed sores. Previously, our group has reported that a mutated form of hFGF1 (sFGF1)
showed an increased activation of the ERK1/2 pathway, which is known to be critical for wound
healing [11, 21]. Therefore, sFGF1 may exert the most potent effect on the treatment of wounds.
Crystallographic analyses of hFGF1 proteins depict a β trefoil structure containing twelve
beta sheet strands, organized into a central domain, five of these sheets form a hairpin binding
structure. The beta-sheets are arranged in an anti-parallel direction and are well conserved
[14,15]. hFGF1 has an intrinsically low thermal, pH and proteolytic stability, and almost half of
the wild type hFGF1 population is denatured at physiological temperature (Tm -37˚C). Stability
of wtFGF1 increases as a consequence of its binding to heparin. As the low stability of hFGF1
limits its potential for practical use, several studies have been conducted on improving the
stability of hFGF1 and consequently facilitate its long-term storage [12,13].
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Several hFGF1 variants have been generated to increase its thermodynamic and
proteolytic stability [12,16]. Among such hFGF1 variants, R133E, R136E, K126N, K132E,
Q40P, S47I, H93G, and cysteine variants (C131S, C97S, C31S) were identified as strong
stabilizing substitutions [8,20]. Compared to individual point mutations (K126N, K132E, S61I,
H107G, and Q54P), combinations of single mutations (K126/K132E),
(K132E/S61I/Q54P/H107G), (K126/K132E/S61I/Q54P/H107G), and
(K126N/S61I/Q54P/H107G) were able to enhance the thermal stability of hFGF1. Previously
reported hFGF1 variant, also known as sFGF1 (R136E/K126N/Q54P/S61L/H107S) has been
suggested to be the most stable variant of hFGF1 so far [11]. In particular, the denaturation
temperature (Tm) of sFGF1 increased up to 68˚C when compared with that of wild type hFGF1
(wtFGF1), Tm - 37˚C. Furthermore, R136E/K126N/Q54P/S61L/H107S exhibited the longest
half-life and the lowest proteolytic susceptibility among all the other hFGF1 variants reported in
the literature. sFGF1 is a heparin-independent variant. This has been evidenced by cell
proliferation experiments which show 70% increased mitogenic activity in sFGF1 than wtFGF1.
This chapter aims at studying sFGF1’s ability to sustain varying pH conditions, stability
in different aliphatic alcohols (ethanol, 2,2,2- trifluoroethanol (TFE), and acetonitrile), and
DMEM cell culture media. The results of this study demonstrate that sFGF1 can sustain the
conformational fluctuations in both, acidic and basic environments. Being able to resist the
change in pH is an important finding for many biomedical applications, including drug delivery
and tissue engineering. Owing to its ability to resist the action of cellular proteases, results of this
study strongly suggest that sFGF1 can effectively regulate pluripotency and cell differentiation in
human embryonic stem cells. Lastly, the extraordinary stability by sFGF1 in aliphatic alcohols
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implies that it can be stored under sterile conditions in alcohols, thereby minimizing potential
microbial infections.
Results and discussion
Effect of pH on the stability of wtFGF1 and sFGF1
Nearly every biological process is pH dependent reflecting the importance of local pH on
all processes in the cell. Ionizable amino acid residues have been shown to have a large influence
on protein structure, stability and solubility [37, 38]. The types of interactions the side chains
have with their environment depend on their protonation state. As a consequence of the change
in protonation of the ionizable residues, the stability of proteins is pH dependent. Changes in
intracellular pH have been shown to regulate essential processes such as cell proliferation and
apoptosis [39, 40]. However, our understanding on the effects of environmental pH on proteins is
limited.
The process of wound healing involves various cellular events, including angiogenesis.
pH within the wound environment directly and indirectly influences all cellular events [41]. It
has been shown that the surface pH of any wound plays an important role in wound healing as it
helps in controlling infection and increasing antibacterial and antifungal activity, oxygen release,
and protease activity [42]. During the wound healing process, the wound site advances from an
alkaline state to a neutral state and lastly to an acidic state. Therefore, alterations in pH can affect
the regular cellular events in wound healing and to work as an efficient wound healing
therapeutic, FGF with a wider range of pH stability is desired [44].
In this context, the stability of wtFGF1 and sFGF1 were monitored using fluorescence
spectroscopy. Fluorescence spectroscopy is an excellent method to determine changes in the
tertiary structure of the protein. wtFGF1 contains one tryptophan and eight tyrosine residues. In
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the native state, fluorescence of a tryptophan residue is quenched by the lysine and proline
residues located in the vicinity of the indole ring. The quenching effect diminishes the expected
350 nm tryptophan peak and therefore, only 305 nm emission peak from the eight tyrosine
residues is observed in the native conformation of the protein. The intrinsic fluorescence spectra
of wtFGF1 and sFGF1 at pH 3.5 and 7.0 are displayed in Fig. 1. The spectra from wtFGF1 and
sFGF1 at pH 7.0 have an emission maximum at 305 nm, which corresponds to the emission of
tyrosine residues. Contrastingly, the spectra at pH 3.5 show a major peak at 305 nm for sFGF1,
but a 350 nm peak for wtFGF1 corresponding to the emission of a Trp residue. This infers that
sFGF1 is stable even at pH 3.5. Absence of the 350 nm emission peak at pH 3.5 suggests that the
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Fig. 1: Overlay of the fluorescence spectra of wtFGF1 and sFGF1 at pH 3.5 and 7.
The ratio of fluorescence intensity at 305 nm and 350 nm (305/350) has been established
to examine the changes in tertiary structure of hFGF1 as a function of temperature, pH or a
chemical denaturant. A greater intensity ratio denotes that the protein is in its properly folded
tertiary structure. On the other hand, a lower value of 305/350 nm indicates perturbed tertiary
structure. Hence, the intensity ratio has been calculated and plotted as a function of pH to
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observe the alteration in the tertiary structure of wtFGF1 and sFGF1 (Fig. 2). 305/350 nm
intensity ratio for wtFGF1 started at ~1 and increased steadily up to ~5. At pH 1.0, 1.5, 2.0, 2.5,
3.0, and 3.5, the intensity ratio was found to be at ~1, suggesting that the tertiary structure of
wtFGF1 is altered from pH 1.0 - 3.5. In contrast, 305/350 nm ratio for pH 4.0 and 4.5 was found
to gradually increase from ~1 to ~5, indicating minor structural perturbations. Fluorescent
intensity ratio was found to be stable at ~5, from pH 5.0 to 7.5, suggesting that the tertiary
structure of wtFGF1 is properly folded. 305/350 nm ratio decreases from pH 7.5 to pH 10,
signifying structural changes in wtFGF1. Intensity ratio stays below 1 from pH 10 to 13,
implying that the native tertiary structure of wtFGF1 is completely altered. On the other hand,
fluorescence intensity ratio for sFGF1 initiates at 1 and gradually increases with an increase in
pH, indicating that the tertiary structure is altered from pH 1.0 to 2.0 and there are some minor
structural changes from pH 2.5 to 4.5. Fluorescence intensity ratio is found to be maximum (~6)
from pH 4.5 to 9.5. This indicates that there is no significant alteration in the tertiary structure of
sFGF1. However, intensity ratio stays below 1 from pH 11.5 to 13, implying that the native
tertiary structure of sFGF1 is significantly altered.
It has been observed that both acute and chronic wounds have a lower healing rate with
an alkaline pH when compared with an acidic pH [43]. Therefore, maintaining the protein
stability under acidic conditions is critical in the biomedical applications, including wound
healing [22,23]. There have been several studies that have examined different approaches to
achieve this stability; including protein engineering and chemical modifications [24,25]. Heparin
binding pocket comprises of positively charged amino acids. These amino acids repel each other
and cause instability of wtFGF1. Two of these positively charged residues in heparin binding
pocket of sFGF1 have been mutated to a negative and neutral amino acid (R136E and K126N).
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These mutations aid in minimizing the repulsions between closely packed basic amino acids.
Moreover, serine to leucine substitution at position 61 might help in rearrangement of the
hydrogen bonds in sFGF1, thereby stabilizing the protein against conformational changes in
different pH. Results from Chapter IV indicate that the thermal stability of the triple variant
(R136E/K126N/Q54P) was found to be 18 °C higher than wtFGF1. The reason for enhanced
stability of the triple variant could be attributed to formation of stable electrostatic interactions
(R133-E136 and N126-S130) involving the mutated residues. It has also been demonstrated that
Q54P mutation leads to the formation of a short 310 helix which increases the β-sheet propensity
of the growth factor [17]. Analyses of main-chain dihedral angles indicates that Ser at position
61 in wtFGF1 was located much closer to the surface (ψ = 149° and ψ = 143°) whereas Ile in the
triple variant structure was positioned in a region favorable for β-strand conformation (ψ = -113°
and ψ = 124°) [17]. H107 residue forms a type I β-turn in wtFGF1. However, glycine is preferred
over His in type I β-turn. Therefore, substitution of His by Gly reduced the steric strain between
the backbone and side-chain C-alpha atoms. Thus, it appears that introduction of R136E, K126N,
Q54P, S61L, and H107S aid in stabilizing hFGF1 against the conformational fluctuations in pH,
thereby qualifying sFGF1 as a better wound healing agent.
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Fig. 2: Effect of pH on the stability of wtFGF1 and sFGF1
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Effect of pH on the reversibility of thermal unfolding of hFGF1
Differential Scanning Calorimetry (DSC) is a useful tool for thermal analyses of proteins
using changes in heat capacity due to exothermic or endothermic reactions. We examined the
thermal stability and refolding of sFGF1 using DSC (Fig. 3). It can be inferred from the
thermograms that fluctuations in pH significantly affect the refolding capacity of sFGF1. It
should be noted that Tm (temperature at which 50% of the protein population exists in denatured
state(s)) of unfolded and refolded sFGF1 from pH 4.0 - 9.0 is found to be ~68°C, indicating that
sFGF1 is stable in a pH range of 4.0 -9.0. On the contrary, Tm of refolded sFGF1 at pH 2.0, 3.0,
and 10 shifts from 68°C to ~50°C (Fig. 4). This signifies that some of the interactions that are
present in sFGF1 (unfolded/native state) are disrupted during the refolding process at pH’s 2.0,
3.0, and 10. Moreover, the DSC thermogram at pH 2.0, 3.0 and 10 are broad indicating that the
protein exists in multiple conformations including a population of conformations which resemble
the native state.
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Fig. 3: Effect of pH on the reversibility of the thermal unfolding of sFGF1
The decrease in Tm of the refolded sFGF1 at pH’s 2.0, 3.0, and 10 could presumably be
due to the loss of stabilizing interactions (salt bridges (R133 and E136) and H-bonding (G129N126, N126-S130, Q141-E136, and E136-R133)) present in the unfolded (native) sFGF1. It
might also be plausible that time period for which the protein is cooled during the refolding
process is not sufficient to form the interactions. Therefore, Tm of unfolded and refolded sFGF1
does not match at pH’s 2.0, 3.0, and 10.
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Fig. 4: Tm of the unfolded and refolded sFGF1 at different pH values.
SDS-PAGE was run on the thermally unfolded wtFGF1 and sFGF1 to examine the
percentage of active protein in each sample (Figs. 5 and 6). Panel A of Figs. 5 and 6 represents
DSC profile of unfolding of wtFGF1 and sFGF1. After the unfolding of hFGF1, samples were
aliquoted for SDS-PAGE (Panel B of Figs. 5 and 6). Densitometric analysis of SDS-PAGE gel
shows that only 5% of wtFGF1 was found in the supernatant (aggregated molecules settle at the
bottom after centrifugation) in comparison to 75% of sFGF1 (Panel C of Figs. 5 and 6). The fully
folded sample before loading into DSC was considered to be 100% unaggregated protein.
Aggregation of wtFGF1 (70%) was evidently visible after centrifugation whereas sFGF1 did not
show any visible aggregates (only 10%). Moreover, lower Cp as observed in DSC thermograms
for the refolding process of sFGF1 could be due to formation of some aggregates (Fig. 3).
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Fig 5: Thermal unfolding of wtFGF1 measured by DSC (Panel - A). SDS-PAGE gel showing
aggregation of wtFGF1 during thermal unfolding by DSC (Panel - B). Unloaded protein (Lane1); Pellet (Lane-2); Supernatant (Lane-3). Densitometric analysis of the SDS PAGE gel showing
the protein aggregated during the thermal unfolding of wtFGF1 (Panel - C).

Overall, the results of thermal unfolding and refolding by DSC indicate that sFGF1 is not
only more stable than wtFGF1, but it also refolds back. Introduction of mutations (R136E,
K126N, Q54P, S61L, and H107S) appear to stabilize sFGF1 by forming new interactions. These
interactions seem to strengthen hydrogen bonds and increase the β-sheet propensity. According
to the statistical analysis, proline is the most preferred amino acid in type I β-turn and leucine
and isoleucine are most preferred amino acids in the formation of β-sheet. Q54 is located within
a turn between β3 and β4 strands. Therefore, replacing Gln with Pro at position 54 is expected to
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enhance the tendency of growth factor to form β-sheets. It was also found that replacing Gln with
Pro leads to formation of 310 helix (two overlapping β-turns). S61 is located in the middle of βstrand IV. Szlachcic et al., observed that substitution of serine by isoleucine aids in
rearrangement of hydrogen bonds [17]. Heparin binding region in hFGF1 (ranging from residues
119-142) consists of positively charged amino acids. Two of the five mutations in sFGF1, R136E
and K126N, belong to heparin binding pocket (HBP). Substitution of Arg by Glu and Lys by Asn
produces a counter-ion and charge neutralization effect which reduces repulsion between the
closely packed basic amino acids in HBP.
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C

Fig 6: Thermal unfolding of sFGF1 by DSC (Panel - A). SDS-PAGE gel showing minimal
aggregation of sFGF1 during thermal unfolding by DSC (Panel - B). Unloaded protein (Lane-1);
Pellet (Lane-2); Supernatant (Lane-3). Densitometric analysis of the SDS PAGE gel showing the
unaggregated protein during the thermal unfolding of sFGF1 (Panel - C).
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Stability of wtFGF1 and sFGF1 in Aliphatic Alcohols
Alcohols have been used as co-solvents to study the hydrophobic effect of solvent on the
structure and stability of proteins [28-30]. Addition of alcohols weaken nonlocal hydrophobic
interactions and enhances local polar interactions [29-31]. This results in destabilization of the
protein’s native hydrophobic core and increased formation of local hydrogen bonds resulting in
extended secondary structures.
Effects of alcohols on the tertiary structure of wtFGF1 and sFGF1 were monitored using
intrinsic fluorescence spectroscopy. It is well known that intrinsic fluorescence of proteins relies
upon microenvironment of three aromatic amino acids, tryptophan (Trp), tyrosine (Tyr) and
phenylalanine (Phe). hFGF1 has eight tyrosine and one tryptophan residues. In native wtFGF1,
intrinsic fluorescence from a tryptophan residue is quenched by adjacent lysine and proline
residues. Therefore, wtFGF1 shows an emission maximum at 305 nm, resulting from the eight
tyrosine residues. These quenching effects are completely alleviated in the denatured state of
wtFGF1, resulting in a significant increase in fluorescence at 350 nm corresponding to the
tryptophan residues. Here, two fluorescence parameters, emission wavelength maximum (λmax)
and fluorescence intensity ratio (305/350 nm), were used to obtain information on the tertiary
structure of hFGF1.
Fig. 7 displays changes in the fluorescence emission spectrum of wtFGF1 and sFGF1
with the addition of different concentrations of 2,2,2- trifluorethanol (TFE). Fluorinated alcohols
such as TFE is extensively used to study conformation of proteins or peptides in monomeric state
[45]. Aqueous TFE solutions are known to induce helix formation in polypeptides and proteins
[46]. However, TFE can induce β-sheet conformation under certain conditions [47]. λmax of
wtFGF1 changes from 308 nm to 350 nm when incrementing the TFE concentration from 0 to
10% v/v (Fig. 7A). However, λmax again drops down to 308 nm with a small peak at 350 nm at
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35% v/v TFE concentration. On the contrary, λmax of sFGF1 changes from 308 nm to 350 nm
when the TFE concentration increases from 0 to 20% v/v. However, sFGF1 behaves in the same
way as wtFGF1 at 35% v/v TFE concentration. An altered λmax suggests that microenvironment
of the Trp residue changes upon addition of TFE. Initial increase in TFE concentration led to the
shift of tryptophan residue from hydrophobic core to hydrophilic surface (solvent exposed). This
red shift suggests the possibility of conformational changes in the structure of wtFGF1 and
sFGF1. However, the fluorescence emission results of wtFGF1 and sFGF1, in the presence of
TFE, indicate that the decrease in λmax might be due to the strong hydrogen bond formation of
TFE with the proteins.
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Fig. 7: Fluorescence emission spectra of wtFGF1 (Panel – A) and sFGF1 (Panel – B) at different
concentrations of 2,2,2- trifluoroethanol (TFE) (0–85%, v/v).

The fluorescence intensity ratio is high when Trp residue is buried inside the hydrophobic
core of protein, while the ratio is low when Trp residue is exposed to the hydrophobic
environment. Fig. 8 displays changes in the fluorescence intensity ratio of wtFGF1 and sFGF1 at
different TFE concentrations. It can be inferred from the graph that sFGF1 is more stable at
varying concentrations of TFE than wtFGF1. In case of wtFGF1, 305/350 ratio decreases to
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almost 0 upon addition of 10% v/v TFE, whereas the intensity ratio remains high for sFGF1 up
to 20% v/v TFE concentration. This indicates that tryptophan is exposed to hydrophilic surface
upon addition of 25% v/v TFE concentration or higher in both wtFGF1 and sFGF1.

Fig. 8: TFE-induced unfolding of wtFGF1 (blue) and sFGF1 (red) as monitored by the ratio of
emission intensities at 308 nm to 350 nm.
Similar to TFE, intrinsic fluorescence of wtFGF1 and sFGF1 was measured in presence
of various concentrations of ethanol. It has been reported that ethanol can affect intermolecular
electrostatic attractions, hydrogen bonds, and hydrophobic interactions, resulting in alteration of
protein conformations [48]. Fig. 9 indicates changes in the fluorescence emission spectrum of
wtFGF1 and sFGF1 as a function of ethanol content. As expected, λmax of wtFGF1 and sFGF1
shifts from 305 nm to 350 nm (Figs. 9 A and B) accompanied by decrease in fluorescence
intensity ratio (Fig. 10) when incrementing the ethanol concentration from 5 to 90% v/v. As
discussed in case of TFE, the red shift in λmax and lower intensity ratio (305/350 nm) indicate
that polarity of the microenvironment of Trp residue is increased.
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Fig. 9: Fluorescence emission spectra of wtFGF1 (Panel – A) and sFGF1 (Panel – B) at different
concentrations of ethanol (0–90%, v/v).
Fig. 9A displays that λmax of wtFGF1 (305 nm) did not change when the concentration of
ethanol was increased up to 20% (v/v), but λmax increases to 350 nm upon further addition of
ethanol up to 90% v/v. On the contrary, λmax of sFGF1 (305 nm) did not change as the
concentration of ethanol was increased up to 80% (v/v), but λmax increases to 350 nm upon
further addition of ethanol up to 90% (v/v) (Fig. 9B). These results demonstrate that addition of
ethanol perturbs the native tertiary structure of wtFGF1 (20% v/v) at a fairly low concentration
when compared to sFGF1 (80% v/v), indicating that wtFGF1 cannot resist the conformational
changes induced by ethanol.

Fig. 10: Ethanol-induced unfolding of wtFGF1 (red) and sFGF1 (green) as monitored by the
ratio of emission intensities at 308 nm to 350 nm.
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It has been reported that acetonitrile can induce protein denaturation by altering the
tertiary structure through hydrophobic interactions [50]. In this context, the intrinsic fluorescence
of wtFGF1 and sFGF1 was measured in the presence of various concentrations of acetonitrile.
Fig. 11 shows the changes in the fluorescence emission spectra of wtFGF1 and sFGF1 with
increasing acetonitrile content. When increasing the acetonitrile concentration from 5 to 90 %
v/v, λmax of wtFGF1 and sFGF1 shifts from 305 nm to 350 nm (Figs. 11 A and B) and is
associated with decrease in fluorescence intensity ratio (305/350 nm) (Fig. 12). This indicates
that polarity of the microenvironment of Trp residue is increased.

A

B

Fig. 11: Fluorescence emission spectra of wtFGF1 (Panel – A) and sFGF1 (Panel – B) at
different concentrations of acetonitrile (0–90%, v/v)
Fig. 11B shows that λmax of sFGF1 did not change as the concentration of acetonitrile was
increased up to 50% v/v, but a decrease in intensity ratio (Fig. 12) was observed. An unaltered
λmax at 308 nm suggests that the tertiary structure of sFGF1 was not significantly perturbed upon
addition of 50% v/v acetonitrile concentration. Under these conditions, the Trp residue could be
buried within the protein core, thereby preventing the exposure of Trp residue to the solvent
environment. On the other hand, λmax of wtFGF1 was shifted to 350 nm upon addition of 15%
v/v acetonitrile. The observed red shift suggests that conformational change in wtFGF1 and
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sFGF1 causes an increased solvent-exposure of the Trp residue. It should be noted that sFGF1 is
able to resist the change in conformation even at 50% v/v acetonitrile concentration, whereas
wtFGF1 is only stable until 15% v/v acetonitrile concentration.

Fig. 12: Acetonitrile-induced unfolding of wtFGF1 (blue) and sFGF1 (red) as monitored by the
ratio of emission intensities at 308 nm to 350 nm.
Overall, intrinsic fluorescence experiment reveals that substituting Arg with Glu at
position 136, Lys by Asn at position 126, Gln by Pro at position 54, Ser by Leu at position 61,
and His by Ser at position 107 helped in stabilizing sFGF1. It has been demonstrated that low
levels of alcohols, in general, are often used in multi-dose protein formulations and drug delivery
systems to prevent microbial growth [32]. However, these alcohols have been shown to induce
protein aggregation [33]. Singh et al., reported that the fundamental physical mechanism
underlying such alcohol-induced protein aggregation is partial unfolding of local protein regions.
Therefore, stabilizing such local regions through site-specific mutations could help in reducing
protein aggregation. In hFGF1, one such conformationally unstable region is heparin binding
pocket which consists of closely placed cluster of positively charged residues. These positively
charged amino acids repel each other leading to hFGF1’s instability. Two of these positively
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charged heparin binding residues in wtFGF1 are substituted by a negative and a neutral amino
acid (R136E and K126N) in sFGF1. R136E and K126N mutations might reduce the repulsion
between the basic amino acids in the heparin binding region, thus conferring extra stability to
sFGF1. Structurally, S61L mutation is expected to make the hFGF1 molecule more compact by
strengthening the hydrogen bonds. Based on molecular dynamic simulation data (Chapter - III),
four new hydrogen bonds (G129-N126, N126-S130, Q141-E136, and E136-R133) and one stable
salt bridge (R133-E136) were identified in sFGF1. These new interactions likely stabilize the
protein against the effect of aliphatic alcohols.
Stability of wtFGF1 and sFGF1 in the cell culture media
Acidic fibroblast growth factor (FGF1) plays an important role in a variety of biological
processes, including embryonic development, morphogenesis, tissue repair, endothelial cell
migration and proliferation. hFGF1 has been shown to be unstable under physiological
conditions, with a half-life of approximately five hours in standard mammalian cell culture
conditions (37°C, 5% CO2). hFGF1 is also known to be degraded by proteolytic enzymes
(metalloproteinase and collagenase) present in the DMEM cell culture medium. At this rate of
decay, hFGF1 activity levels drop substantially after 48 hours at 37 °C [49]. Susceptibility of
hFGF1 to enzymatic digestion might pose a significant challenge for the use of hFGF1 in cell
culture, often requiring higher growth factor concentrations or daily media changes or FGF1
supplementation. In this context, stability of wtFGF1 and sFGF1 in culture medium was
examined. Fig. 13 shows that wtFGF1 was found to be completely degraded at 37°C after 24
hours of incubation in the growth medium. On the other hand, sFGF1 showed insignificant
degradation. Based on SDS-PAGE gel results, it was found that wtFGF1 band in lane 2 (1 day/
24 hours) decreases by almost 80% of its original concentration as compared to the protein
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(wtFGF1) which was not incubated in the culture medium. These results suggest that wtFGF1 is
susceptible to the action of proteolytic enzymes present in the culture medium. In marked
contrast, the concentration of the band corresponding to sFGF1 remains mostly unaltered
implying that sFGF1 is significantly more stable in the culture medium conditions than wtFGF1.
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Fig. 13: SDS-PAGE analysis of stability of wtFGF1 (Panel – A) and sFGF1 (Panel-B) in cell
culture medium. 50 ng/mL of proteins (Lane-1); 1 day (Lane-2); 2 days (Lane-3); 3 days (Lane4); 4 days (Lane-5); 5 days (Lane-6); 6 days (Lane-7); 7 days (Lane-8); 14 days (Lane-9). The
top red arrow represents the band corresponding to serum albumin whereas the bottom green
arrow represents the hFGF1 protein band.
Densitometric analysis of the SDS PAGE gels suggest that sFGF1 is mostly resistant to
the action of proteases present in cell culture medium. On the other hand, about 80% of wtFGF1
is digested within 24 hours under similar conditions (Fig. 14). These results clearly indicate that
introduction of mutations in wtFGF1 has increased the resistance of protein to proteolytic
digestion.
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Fig. 14: Densitometric analysis to assess the stability of wtFGF1 and sFGF1 in cell culture
medium as monitored by SDS-PAGE.
Chen et al., reported that the thermal instability of FGF2 is because of the heparin
binding region. Thus, they mutated one of the heparin binding residue (K128) to a neutral, polar
amino acid (N). Surprisingly, they found that the mutation (K128N) helped hFGF2 maintain its
activity in the cell culture medium at 37°C incubation [35]. Similarly, the stability provided by
sFGF1 in DMEM cell culture media appears to be due to the presence of two mutations in the
heparin binding pocket (R136E and K126N). Replacement of Arg with Glu and Lys with Asn
could have plausibly reduced the repulsion between the positively charged residues in the
heparin binding region.
Conclusions
Acidic fibroblast growth factor exhibits a wide array of activities such as, mitogenic
activity, angiogenic activity, wound healing, and bone growth. However, there are some
limitations to its use due to the thermal instability of hFGF1. Introduction of mutations in hFGF1
led to new interactions (hydrogen bonds and salt bridges) which increased its inherent structural
stability. Results of the present study show that sFGF1 is more resistant in a broader pH range
than wtFGF1. Unlike wtFGF1, sFGF1 is stable at higher concentration of aliphatic alcohols
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(acetonitrile, TFE, and ethanol). wtFGF1 is only stable upto 10% v/v TFE, 20% v/v ethanol, and
15% v/v acetonitrile concentrations. Contrastingly, sFGF1 is stable upto 20% v/v TFE, 80% v/v
ethanol, and 50% v/v acetonitrile concentrations. Native wtFGF1 is highly unstable under normal
cell culture conditions, with a half-life of approximately 5 hours. Findings of this study
demonstrate that wtFGF1 is susceptible to the action of proteases in cell culture media and
degrades in 24 hours. On the other hand, sFGF1, highly stable human acidic fibroblast growth
factor, exhibits increased stability in the cell culture medium up to 14 days. As, sFGF1 stays
biologically active for a longer period than wtFGF1 in standard cell culture conditions, it may be
now possible to design cost effective cell culture medium and also design new FGF1 based
therapeutic formulations for chronic wound care.
Materials and methods
Materials
The site-directed mutagenesis kit (QuikChange lightning kit) was from Agilent, and the
DNA plasmid isolation kit was from Qiagen. Escherichia coli strain BL21(DE3)pLysS was from
New England Biolabs. Heparin-Sepharose affinity resin was from Amersham Biosciences. The
basic components of culture media were purchased from IBI Scientific. Complete protease
inhibitor mixture was from Roche Applied Science. The buffer components were from VWR
Scientific. NIH 3T3 cells were purchased from ATCC and all the cell culture reagents including,
DMEM media, fetal bovine serum (FBS) and penicillin, streptomycin were obtained from
Thermo Fisher Scientific. All other chemicals were purchased from Sigma and were of highquality grade.
Purification of wtFGF1 and sFGF1
A construct comprising a truncated form (residues, 21–154) of human FGF1 in the pET20b expression vector was used. Mutagenesis and protein expression were performed as reported
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previously [36]. wtFGF1 and sFGF1 were expressed at 37 °C in E. coli BL21(DE3)pLysS strain
and were cultured at 37 °C to an A600 of 0.5 and induced with 1 mM isopropyl-L-thio-

-D-

galactopyranoside (IPTG) for 3.5 h. The cells were then lysed using the sonicator, and the
soluble proteins were purified on a heparin-Sepharose affinity column, followed by sizeexclusion chromatography on Superdex-75 using AKTA Explorer system (Amersham
Biosciences). Protein purity was confirmed by Coomasie blue-stained SDS-PAGE. The purity of
wtFGF1 and sFGF1 was estimated to be >98% based on SDS-PAGE analysis. The
conformational changes in wtFGF1 and sFGF1 were examined by circular dichroism and
fluorescence spectra measurements. The numbering system used to identify amino acids in
hFGF1 has been reported previously [36]. Purified hFGF1C protein was stored at -80°C until
further use.
SDS-PAGE was also performed to validate the thermal refolding and unfolding of
wtFGF1 and sFGF1. After the thermal unfolding of proteins, the protein samples were pipetted
out of the DSC machine and centrifuged at 13000 rpm for 3 minutes. The supernatant (active
protein sample) was separated from the pellet (aggregated protein sample) into a different
Eppendorf tube. TCA preparation was performed on each sample (aggregated and soluble
wtFGF1 and sFGF1) immediately after the centrifugation. The results were assessed using SDSPAGE analysis. The percentage of unaggregated protein was measured by comparing the band
intensities in lane 1, 2 and 3 using UN-SCAN-IT software. The native protein (unfolded) was
considered as 100% unaggregated protein (lane -1), the pellet and supernatant after the unfolding
of proteins were considered as lane 2 and 3, respectively. After obtaining the values from the
UN-SCAN-IT software, Microsoft excel was employed to obtain the graph of percentage active
protein versus the protein samples.
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Fluorescence and Circular Dichroism spectroscopy
Circular dichroism and intrinsic fluorescence spectra were measured using a Jasco J-1500
Spectrophotometer. Circular dichroism provides the information regarding the secondary
structural changes whereas fluorescence spectroscopy determines the tertiary structural changes
between wtFGF1 and sFGF1. All measurements were carried out at a protein concentration of 33
µM in a 10 mm quartz cuvette. CD spectra were recorded in the wavelength range 195–250 nm
in 10 mM phosphate buffer with 100 mM NaCl (pH 7.2) at 25⁰C with a scan speed of 20
nm/min, slit width set to 2 nm and a response time of 1 second. To acquire intrinsic fluorescence
spectra, an excitation wavelength of 280 nm was used, and emission spectra were collected from
300 to 450 nm in a 1 cm quartz cuvette.
Differential Scanning Calorimetry
The protein samples of wtFGF1 and sFGF1 at a concentration of 0.5 mg/ml in 10 mM
phosphate buffer containing 100 mM NaCl, pH 7.2 was used to determine the thermal
denaturation on a N-DSC III Differential Scanning calorimeter. Prior to loading, all samples
were subjected to degassing at 25°C for 15 minutes and after loading, the cells were equilibrated
for 10 minutes at the same temperature. Scans were performed from 10 to 90 °C with a 1 C/min
ramping temperature and variable pH solutions. To obtain a stable baseline, buffer blanks
experiments were conducted before running the protein scans. Data obtained was processed
using CpCalc Version 2.2.0.10 software provided by the manufacturer.
15% of sFGF1 protein was found to be aggregated. As it was difficult to remove the
aggregates due to the process of unfolding, thermograms provided by DSC showed lower
intensities for the refolded sFGF1. Therefore, normalization of protein concentration was done
(multiplied the refolded intensities by a factor of 7.5 because 75% of sFGF1 was found to be
active as shown in Fig. 6C) using Microsoft excel.
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Cell culture experiments
The NIH 3T3 fibroblast cell line was obtained from ATCC (Manassas, VA). NIH 3T3
cells were grown in complete media consisting of Dulbecco's modified Eagle's medium
supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were grown to 80-90%
confluency and were incubated overnight at 37°C with 5% CO2 in serum free media before
further use. Cells were seeded into tissue culture plates the day preceding the start of the
experiments. Cells were then co-incubated individually with wtFGF1 and sFGF1 at
concentrations of 50 ng/mL for 1, 2, 3, 4, 5, 6, 7, and 14 days. TCA preparation was performed
on each sample immediately after being removed from the culture plate. The results were
assessed using SDS-PAGE analysis along with UN-SCAN-IT gel software. The proteins
(wtFGF1 and sFGF1) were loaded in the first lane on SDS-PAGE (without media) to identify
hFGF1 out of all the other proteins in culture media.
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
Fibroblast growth factor (FGF) family is comprised of 23 highly regulated monomeric
proteins which control a plethora of developmental and pathophysiological processes, including
tissue repair, wound healing, angiogenesis, and embryonic development. Human acidic fibroblast
growth factor (hFGF1) is a 16kDa protein characterized by its mitogenic properties and high
affinity for heparin. It has been known that heparin protects the unstable form of the growth
factor against heat and proteolytic degradation. Thus, the putative role of heparin is to prevent
the degradation of the hFGF1 molecule. But, the kind of structure stabilization and new forces
brought into place by heparin is still unclear.
The major focus of this dissertation was to construct a hFGF1 variant that exhibits
increased thermal, chemical, and proteolytic stability, enhanced bioactivity, and reduced heparin
binding affinity. These characteristics form the basis for a better wound healing agent. We also
wanted to gain some insights into the role of heparin in hFGF1-FGFR complex formation and
activation. In this context, wtFGF1 was subjected to mutation at positions 54 (Q54P), 61 (S61L),
107 (H107S), 126 (K126N), and 136 (R136E). Site directed mutagenesis technique was
employed to construct the mutations mentioned above.
Interestingly, with contradicting studies showing that heparin either influences the
receptor activation of hFGF1 or fosters hFGF1 stability with electrostatic interactions, the
hFGF1-heparin complex becomes the most studied protein-glycosaminoglycan complex.
Inferences from Chapter II indicate that although heparin affects the stability of the growth
factor, it could have little implications on the proliferation efficiency of the protein. Isothermal
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titration calorimetric studies reveal that the positions crucial on hFGF1 for heparin binding are
K126 and R136. Additionally, other results pertaining to the mutation at positions Q54P, S61L,
H107S, K126N, and R136E correspond to heparin-independent hFGF1 proficiency with
increased thermal, chemical, and structural stability and improved cell proliferation activity.
The members of the FGF family has a characteristic β-trefoil conformation which helps
in the functioning of the protein but there still remains an elusive understanding of its functional
capability. In Chapter III, it was verified that with the decrease in the repulsion of positive
charges in the heparin binding site, the structural stability of hFGF1 can be improved. Apart
from this, limited enzymatic digestion, thermal and urea unfolding, and isothermal titration
calorimetry were also performed. It was noticed that sFGF1 showed superior characteristics
when compared to wild type in all aspects of the analyses mentioned. Furthermore, investigating
the findings of molecular dynamic (MD) simulations, results showed that the flexibility of the
heparin-binding site was hindered by the mutations, and increased stability was achieved due to
the formation of salt bridges and hydrogen bonds. Also, with sFGF1 there was an elevated cell
proliferation activity and a considerable rise in the activation of pathways such as Erk 1/2 and
Akt. Thus, the above-mentioned results qualify sFGF1 as a promising wound healing drug.
In chapter IV, we indicate that modification of amino acids to reverse the charge in the
heparin binding pocket of hFGF1 increases its stability without disrupting its structure. We have
experimentally demonstrated that introduction of Q54P, K126N, and R136E mutations on
wtFGF1 lead to reversible thermal and chemical denaturation of the growth factor. Thermal and
urea induced unfolding and refolding results indicate that a triple variant of wtFGF1
(Q54P/K126N/R136E) render more stability and facilitates refolding of the growth factor. In
fact, the triple variant has shown to exhibit hysteresis between unfolding and refolding processes
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with difference in temperature and urea concentration gradient. MD simulations suggest that the
triple variant render less flexibility to the heparin binding region and enhances the stability of
hFGF1 by forming stable electrostatic interactions such as R133-E136 and N126-S130. 1H-15N
HSQC experiment reveals that the triple variant does not significantly affect the gross threedimensional structure of hFGF1. Interaction analyses from MD simulations and NMR thus
indicate that the variant residues in the heparin binding region (R136E and K126N) along with
Q54P mutation are critical to the stabilization of the protein observed in silico and the refolding
process observed experimentally.
In chapter V, we noticed that although human acidic fibroblast growth factor renders
many advantages in terms of wound healing and tissue repair, its potential is limited due to its
short half-life and structural instability. Therefore, to increase the structural stability, several
mutations were studied in hFGF1. The results showed that when compared to wtFGF1, sFGF1
was not only resistant to a wider pH range, but also stable in predominantly higher
concentrations of aliphatic alcohols (ethanol, 2,2,2- trifluoroethanol (TFE), and acetonitrile).
Additionally, sFGF1 is also stable in the cell culture media for up to 14 days, thereby implying
that it could be potentially be used to design cost effective wound healing treatment options.
The implications of these findings imply that binding to heparin is not mandatory for the
FGF-FGFR signal transduction, further challenging the central dogma of FGF receptor
activation. In conclusion, binding of heparin to wtFGF1 and hFGF1 variants stabilizes and
protects the proteins from thermal and proteolytic degradation prior to FGFR activation.
However, with the engineered hFGF1, since heparin is not required for increased stimulation and
complexation with the FGF receptor, it has the potential to play a pivotal role in shaping the
development of wound healing treatment.
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Significance of this dissertation
hFGF1 has an intrinsically low thermodynamic stability and almost half of the wild type
hFGF1 population is denatured at physiological temperature. Several studies have been
performed to increase the thermal and proteolytic stability of hFGF1. Prior work conducted in
our lab resulted in the generation of variant hFGF1 referred to as single variant R136E, which is
located in the heparin binding region. This study is focused on generating hFGF1 variants with
four more mutations on R136E-hFGF1, to determine the significance of the heparin independent
sFGF1 (Q54P, S61L, H107S, K126N, R136E).
Another important aspect of the heparin-binding region is that it contains the secondary
thrombin cleavage site between Arginine-136 and Threonine-137. Thrombin is a serine protease
that is generated after endothelial cell damage and during the coagulation cascade. It has also
been demonstrated to cleave hFGF1 at Arg-136, thus, diminishing the mitogenic activity of
hFGF1. Many studies have focused on designing hFGF1 variant with increased resistance to
thrombin with the aim of enhancing its wound-healing potency. Studies have demonstrated that
the binding of hFGF1 to heparin increases the possibility of degradation of the protein imposed
by thrombin. Therefore; designing a hFGF1 variant with complete loss of heparin binding
affinity will be advantageous in pharmaceutical wound healing applications. Topical applications
of human fibroblast growth factor are believed to accelerate cell proliferation at wound sites
while leaving other bodily processes intact. The significance of the hFGF1 variants studied in
this dissertation widens the opportunity for the use of the growth factor in pharmaceutical
industry.
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Future directions
It is evident that there have been significant advances in improving the stability and
decreasing the heparin binding affinity of hFGF1 through site directed mutagenesis technique.
However, none of the hFGF1 variants reported so far in the literature exhibit complete loss of
heparin binding ability. Here, we have generated a hFGF1 variant known as sFGF1 which has
significantly higher thermal and proteolytic stability and confers zero heparin binding affinity.

While our variant has shown enhanced mitogenic activity, there has been a recent study
of another hFGF1 variant (K132E) demonstrating increased metabolic activity and decreased
potential to promote cell proliferation. Therefore, to take this research a step further we could
consider combining both, the attributes of increased metabolic and mitogenic activities. This
variant could especially be used in the field of diabetic research, wherein the role of hFGF1
variant will be to increase the glucose-lowering activity and enhance the cell proliferation ability.
This variant great hope for the evolution of a new class of FGF-based protein therapeutics
against Type-1 & Type-2 diabetes.
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APPENDIX
Biosafety committee approval
Kumar lab biosafety protocol number – 13004
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